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 Abstract 
 
Spinal cord injury (SCI) is a devastating condition, which results from trauma to the 
cord, resulting in a primary injury response which leads to a secondary injury cascade, 
causing damage to both glial and neuronal cells. Following trauma, the central nervous 
system (CNS) fails to regenerate due to a plethora of both intrinsic and extrinsic factors. 
Unfortunately, these events lead to loss of both motor and sensory function and lifelong 
disability and care for sufferers of SCI.  There have been tremendous advancements 
made in our understanding of the mechanisms behind axonal regeneration and 
remyelination of the damaged cord. These have provided many promising therapeutic 
targets. However, very few have made it to clinical application, which could potentially 
be due to inadequate understanding of compound mechanism of action and reliance on 
poor SCI models. This thesis describes the use of an established neural cell co-culture 
model of SCI as a medium throughput screen for compounds with potential therapeutic 
properties. A number of compounds were screened which resulted in a family of 
compounds, modified heparins, being taken forward for more intense investigation. 
Modified heparins (mHeps) are made up of the core heparin disaccharide unit with 
variable sulphation groups on the iduronic acid and glucosamine residues; 2-O-sulphate 
(C2), 6-O-sulphate (C6) and N-sulphate (N).  2-O-sulphated (mHep6) and N-sulphated 
(mHep7) heparin isomers were shown to promote both neurite outgrowth and 
myelination in the SCI model. It was found that both mHeps decreased oligodendrocyte 
precursor cell (OPC) proliferation and increased oligodendrocyte (OL) number adjacent 
to the lesion. However, there is a difference in the direct effects on the OL from each 
of the mHeps; mHep6 increased myelin internode length and mHep7 increased the 
overall cell size. It was further elucidated that these isoforms interact with and mediate 
both Wnt and FGF signalling. In OPC monoculture experiments FGF2 treated OPCs 
displayed increased proliferation but this effect was removed when co-treated with the 
mHeps. Therefore, suggesting that the mHeps interact with the ligand and inhibit FGF2 
signalling. Additionally, it was shown that both mHeps could be partially mediating their 
effects through the Wnt pathway. mHep effects on both myelination and neurite 
outgrowth were removed when co-treated with a Wnt signalling inhibitor, suggesting 
cell signalling mediation by ligand immobilisation and signalling activation as a 
mechanistic action for the mHeps. However, the initial methods employed in this thesis 
were not sufficient to provide a more detailed study into the effects the mHeps have on 
neurite outgrowth. This led to the design and development of a novel microfluidic 
device (MFD), which provides a platform to study of axonal injury. This novel device is a 
three chamber device with two chambers converging onto a central open access 
chamber. This design allows axons from two points of origin to enter a chamber which 
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can be subjected to injury, thus providing a platform in which targeted axonal injury 
and the regenerative capacity of a compound study can be performed.  
In conclusion, this thesis contributes to and advances the study of SCI in two ways; 1) 
identification and investigation of a novel set of compounds with potential therapeutic 
potential i.e. desulphated modified heparins. These compounds have multiple 
therapeutic properties and could revolutionise both the understanding of the basic 
pathological mechanisms underlying SCI but also be a powered therapeutic option. 2) 
Development of a novel microfluidic device to study in greater detail axonal biology, 
specifically, targeted axonal injury and treatment, providing a more representative 
model of SCI than standard in vitro models. Therefore, the MFD could lead to 
advancements and the identification of factors and compounds relating to axonal 
regeneration.  
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1 The Spinal Cord 
1.1 Physiology of the Spinal cord 
The spinal cord is a thick bundle of nervous tissue situated in the vertebral column of 
vertebrates. It is one of the two major components of the central nervous system (CNS) 
along with the brain. The spinal cord is divided into four regions; cervical, thoracic, 
lumbar and sacral. Each region is segmented with a total of 31 nerve paired segments. 
These are divided unevenly between each region; cervical (7), thoracic (12), lumbar (5), 
sacral (5) and coccygeal (1) (Fig.1.1) (Kayalioglu 2009). The spinal cord averages 
between 40-45 cm long and is approximately 1.25 cm in diameter. It extends from the 
foramen magnum, becomes one with the medulla oblongata, and continues to the 
beginning of the lumbar region. Below this level the vertebral column is populated with 
spinal nerve roots. The spinal cord is supplied with blood from the meningeal net which 
is in turn supplied by segmental arteries (Johns 2014).  
The spinal cord is composed of both white and grey matter. White matter is composed 
of bundles of myelinated axons, which give it its white colour while grey matter is made 
up primarily of nerve cell bodies. White matter is composed of three defined areas the 
posterior, anterior and lateral funiculi which are further subdivided into groups called 
fasciculi or tracts. Grey matter is composed of four parts: the posterior or dorsal horns, 
the anterior or ventral horns, the intermediate zones and the lateral horns (Fig.1.2) 
(Johns 2014). Dorsal and ventral nerve roots allow information to enter and leave the 
column, transmitting nerve impulses along the cord to appropriate targets, either the 
brain or peripheral regions (Crossman AR and Neary D 2010).  
The spinal cord has two enlarged areas where large bundles of nerve fibres cross the 
CNS boundary. The first is the cervical enlargement where the spinal nerves exit the 
cord and form the brachial plexus, which supply nerves to the upper extremities. The 
second area, known as the lumbosacral enlargement, is where spinal nerves exit the 
cord and form the lumbar and sacral plexuses, which supply nerves to the lower 
extremities (Watson and Kayalioglu 2009). The anterior horns of the grey matter house 
the anterior nerve root cell bodies, whereas the posterior nerve roots cell bodies are 
housed as a mass of soma in the posterior root ganglia outside the cord.  
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Figure 1.1 Spinal Cord 
The spinal column can be split into 5 sections: cervical, thoracic, lumbar, sacral and 
coccygeal. The spinal cord extends from the brain to L4/5 region (yellow), past here the 
spinal nerve roots (green) extend down the rest of the column. Image adapted from (Drake 
et al. 2015) 
 
The spinal cord is encased in meninges and cerebrospinal fluid (CSF). The meninges 
provide support and stability. The CSF surrounds both the brain and cord and it supports 
and cushions these whilst also removing waste products, which it returns to the blood 
stream (Scremin 2009). 
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Figure 1.2 Cross section of the spinal Cord  
The spinal cord can be seen here with the grey matter in the centre with the typical butterfly 
shape. This section is divided into dorsal, ventral and lateral horns containing sensory 
nerve tracts. The white matter houses the motor neuron tracts. Dorsal spinal nerves can be 
seen either side of the cord The nerves enter/leave the cord enabling communication with 
the CNS and the body. Adapted from (Drake et al. 2015) 
 
The structure and organisation of the spinal cord is crucial to is function. The spinal 
cord is surrounded by aqueous CSF and is housed in the vertebral column, 31 bone 
sections designed to protect the cord within. The cord and vertebrae are sectioned into 
5 distinct regions’ cervical, thoracic, lumbar, sacral and coccygeal.  The spinal nerves 
branch out of the cord through the vertebrae foramen and enter the peripheral nervous 
system. 
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Spinal cord development begins in the neural tube at around 21 days post fertilisation. 
Primitive nerve cells or neuroblasts arise from the neural epithelium within the neural 
tube. Neuroblasts found at the alter plate develop into the sensory neurons which 
reside in the dorsal horn, whereas those found at the basal plate differentiate into 
motor neurons within the ventral horns. Finally, neuroblasts differentiate into 
preganglionic sympathetic and parasympathetic neurons in the intermediate and lateral 
horns (Ashwell 2009). These mature neurons comprise of a cell body or soma with 
dendritic and axonal projections which deliver signals to and from the soma, 
respectively. Once these mature neurons have developed, cellular division ceases and 
these neurons remain in place for the rest of the organism’s life (Eyre 2003).  
The mature neurons lack the ability to dedifferentiate and divide. This absence of CNS 
cellular renewal presents a major clinical challenge as injury to the spinal cord often 
results in neuronal cell loss. 
1.1.1 Clinical Pathology following spinal cord injury 
Damage to the spinal cord causes a disruption in the communication between the brain 
and parts of the body that are innervated below the point of injury. Following SCI the 
extent of the injury is assessed medically, using an established international standard 
clinical tool known as the American Spinal Injury Association scale or ASIA scale. This 
characterises the injury and grades it on completeness, examining both sensory and 
motor outputs The classifications of the ASIA scale are:  
 A=Complete: No sensory or motor function, 
 B=Incomplete: sensory, but not motor function preserved below site of injury,  
 C=Incomplete: motor function is preserved with key muscles at grade response 3 
or less below site of injury,  
 D=Incomplete: motor function is preserved with key muscles at grade response 3 
or higher below site of injury, and finally,  
 E=Normal: both sensory and motor function normally (Kirshblum et al. 2011). 
Epidemiologically, the occurrence of traumatic SCI lies within four major areas; with 
motor vehicle accidents attributing 40-50%, sports related accidents at ~24%, falls 12-
20%, and violence at 7-23% of cases. Non-traumatic injuries or illnesses include bone 
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cancers or osteoporosis, inflammation of the cord and multiple sclerosis and these can 
have similar pathological outcomes as traumatic injury (Figure. 1.3) (NSCISC 2013). The 
occurrence of any of these events can cause damage to the spinal cord by at least one 
of: direct trauma, compression by bone fragmentation, or ischemia (See Fig.1.4).  
 
 
 
 
Figure 1.3 Percentage incidences of traumatic spinal cord injury 
Motor vehicle accidents account for the highest incidence of SCI with 45% of cases with 
sports related injury at 24%, falls at 12% and violence accounting for 19%. Each injury 
causes damage to the cord leading many of the characteristics of SCI with paralysis being 
the most severe. (NSCISC 2013). 
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Figure 1.4 Traumatic SCI  
Here is a depiction of a common injury to the spinal cord. A bone fragment is protruding 
into the spinal column and compressing the spinal cord and blocking arterial blood flow. 
Red arrow highlights the protrusion into the cord. This type of injury is commonly 
diagnosed using MRI and requires immediate surgery to stabilise the bone fragments, 
halting further movement and more damage. Image adapted from (Drake et al. 2015). 
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Life expectancy and mortality of SCI patients have improved drastically with the 
medical control of pneumonia (Berlly and Shem 2007) and urinary tract infection 
(Pannek 2011). However, the major causes of immediate mortality for SCI patients are 
pulmonary embolism and septicaemia (Thietje et al. 2011). Chronic psychological 
trauma also contributes to mortality with both alcohol-related death and suicide being 
prevalent amongst SCI patients (NSCISC 2013). 
SCI sufferers are provided with constant pain management regimes and pain control is a 
key factor in quality of life. Rehabilitation programmes are available but the extent of 
recovery from rehabilitation relates to the extent of the injury. Unfortunately, many 
suffers experience little improvement, even with customised physiotherapy (Nagoshi et 
al. 2015).  
1.2 Stages of SCI 
1.2.1 Primary injury cascade 
Immediately following spinal cord trauma the primary insult begins, this stage generally 
lasts under two hours. The initial site of injury manifests in the central grey matter with 
the white matter being largely spared at this time. The reason for this is not fully 
understood but it could potentially be related to the relatively softer consistency and 
vascularisation of the grey matter compared to white matter, making it more 
susceptible to mechanical stress (Wolman 1965).  
In most cases of SCI there is evidence of disrupted blood flow and haemorrhage within 
the cord, through the loss of blood brain barrier (BBB) integrity. This disruption then 
leads to further damage from hypoxia and ischemia, which is detrimental to the 
surrounding tissue (Higashida et al. 2011). The insult then leads to neural loss, 
disruptions to axons and membrane integrity of the surrounding cells, which then 
triggers the cellular and molecular processes associated with the secondary cascade 
(Fitch et al. 1999). These are followed by the release of inflammatory mediators such 
as; IL-1β, TNFα and IL-6 triggering resident CNS immune cells (microglia) activation and 
migration (Pineau and Lacroix 2007) (Carlson et al. 1998) and oligodendrocyte 
loss/demyelination of spared axons (Li et al. 1999). The primary injury cascade is an 
important determinant of severity in SCI and a prime target for treatment and 
intervention.  
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1.2.2 Secondary injury cascade 
Secondary injury is characterised by an immunological cascade with the influx of 
immunological factors resulting in wide spread cell death. The immunological cascade 
begins minutes after injury and can remain active for months following injury (Snyder 
and Teng 2012) (Leal-Filho 2011). The secondary phase can be characterised by 
vascular, biochemical and cellular consequences of injury (Mautes et al. 2000). These 
processes occur from progressive damage of the cord at the site of injury. 
Vascular disruption involves breaching the blood brain barrier (BBB) or blood spinal cord 
barrier (BSB). This disruption results in oedema and invasion of systemic inflammatory 
cells, such as neutrophils and macrophages (Tator and Koyanagi 1997). In addition, the 
hypoxia caused by this vascular damage makes both glia and axons more susceptible to 
the detrimental effects of rising glutamate levels (Rothman and Olney 1986). 
Biochemical events relate to the increase of extracellular excitatory amino-acid levels 
leading to glutamate receptor excitotoxic damage, which can induce local neuronal cell 
death (McAdoo et al. 2005). Additionally, Ca2+ ions are related to glutamate-cell death, 
with increased intracellular Ca2+ recorded in neurons at the injury site. Ca2+ is also 
related to the generation of free radicals through mitochondrial damage, which can 
induce further neural cell death (Park et al. 2004). 
Cellular events are related to the influx of resident microglia and peripheral immune 
cells such as neutrophils and macrophages to the injury site. Microglia, which are the 
initial immune responders to injury in the CNS, migrate to the injury site (Dibaj et al. 
2010). These activated microglia are not yet phagocytic macrophages as this phenotypic 
change only occurs following further activation through their exposure to certain 
cytokines and chemokines such as interleukin-1 (IL-1) and tumour necrosis factor-α 
(TNF- α) (Basu et al. 2002) (Probert et al. 2000). These then phagocytic microglia 
remove tissue debris and release neurotrophins such as nerve growth factor (NGF) and 
neurotrophin-3 (NT-3), to control the inflammatory response (Elkabes et al. 1996) 
(Nakajima et al. 2001). The peripheral immune cells can only enter the CNS following 
vascular damage (to the BBB) and chemotactic cues (Taoka and Okajima 2000). These 
cells are phagocytic and remove tissue debris from the site of injury. These cells also 
function to limit the BBB breach by accumulating at the  site of vascular damage (Zhou 
et al. 2014).  
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1.3 Glial cells in CNS health and injury 
Glial cells are known as the support cells of the CNS. ‘Glia’ meaning ‘glue’ in Greek, 
this term coined by  Rudolf Virchow in 1858 (Kettenmann and Verkhratsky 2008), are 
the major component of the CNS cellular environment (Purves D et al. 2001). Glial cells 
comprise a broad category of cells which include: astrocytes, oligodendrocytes 
microglia and ependymal cells with glial cells outnumbering neurons in the CNS (Jessen 
2004).  
Glial cells were deemed to be of little importance in SCI pathology with much research 
focusing on the neuron. However, studies are now suggesting that these cells play vital 
roles not only in neuropathology but in also neurogenesis (Jessen 2004), neuronal 
communication/ synapse formation and even in higher brain functions such as 
intelligence (Pfrieger and Barres 1997). 
1.3.1 Astrocytes and myelinating glia in CNS 
The focus of this thesis will be on astrocytes and myelinating glia known as 
oligodendrocyte progenitor cells (OPC) and oligodendrocytes (OL). The morphological 
and functional characteristic of these cell types are quite distinct.  
1.3.1.1 Astrocytes 
Astrocytes are intimately involved with many cells of the CNS. They are highly secretory 
cells and have many intricate processes, expanding outwards allowing interaction with 
thousands of surrounding neurons and glia (Araque et al. 1999). Astrocytes originate 
from the neuroectoderm as progenitor radial glial cells which become gliogenic and 
differentiate into astrocytes (Cepko et al. 1996; McConnell 1992). Within the grey 
matter the ‘protoplasmic’ astrocytes encase synapses whilst in the white matter 
‘fibrillary’ astrocytes contact nodes of Ranvier and blood vessels (Bushong et al. 2002).  
Both of these astrocyte subtypes form gap junctions between distal processes of 
neighbouring astrocytes allowing astrocytic communication (Ogata and Kosaka 2002).  
Astrocytes can have multiple different phenotypes depending on their position and the 
environment in which they reside, for example, triggering active and reactive astrocytic 
phenotypes in inflammatory environments (Khakh and Sofroniew 2015) (Sofroniew 
2015). 
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Astrocytic functions in the CNS include energy metabolism, regulation of blood flow, 
immune system mediation and even adult neurogenesis. The main characteristic of the 
astrocyte to allow these functions is the mediation of signals  between neural cells, glial 
cells and neuroendothelial cells within the CNS (Sofroniew and Vinters 2010).  
Astrocytes are involved with the release of energy substrates and growth factors to the 
synapse. Astrocytes have been shown to endocytose certain neurotransmitters which 
can regulate and remove these molecules from the synaptic cleft which could otherwise 
result in overactive stimulation and nerve damage (Hamilton and Attwell 2010). They 
have vascular endfeet which are in direct contact with the blood vessel endothelial cells 
and express high levels of glucose transporters for passage of glucose (Kacem et al. 
1998) to the dendrites, synapses and axons.  
Astrocytes have been shown to have bidirectional interaction with blood vessels and 
synapses, forming a tripartite complex. Recent studies have shown astrocytes having 
the ability to control blood vessel dilation, thus altering blood flow to desired regions of 
the spinal cord (Abbott et al. 2006). Astrocytes have been observed encasing synapses 
forming a veil-like structure whilst extending other processes to contact capillaries, 
directly modifying the signals in an interaction termed neurovascular coupling (Haydon 
and Carmignoto 2006). Astrocytes have also been shown to be critical in synapse pruning 
and regulation in close association with microglia (Persidsky et al. 1999). Adult 
neurogenic niches are highly controlled areas within the CNS. Astrocytes have been 
shown to participate in CNS plasticity (Wilhelmsson et al. 2012). The activation and 
differentiation of adult neural stem cells (NSC) is crucial in memory formation. 
Astrocytes have been shown to mediate the differentiation of NSCs to neurons in the 
hippocampus through juxtacrine signalling and presentation of ephrin-B2 (Ashton et al. 
2012). This is key, as new neurons are generated here, so the CNS has the capacity to 
form new neurons and connections, this may be the case following injury to the cord if 
the mechanisms behind this are fully understood. 
1.3.1.2 Oligodendrocytes & progenitors 
Oligodendrocyte precursor cells (OPC) are the progenitor cell that form 
oligodendrocytes (OL) and account for around 5%-8% of the CNS cell populations 
(Dawson et al. 2000). OLs are crucial in the CNS by allowing rapid saltatory signal 
transduction and neuroprotection as these specialised cells provide the lipid insulation 
or myelin sheaths around axons. OL morphological characteristics are very distinct from 
the astrocytes, even though still a process bearing cell, they can be seen to physically 
wrap axons with a myelin sheath (Simons and Nave 2015). A single OL can 
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form/contribute to up to 25 internodes of myelin, this number depends upon many 
factors such as the diameter of the axon and the region of the cord (Snaidero and 
Simons 2014). 
OPCs are generated in the ventral neuroepithelium of the neural tube in early 
embryogenesis where they provide guidance for immature neuron migration. These cells 
are characterised by expressing the chondroitin sulphate proteoglycan-NG2 (NG2), and 
have now become known simply as NG2 cells. NG2 cells have both perinatal and adult 
forms (Noble 2000). OPCs can also arise from the dorsal spinal cord and 
hindbrain/telencephalon of the brain from early to post-natal development (Vallstedt et 
al. 2005). OPCs proliferate and migrate throughout the CNS during development and 
into adulthood, where they differentiate into mature oligodendrocytes forming myelin 
around axons (Simons and Lyons 2013). OPCs within the grey matter tend to have 
processes of a radial orientation whereas, in the white matter the processes are more 
longitudinal (Levine et al. 2001).  
OPC proliferation, differentiation and migration are under the control of many 
endogenous factors. Astrocyte-derived growth factors include, insulin-like growth factor 
1, (Komoly et al. 1992), platelet derived growth factor α and fibroblast growth factor-II. 
These factors promote the proliferation and inhibit the differentiation of OPCs  (Noble 
et al. 1988) (McKinnon et al. 1990). Neuregulin is a neuron-derived factor which 
contributes largely to the survival of OLs and inhibits the proliferation of OPCs (Canoll 
et al. 1996). Myelinated axons actively inhibit the differentiation of OPCs through the 
release of ATP and certain neurotransmitters. Pre-myelinated axons, which initiate 
action potentials, release adenosine, which causes the resident OPCs to drop out of 
their proliferative state and begin differentiation towards a mature OL state, with the 
aim of myelinating the axon (Stevens et al. 2002). Perinatal OPCs have been shown to 
alter their differentiation to OL in the presence of CNS myelin (mature OL), with Notch 
1 receptors being implicated as the receptor present on the OPC which inhibits 
differentiation in the presence of CNS myelin (Wang et al. 1998).  
It is clear that astrocytes and OPCs/OLs are critical to spinal cord homeostasis. With 
astrocytes being central to glial and neuronal interactions, they are in a prime position 
for mediating the SCI response. With demyelination a key pathological outcome of 
trauma the reaction of OPCs/OLs to the injury site makes these cells high priority for 
targeting in the pursuit of CNS injury recovery, as these cells are crucial for cord 
homeostasis and protection of the axons. Therefore, understanding the processes that 
drive these cells during injury will allow for the identification of potential targets for 
clinical intervention.  
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1.3.2 Formation of the Glial scar 
The pathological hallmark of SCI is the generation of the glial scar, which is seen as a 
major barrier for innate axonal regeneration (Yiu and He 2006). The glial scar contains a 
heterogeneous population of cells and factors which form both a chemical and physical 
barrier (See Figure. 1.5).  
Ramon Y Cajal observed the limited regenerative capacity of the CNS in the early 1900s 
(Caja 1928). However, studies have shown that the CNS may have some intrinsic 
regenerative abilities. It has been observed that CNS neurons can regenerate if given a 
peripheral nerve environment (Richardson et al. 1980). This study demonstrated that 
the inhibition to growth within the CNS reflects a non-permissive environment as 
opposed to an innate inability of CNS axons to regenerate. This suggests that the 
components of glial scar which form the injury microenvironment around damaged 
axons can be responsible for the lack regeneration at the site of insult following SCI 
(Fehlings and Hawryluk 2010). 
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Figure 1.5 The glial scar  
Trauma to the spinal cord elicits a major cellular and molecular response. The injury site is 
invaded by many different cells whose aim is to barricade the damaged area and remove 
any dead of damaged cells. The injury site is a non-regenerative environment with loss of 
axons and myelination a permanent feature of the injury leading to lifelong loss of function. 
The glial scar is the main target for therapies, it is known that a combinational approach is 
necessary due to the many components of injury. Image adapted from (Obermair et al. 
2008). 
 
 
The cellular composition of the glial scar includes, innate microglia, invading immune 
cells and fibroblasts from the peripheral vasculature, damaged axons, OL/OPC and 
astrocytes (Fig.1.5). Disruption of the BBB due to trauma contributes heavily to the glial 
cell component of the scar, as this enables an influx of immune cells, which adds to the 
cellular component of the glial scar (Fitch and Silver 1997). This disruption to the BBB is 
further exacerbated through the release of cytokines and chemokines, damaged cells, 
which leads to infiltration of systemic immune cells into the CNS or spinal cord space 
where the trauma has occurred (Leal-Filho 2011). The cellular components of the glial 
scar releases a plethora of molecules which have different effects on the cells 
constituting the glial scar and the surrounding tissue (Fitch and Silver 2008). 
Astrocytes are major mediators of the glial scar. The astrocytes at the injury site and 
those which migrate to the site adopt a reactive phenotype altering their morphology, 
behaviour and function. Damaged cells release many factors, which contribute to 
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inducing the reactive phenotype of astrocytes including cytokines and growth factors 
(LIF, CNFT, TNFα and TGFβ), small molecules such as ATP, oxidative stress molecules- 
radical oxygen species and nitrous oxide (ROS and NO) and cell damage leads to 
ischemia (hypoxia and glucose loss). Furthermore, it has been shown that in astrocyte 
depletion studies, neurite outgrowth can be achieved in the absence of the reactive 
astrocyte at the site of injury (Bush et al. 1999). 
Other major constituents of the glial scar are both the OLs and their progenitor the 
OPCs. OL loss is a major event following injury to the CNS resulting in demyelination 
occurring during the secondary injury cascade (Levine et al. 2001). OPCs, similar to 
astrocytes alter their morphology and proliferation rate following injury, with 
accelerated OPC proliferation remaining high for up to a week following injury (Tripathi 
and McTigue 2007). Although OPCs’ main function within the CNS is to differentiate into 
myelinating OLs, this function is inhibited following injury as OPCs are instead 
stimulated to proliferate by the glial scar factors. This results in focal demyelination in 
and around the site of injury (Fitch and Silver 2008). 
A major molecular inhibitor within the glial scar is NG2, the chondroitin sulphate 
proteoglycan (CSPG), which is highly expressed on the cell surface of OPCs (Lytle et al. 
2009). NG2+ OPCs have also been observed in the fibrotic core of the scar suggesting 
that these cells may be directly involved in the scar formation and may be promoting 
the inhibitory environment (Buss et al. 2009). NG2+ OPCs have been shown in vitro to 
affect cells distal to the injury site, including OLs whose processes are altered, both in 
length and number, causing further spread of demyelination. NG2 has been shown to be 
a potent axonal repulsion guidance cue causing growth cone collapse and axonal 
retraction (Ughrin et al. 2003). 
The final phase of glial scar formation sees the generation of a fluid-filled cavity or 
syrinx. The syrinx is a second form cavity comprised of a very dense astrocytic wall. This 
cavity is highly pressurised which can lead to further compression of the cord, however, 
the exact mechanisms of syrinx formation are unknown (Klapka et al. 2005) (Norenberg 
et al. 2004).  
1.3.3 Preservation of function following astrocytosis and glial 
scar formation 
 
Although it may seem that the reactive astrocytes are solely detrimental to 
regeneration, astrocytic response to injury has also been suggested as a protective 
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mechanism (Faulkner et al. 2004). This response of the astrocyte to insult leading to the 
formation of a reactive phenotype is conserved throughout vertebrate evolution (Larner 
et al. 1995). A study using GFAP-TK mice (thymidine kinase from herpes simplex virus 
targeted to reactive astrocytes), which removed dividing reactive astrocytes from the 
injury site showed that spinal insult to the mutant GFAP-TK mice was more detrimental 
than that same insult to wild type mice (Faulkner et al. 2004). Specifically in the GFAP-
TK mice there was greater damage including failure of the BBB, leukocyte infiltration, 
severe cell loss in both neurons and glia (OL) with demyelination, compared to wild type 
(Bush et al. 1999). This study suggests that a primary function of reactive astrocytes and 
the glial scar is defensive and these cells should not necessarily be looked at as the 
enemy.  
Similarly, the OPCs’ role in the glial scar may have beneficial effects. A study which 
transplanted OPCs into an injury site. Lac-Z-transfected OPCs were transplanted into an 
irradiated cord, OPC survival was recorded and by 15 days there was a marked increase 
in remyelination (Franklin et al. 1996).  Alterations to OPC phenotype have been 
suggested as having a potential regenerative role following injury. OPC ‘activation’ is 
required for remyelination to occur (Miron et al. 2011) and this activation leads to an 
altered phenotype both behaviourally and morphologically. Cellular hypertrophy and 
altered gene expression for certain genes, such as OLIG2 and NK2, are seen in activated 
OPCs (Fancy et al. 2004). OPCs require the inflammatory cascade to induce their 
activation or their priming for remyelination and their activation is proportional to the 
local inflammatory response (Chari et al. 2006). This understanding of the beneficial 
pro-remyelinating phenotype of the OPC suggests that treatments which dampen the 
immune response may be actually detrimental to the remyelination process. 
1.4 Strategies for SCI repair and regeneration 
SCI regeneration will be a combination of multiple therapeutic strategies. Regeneration 
encapsulates; cell survival, axonal growth, remyelination and synapse formation. 
Therefore, successful therapies will aim to promote a number of these regenerative 
factors. 
1.4.1 Current Clinical therapies for SCI 
Current therapeutic options for SCI are limited, with no adequate treatment available in 
the clinic to allow for complete functional repair. Numerous clinical trials have been 
carried out using both pharmacological and cellular strategies, with many yielding 
negative results, whether due to adverse effects of the drug or lack of statistical power 
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in the trial. Although in general these trials have been phase 1 and principally 
investigated for safety not efficacy, they still provide important insights into how we 
can improve and advance new therapies into the clinic. 
Methylprednisolone Sodium Succinate (MPSS) is a corticosteroid used as a treatment in 
many inflammatory disorders such as arthritis and dermatosis (Hayball et al. 1992) 
(Goldberg and Barkoff 1960). It has also been posed as a potential treatment option for 
SCI, although controversially. Neurologically, MPSS has been shown to function through 
the enhancement of blood flow to the spinal cord and is also as a neuroprotective agent 
via the reduction of axonal die back post trauma (Hall 1992). There is also evidence that 
MPSS preserves OL death following injury (Lee et al. 2008). Furthermore, MPSS has been 
shown to be an anti-inflammatory agent reducing TNF-α and NFß synthesis (Oudega et 
al. 1999). MPSS was originally thought to be most effective in the first few hours after 
injury (2002) and 5 clinical trials have been conducted looking at the therapeutic 
benefit of MPSS in SCI. However, following the trials, MPSS has been implicated in 
adverse side effects such as pulmonary compilations (Matsumoto et al. 2001). These 
adverse effects have left many clinicians divided, with some continuing to employ MPSS, 
feeling that the risks are justified in the context of the severe deficits that accompany 
SCI (Fehlings 2001). 
Two other potential pharmacological therapies, gacyclidine (GK-11), an anti-
glutamatergic agent (Feldblum et al. 2000), and Thyrotropin releasing hormone (TRH), a 
mediator of other excitotoxic agents (Dumont et al. 2001), also  underwent clinical 
trials (Pitts et al. 1995). However, both trials suffer from poor experimental designs 
which lead to doubts over the outcomes.  
GK-11 showed some potential therapeutic benefit 1 year post treatment for motor 
function following certain types of injury (cervical patterned injury) but the trial 
outcome was non-significant. However, the data obtained could be misleading due to 
non-significant statistical power, GK-11 is no longer being pursued (Bond and 
McKerracher 2014).  
Similarly, TRH had shown promising results with statistical improvement following 
treatment with TRH versus untreated controls. However, only 20 patients were analysed 
so caution is needed as a statistical type I error could be confounding the true 
therapeutic effect of the drug (Pitts et al. 1995).  
Following the pitfalls of past trials, newer more strictly controlled trials have been 
devised. Moreover, details for SCI trials conducted are published by scientists and 
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research organisations including, the International Campaign for Cures of Spinal Cord 
Injury Paralysis who have produced a publication to improve trial structure and design 
(Steeves et al. 2007). There are a number of promising neuroprotective treatments 
currently in clinical trials including Minocycline and Riluzole. Minocycline is a 
tetracycline derivative used in dermatological treatment but has been shown to be 
effective in animal models of stroke and multiple sclerosis (Festoff et al. 2006). Riluzole 
is an anti-convulsant used to treat amyotrophic lateral sclerosis patients (Bhatt and 
Gordon 2007). It has shown neuroprotective activity through the blocking of voltage-
sensitive sodium channels release, which is dysregulated following insult to the spinal 
cord (Schwartz and Fehlings 2001).   
1.4.2 Axonal outgrowth and removal of growth inhibition 
The CNS has very limited innate axonal regeneration capacities (Fawcett 2006). It is 
believed that the inhibition of axonal outgrowth is due to both extrinsic and intrinsic 
factors. Extrinsic inhibitory factors are mainly released by cellular components of the 
glial scar into the injury environment and repel the axons from the site of injury 
(Fawcett and Asher 1999). Intrinsic inhibitory factors are synthesised within the 
damaged neurons/axons and inhibit the outgrowth into and across the site of injury 
(Filbin 2003). 
A major proportion of extrinsic axonal outgrowth inhibitors  is  cellular debris from the 
myelin sheath such as myelin-associated glycoprotein, (MAG), oligodendrocyte myelin 
glycoprotein, (OMgp) and Nogo-A (Chen et al. 2002) (Wang et al. 2002) (Geoffroy and 
Zheng 2014) (Chong et al. 2012). MAG and OMgp are protein components of the myelin 
sheath and have been associated with causing OPC and OL death (Kotter et al. 2006). 
Moreover, these are the primary repulsion mediators leading to inhibition of axonal 
outgrowth into and across the injury site (Filbin 2003). The identification of these 
axonal outgrowth inhibitors has uncovered a potential treatment target. Experiments 
using antibodies blocking Nogo receptor-1, the receptor for MAG and OMgp,  have been 
reported to facilitate long-distance regeneration and sprouting of corticospinal axons in 
rodent models (Zorner and Schwab 2010) (Fournier et al. 2001). However, targeting only 
the extrinsic inhibitor molecules has had limited regenerative success (Yiu and He 
2006), suggesting that a two-pronged approach of both extrinsic and intrinsic targeting 
is necessary for adequate axonal outgrowth.  
Due to the apparent intrinsic ability of peripheral neurons to regenerate following 
injury, this has led to intense studies into the differences between the PNS and CNS 
nervous tissue microenvironments which may hold the key to PNS regeneration (Huebner 
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and Strittmatter 2009). Gene profiling has been performed to identify genetic 
differences of the CNS and PNS neurons, and this has led to the identification of 
regenerative associated genes (RAG), active only in regenerating PNS neurons after 
injury (Schmitt et al. 2003) (van Kesteren et al. 2011). Therefore, a promising strategy 
for CNS axonal outgrowth is the targeted activation and up-regulation of these RAGs in 
the regenerating injured CNS neurons.  
Studies have identified that successful regeneration requires the axons to synthesize 
proteins at the exact position along the axon which is injured (Jung et al. 2012). It has 
been shown that there is a difference in regenerative capacity in a given axon. This 
could depend on the number of ribosomes and other protein synthesis machinery 
present at the position of injury or at the growth cone (Court et al. 2008) (Sotelo-
Silveira et al. 2006).  Based on this observation, axons with low regenerative potential 
tended to have fewer ribosomes and protein synthesis machinery present at the injury 
site of the axon. The reason for variation in axonal ribosomal accumulation is not well 
understood (Verma et al. 2005). It is predicted that the CNS neurons have similar, if not 
the same, axonal protein synthesis machinery as the PNS neurons but the difference in 
axonal regeneration lies in their translational responses to nerve injury (Park et al. 
2008). However, therapies which could activate or up regulate ribosomal presence at 
the site of axonal injury in the CNS could increase the regenerative capacity of the 
injured CNS neurons and promote axonal outgrowth (Gumy et al. 2010).  
Similarly, the presence of mRNAs in the proximity of the site of injury of the axon can 
affect intrinsic axonal outgrowth (Kalinski et al. 2015). Studies have identified that the 
mRNA species present in axons and growth cones vary between axons within the CNS 
(Zivraj et al. 2010). These mRNAs are mostly related to the cytoskeleton and the control 
of cytoskeletal dynamics, but at varying levels (Willis et al. 2005). Therefore, the 
difference in regenerative capacities between axons at the injury site could be related 
to the mRNA species present within the axons at the site of damage. If we are able to 
understand these differences, a potential therapeutic approach could be to introduce or 
promote specific mRNA species to the axons at the site of injury.  
1.4.3 Modulation of immune response 
The role of the immune system in SCI regeneration is subject to debate, as to whether 
it is beneficial or not. Studies have provided evidence for both sides of the debate, with 
data suggesting a primary protective role of the native immune cells in injury and 
regeneration (Donnelly and Popovich 2008). Conversely, excess immune involvement can 
be detrimental to regeneration (Hausmann 2003) (Beck et al. 2010). 
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Following traumatic injury to the spinal cord, a number of events lead to immune 
involvement in the injury site and the surrounding area. Inflammatory cytokines and 
chemokines are released from damaged or dying cells (Bartholdi and Schwab 1997) (Lee 
et al. 2010). These signal to neighbouring cells which then respond to the damage by 
releasing more cytokines and chemokines, further recruiting cells to the injury site 
(Pineau and Lacroix 2007). The initial responder immune cells are the native microglia 
which migrate to the injury site and proliferate and begin phagocytosing the damaged 
and dead cells. Depending on the injury, the BBB may be breached, which then allows 
peripheral immune cells to respond to the injury. Both native microglia and peripheral 
immune cells help to establish the secondary cascade and initiate the immunological 
phase of SCI (Zhou et al. 2014).  
Treatment options which focus on the mediation of the immune response look to control 
the chronic inflammatory phase which persists long after the initial immune activity has 
ceased. Treatment options here have two focuses; targeting the cells directly or their 
damaging excretory products. One approach is to target the pro-inflammatory factors 
on the cell surface of immune cells. TNF, a family of pro-inflammatory cytokines, is a 
prominent target in immune-mediated therapy with the identification and development 
of TNF inhibitor molecules (He et al. 2005). TNF-α has been implicated in cFOS 
activated glutamate-mediated cell death (Hermann et al. 2001) and activation of NF-kβ, 
a key regulator of inflammation and cell death (Orange and May 2008) (Brambilla et al. 
2005). Transforming growth factor-ß2 (TGF-ß2) is another therapeutic target. TGF-ß2 is 
expressed on astrocytes and is involved in the early inflammatory response (McTigue et 
al. 2000). A study which inhibited TGF-ß2 resulted in significantly decreasing the spread 
of scarring and tissue loss (Logan et al. 1999). 
Another approach to modulate the immune response to SCI is the addition of autologous 
primed immune cells, specifically peripheral macrophages, into the injured cord 
(Rapalino et al. 1998b). These cells have been shown to play a role in active PNS 
regeneration (Perry et al. 1987). Activated autologous macrophages were the very first 
cells to be transplanted into the injured cord and reach clinical trials (Knoller et al. 
2005). Furthermore, it was shown that macrophages primed with peripheral myelin 
products could promote regeneration and functional recovery in the CNS (Rapalino et al. 
1998a). Activated macrophages also were shown to benefit CNS regeneration through 
the synthesis and release of beneficial trophic factors; interleukin-1B (IL-1B) and brain 
derived neurotrophic factor (BDNF) at the injury site (Rapalino et al. 1998b). However, 
it has been shown that depletion of peripheral macrophages leads to tissue sparing and 
increased neural sprouting following injury (Perry et al. 1987), suggesting that the role 
of macrophages is complex having seemingly contradictory effects on SCI. 
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1.4.4 Bioscaffolds 
Bioscaffolds have been widely employed as both physical scaffolds and as drug delivery 
vehicles for SCI (Nomura et al. 2006). They have been constructed with many 
components of the extracellular matrix (ECM) including collagen (Marchand et al. 1993), 
fibronectin (Sterne et al. 1997) and hyaluronic acid (HA) (Rochkind et al. 2002). 
Bioscaffolds have also been fabricated out of naturally occurring polymers such as 
alginate/agarose and chitosan (Freier et al. 2005), as well as synthetic polymers such 
polyglycolic acid (PGA) (Chen et al. 2010) and polyethylene glycol (PEG) (Luo and Shi 
2004). These materials have been selected as they are non-immunogenic and so do not 
elicit an immune response (Shoichet MS et al. 2008). Bioscaffolds have two major 
functions as a treatment for SCI; to provide physical guidance channels for regenerating 
neurons/axons and as a delivery medium for repair and regenerative treatments, both 
pharmacological and cellular (Nisbet et al. 2008), or occurring as a combination of the 
two. 
Bioscaffolds aim to reconstruct the damaged or lost ECM of the spinal cord (Straley and 
Heilshorn 2009; Straley et al. 2010). They are often tubular structures, with porous 
fibre-like membranes which provide physical guidance for regenerating axons to grow 
along (Dalton et al. 2002), whilst also allowing therapeutic molecules to be bound for 
increased therapeutic effect (Wells et al. 1997). Bioscaffolds can also occur as gels 
which are semisolid liquids and have the quality of being able to fill cavities and gaps 
created by the injury. This type of structure could potentially lead to the prevention of 
astrocytosis and the spread of extrinsic inhibitory molecules at the injury site (Nomura 
et al. 2006).  
Many treatments for SCI are introduced systemically and there is the possibility that the 
BBB may inhibit some molecules from entering the CNS, as well as the potential of 
undesirable systemic effects (Rossi et al. 2013) (Kabu et al. 2015). However, the 
introduction of a bioscaffold at the site of injury addresses this problem as certain 
molecules can be bound to the scaffold and be delivered specifically to the site of 
injury. A study using a nanowire scaffold to locally deliver therapeutic molecules to the 
injured cord resulted in enhanced neuroprotective effects of these treatments 
compared to standard non-scaffold delivery (Tian et al. 2012).  
Hyaluronic acid hydrogels are emerging as one of the most important sources of 
artificial scaffolds in the tissue engineering field (Collins and Birkinshaw 2013).  A 
recent study adopted a HA hydrogel, modified with multi-tubular structures, bound with 
anti-Nogo receptor antibody, and a cocktail of BDGF and VEGF for transplantation into a 
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rat spinal cord lesion (Wen et al. 2015). They observed retardation of gliosis and 
inflammation as well as large nerve fibre outgrowth and even new blood vessels in and 
around the implant. This approach encapsulates in its entirety the possibilities of 
bioscaffolds, with gel structure for cavity filling, combined with physical structure for 
outgrowth and binding of therapeutics for drug delivery.  
Biomaterials have also shown promise as part of a combined treatment strategy with 
transplanted cells. One study used bioscaffolds to provide physiological cues for axonal 
outgrowth and cellular support for damaged or lost cells at the injury site (Zhong and 
Bellamkonda 2008).  
Bioscaffold are a promising candidate for a ‘combined therapeutic approach’  to SCI 
treatment as this strategy enables; pharmacological, cellular, physical guidance and  
localised delivery approaches in one single treatment.  
1.4.5 Cellular transplantation 
Cell transplantation is a promising therapeutic strategy for SCI injury and has been 
studied extensively (Tewarie et al. 2009) (Mothe and Tator 2012). Stem cells have been 
intensively study as a potential SCI treatment. However, somatic cells such as unipotent 
and terminally differentiated cells from the glial cell lineages such as, OPC, Schwann 
cells (SC) and olfactory ensheathing cells (OEC) have arisen as potential candidates for 
transplant-mediated repair. 
The consensus by the SCI research community is that a combinational treatment 
approach to SCI is needed and cellular transplantation appears to be the first name on 
the treatment option team sheet.  
1.4.5.1 Glial cell therapy 
Promising candidates for transplant-mediated repair for SCI are glial cells. There are 
three well documented options, which include two resident CNS glia; OPC/OL and OEC 
with the candidate from the PNS being the SC (Crang and Blakemore 1991) (Ramon-
Cueto 2000) (Kuhlengel 1988). 
Due to the role of OPCs as precursors of myelinating OL, cell therapies have 
investigated introducing these cells into the damaged cord with the aim of promoting 
re-myelination after trauma. OPCs can and have been isolated from neural stem cells 
which in turn can be used in transplant-mediated repair (Zhang et al. 1998).  
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SCs are the peripheral myelinating glial cell, providing myelin sheaths for PNS axons 
allowing rapid saltatory signal transduction (Villegas 1972). SCs were identified as 
potential candidates for SCI as far back as the 1970s (Blakemore 1977). Although these 
cells are the myelinating glial cells of the PNS, if presented with the correct diameter 
of axons in the CNS they can in fact myelinate CNS axons. These cells are extracted 
from peripheral nerve grafts and can be expanded in culture to increase the number of 
cells available for transplant (Kuhlengel et al. 1990). Interestingly, SCs have been shown 
to invade the CNS following trauma to the cord and can myelinate the resident CNS 
axons at the site of injury (Beattie et al. 1997). The SCs in the periphery have many 
other functions unlike their CNS counterpart, OLs, such as phagocytosing damaged cells 
and moderating the immune response (Reichert et al. 1994) (Hirata and Kawabuchi 
2002). These combined therapeutic effects led to SC transplantation into patients with 
acute thoracic spinal cord injury performed at The Miami Project, University of Miami 
Miller School of Medicine 2013. This phase 1 clinical trial used autologous SCs from the 
sensory nerve in the leg, cultured up to 5 weeks then surgically transplanted into the 
injury site (NCT01739023). Although these cells have gone into clinical trial, there has 
been evidence calling into question the benefit of SC in the repair process. Studies have 
shown that the SC may interact negatively with the astrocyte and exacerbate the glial 
scar (Higginson et al. 2012). This study used an in vitro confrontational assay where 
astrocytes were plated as a strip in front of a strip of SCs and allowed to migrate 
towards each other. It was found that SCs approached the astrocytes but did not cross 
into their domain but formed a boundary. This had been likened to the undesirable 
response seen in vivo as exacerbating the glial scar. 
OECs have also been put forth as a candidate for transplant-mediated repair (Graziadei 
and Graziadei 1979) (Graziadei 1973). These cells are specialised glial cells that have 
been shown to play a role in olfactory nerve regeneration in the olfactory bulb, the only 
known site within the CNS which has regenerative capabilities in the mature CNS 
(Graziadei and Graziadei 1979). OECs support the outgrowth of olfactory nerves during 
normal cell turnover (Farbman 1990). These glial cells do not reside in the spinal cord, 
they originate in the outer layer of the olfactory bulb, which is a transitional zone 
between the PNS and CNS (Barnett et al. 1993). Using the confrontation assays 
described above and in (Lakatos et al. 2000), it was shown that unlike SCs, OECs can 
mingle with astrocyte and do not form a boundary. Thus, it is believed that due to their 
inherent property to coexist with astrocytes, they could be a better candidate for SCI 
therapy than SCs (Higginson et al. 2012). However, using incomplete injury models it 
has been shown OECs promote neuroprotection and re-myelinate demyelinated axons 
(Toft et al. 2012). The precise mechanisms of the regenerative abilities of OECs are still 
poorly understood but research so far has shown promise. 
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1.5 Sulphation and signalling mechanisms in SCI 
Data from the Barnett lab and others suggest modifying the level of sulphation of 
resident cell surface sugars around a lesion may be a beneficial strategy in SCI repair 
(Higginson et al. 2012; Properzi et al. 2008) (Hering et al. 2015) (Rauvala and Peng 
1997). Sulphation is the biochemical process of enzymatic conjugation of a sulphate 
group from a donor molecule to another molecule (Chapman et al. 2004). Sulphation is 
implicated in a wide variety of biological processes including detoxification, hormone 
regulation and importantly cell signalling (Rosen and Lemjabbar-Alaoui 2010).  
Cell signalling encapsulates all cellular communication. The signalling process involves a 
ligand and a receptor and in some cases a co-factor which mediates the ligand-receptor 
binding. In many cases the co-factor is a sulphated sugar moiety present at the site of 
signal initiation (Rosen and Lemjabbar-Alaoui 2010).  
There are many types of cell signals which are usually chemical in nature. Their 
function in biological activities is dictated by cell signalling molecules such as growth 
factors, immune factors, neurotransmitters and even components of the ECM (Alberts B 
et al. 2002). Many of these signals can be sent to the immediate surroundings, as seen 
in paracrine signalling, as opposed to endocrine signalling, which can travel vast 
distances via the vascular system. There is also juxtacrine signalling that occurs 
between two cells in very close contact, where their surface receptors interact directly.  
There is great variation in the receptor profiles found on the extracellular cell surface 
of glial/neuronal cells and this receptor line up is dictated by the role of that cell in the 
tissue. The signalling cascade cannot be initiated without the binding of a ligand to its 
appropriate receptor. In the case of certain specific pathways, such as the fibroblast 
growth factor (FGF) family, the signalling cascade cannot be initiated without a 
sulphated extracellular co-factor (Turner and Grose 2010).  Biochemical studies have 
demonstrated that certain members of the heparan sulphate (HS) class of 
glycosaminoglycans (GAG) are necessary for FGF to bind and dimerise its receptor 
(Turnbull et al. 2001). The sulphation of these HSs play a role in strengthening the 
ligand-receptor binding. In some cases, signalling ligands which require sulphated co-
factors also require a concentration gradient of the ligand to initiate the signalling 
cascade (Jullien and Gurdon 2005). The diffuse positioning and binding strengths of 
these HS molecules on the cell surface or in the ECM form this concentration gradient 
and are highly controlled to fine tune cell signalling pathways (Yan and Lin 2009).  
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1.5.1 Injury and changes in sulphation 
The ECM is a supportive network of molecules which can mediate cellular interactions 
(Bowers et al. 2010). The ECM is a fundamental component of any cellular network as it 
is crucial in maintaining homeostasis. The ECM in the CNS also plays a role in the 
mediation of neuronal firing. A major class of molecules dominant in the ECM are the 
proteoglycans (PG) and their bound sulphated GAG. These are major regulators of the 
cellular interactions which occur in the ECM and are major factors in the injury 
environment.  
Once the ECM and the sulphated cell surface GAG become disrupted following trauma, 
they induce sustained dysregulation of the surrounding cellular populations, 
exacerbating the injury. This makes the ECM and associated GAGs an attractive target 
for therapeutic intervention, as ameliorating their detrimental effects on injury might 
limit the pathology of SCI. 
1.5.1.1 GAGs and PGs 
Sulphated GAGs have a negative charge, which then can interact with a diverse set of 
proteins, and are involved in many biochemical processes. PGs are a family of proteins, 
all of which contain a core protein where one or more covalently attached GAG chains 
are bound (Sarrazin et al. 2011). GAGs bound to the PG consist of a linear 
polysaccharide backbone, which are made from repeating units of amino sugars 
specifically, N-acetylglucosamine (N), N-substituted glucosamine (GlcNS) or N-acetyl-
galactosamine (GalNAc) and uronic acid specifically, glucuronic acid (GlcA) or iduronic 
acid (IdoA). The major functions of the GAG-PG are largely determined by the GAG side 
chain, as these dominate the chemical nature of the structure dictating their 
interactions at the biochemical level. GAGs are extremely important in the CNS and are 
characterised based on their disaccharide backbone. The major groups are; chondroitin 
sulphate (CS), heparan sulphate (HS), dermatan sulphate (DS), keratan sulphate (KS) 
and hyaluronic acid (HA) (Cui et al. 2013). The sulphation state of these molecules 
provides a specific charged structure and is key to their binding properties, with each 
CS, HS, DS and KS all having various sulphation state, with HA being the only sulphate 
null GAG (Small et al. 1996).  
HS and CS are the two major abundant GAGs present as PGs throughout the CNS (Swarup 
et al. 2013) commonly referred to as HSPG and CSPG. HS is composed of mainly GlcA 
with some IdoA and has on average one sulphate group per disaccharide unit (Castillo et 
al. 1998), which is far less sulphated moieties compared to its isomer Heparin which 
 
 
39 
 
contains 2.7 sulphate groups per disaccharide unit (Lindahl et al. 1998).  CS is composed 
of GalNAc which is attached to GlcA and IdoA via a glyosidic bond. The sulphation state 
of CS can vary with multiple positions in which the disaccharide can be sulphated, such 
as at 4- and 6- position of the GalNAc and 2- position on GlcA with combinations of 
these creating sub types of the CS (Silbert and Sugumaran 2002).   
Changes in the sulphation state of the GAGs are both cell type and growth condition 
specific. Alterations to the cell environment such as trauma, cause a change in the 
orientation, pattern and level of sulphate moieties present on the GAGs (Swarup et al. 
2013). This change in microenvironment also leads to a change in the presence/level of 
the proteoglycans which in turn alters the availability of the GAGs which are to be 
sulphated (McKeon et al. 1995). 
1.5.1.2 GAG Sulphation 
Sulphation of the GAGs occurs in the Golgi apparatus, with a sequential enzymatic 
process, which adds sulphate moieties to the sugar backbone in a non-template process 
(Silbert and Sugumaran 2002). There are two forms of sulfotransferase (ST) both 
catalysing the transfer of a sulfuryl group (SO3) from the doner molecule to the GAG 
chain (Bishop et al. 2007). Cytosolic ST sulfonate intracellular molecules such as 
hormones and tends to be more promiscuous in their targeting, whilst membrane-
associated ST sulfonate large extracellular molecules such as carbohydrates and tends 
to be more specific in its targeting (Chapman et al. 2004). 
Studies have identified large numbers of ligands which interact with HS but relatively 
few are known for CS, KS and DS, suggesting alternative roles for sulphation of the GAG 
than just ligand interaction (Tumova et al. 2000). 
A factor which may also determine the greater ligand binding capabilities of HS and 
Heparin over their fellow GAG members could be related to the conformational and 
sequence composition of the sugar residues in their backbone (Coombe and Kett 2005; 
Fuerer et al. 2010; Turnbull et al. 2001; Xu and Dai 2010). HS and Heparin have high 
sequence heterogeneity and contain highly modifiable domains in their oligosaccharide 
structure (Turnbull et al. 2001; Xu and Dai 2010). Following the initial binding of a 
ligand, there is a conformational change in the sugar residue position to enhance 
binding, which does not occur in CS, KS and DS. This suggests that there may be more to 
the GAG binding than the sulphation level of the saccharide unit, that the flexibility and 
conformation in the sugar residues play a huge role in ligand interaction. Therefore, 
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studying sulphation in isolation may not provide a complete picture of the whole 
process.  
1.5.1.3 CSPGs and HSPGs in CNS homeostasis and injury 
As mentioned earlier, CSPG and HSPG are the two most abundant proteoglycans present 
in the ECM of the CNS (Swarup et al. 2013). CSPGs have crucial roles in the developing 
CNS. They are highly expressed in the embryonic nervous system and brain. They 
function by providing guidance cues for neurite outgrowth (Masuda et al. 2004). CSPGs 
also negotiate cellular migration and certain classes of CSPG have been shown to aid 
proliferation of neural crest cells in the developing brain (Kubota et al. 1999). 
Moreover, in the mature CNS, CSPGs have been shown to be present at high 
concentrations in the perineuronal nets that occur around the soma and proximal 
dendrites aiding in synapses stabilisation (Miao et al. 2014). The HSPGs are known to 
provide co-factor binding and signal stabilisation for a number of signalling complexes, 
importantly, the growth factors required for proliferation, differentiation and migration 
in the CNS (Bernfield et al. 1999). HSPGs are thought to lead to active growth responses 
in axons (Johnson et al. 2004).  
The field of SCI repair is littered with research focusing on the CSPG involvement in 
injury mechanism, rather than the HSPG aspect. CSPGs have been considered as the 
primary inhibitors of CNS axonal outgrowth and regeneration. CSPGs are highly 
expressed within the glial scar (Buss et al. 2009). Chondroitinase ABC is a potent CSPG 
degrading enzyme showing promise in initiating axonal outgrowth and functional 
recovery following SCI (Bradbury et al. 2002). It is thought that the CSPG are the yin to 
the HSPG yang in axonal growth and guidance (Laabs et al. 2005). There is little 
evidence, however, which clearly shows the HSPGs role during the injury response and 
their role in the chronic phase following the insult (Jones et al. 2003). The role of 
HSPGs in development suggests that HS-mediated signalling could possibility be a factor 
in CNS repair and regeneration. 
1.5.2 Signalling disruption and SCI pathology  
Cell signalling and communication come in many different molecular forms and there 
are a wide variety of signal transmitters ranging from simple gases to complex proteins. 
The signalling range varies with certain signals transmitting over long distances such as 
between organs systems, while others act locally, such as on neighbouring cells. Certain 
signalling cascades are initiated through the release of ligands from neighbouring cells 
but also from the ECM.  
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The ECM houses many ligand depots (binding sites), which can modulate many signalling 
cascades. Therefore, ECM remodelling enzymes can have profound effects on signalling 
cascade activation.  Heparanase is the only endo-glucuronidase found in mammals 
(Vlodavsky et al. 2007). The enzyme breaks down HS specifically, but also other 
Heparin-like structures bound to the cell surface or present in the ECM (Zhang et al. 
2015). Therefore, heparanase is a major ECM remodelling factor, liberating any 
tethered growth factors, immune related factors and enzymes bound to the ECM, 
freeing these to exert their effects on surrounding cells. In addition to releasing bound 
factors, the small HS fragments are able to further interact with additional ligands and 
mediate their activity (Escobar Galvis et al. 2007). Heparanase has been implicated in 
multiple pathologies, including an increased expression by migrating astrocytes in 
cerebral ischemia and even following SCI (Li et al. 2012a) (Zhang et al. 2006).  
The vastly complex molecular signalling mechanisms involved following trauma and 
progression of the pathological state in the CNS remain largely unknown. Many signalling 
pathways have been investigated and are dysregulated after SCI (Fancy et al. 2009) 
(Chen et al. 2005). Following a traumatic event, certain signalling cascades can alter 
the phenotype of a cell. Cellular priming is defined as a state in which an agonist alters 
the phenotype of the affected cell (Friese et al. 1994). Cellular priming can be 
beneficial, in that the altered phenotype attempts to alleviate further spread of the 
injury, as seen with reactive astrocytes following SCI. However, cellular priming can 
also be detrimental, leading to a chronic negative state after injury, as seen with 
activated immune cells present at the site of injury which sustain a pro-inflammatory 
state, leading to further damage to the surrounding spinal cord cells (Fitch and Silver 
2008).   
Many signalling cascades are activated and deactivated during SCI (Abe and Cavalli 
2008). Injury can lead to altered secretion of certain ligands and alterations to the 
expression of certain cell surface receptors. 
1.6 In Vitro models of CNS injury and regeneration  
The complex nature of SCI creates many challenges in the pursuit of identifying 
potential therapies. Many models have been developed with the aim of providing a 
platform to study SCI and the regeneration processes. The history of SCI modelling dates 
back to 1911, with the first documented in vivo experiments using weight-drop 
techniques on dog spinal cord (Allen 1911). In vivo models have been employed to study 
the primary and secondary events of injury and therapeutic potential of novel 
compounds. However, due to the complexity of the in vivo system and the restricted 
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follow up studies due to ethical consideration, this results in investigations of the basic 
underlying mechanisms of any biological process being extremely difficult. To this end, 
in vitro models have been developed to simplify the investigation of complex CNS 
mechanisms. Using both in vivo and in vitro models in parallel create a more complete 
approach to understanding SCI and regeneration. 
In vitro models offer a more controlled study of the cellular and molecular aspect of the 
injury and regenerative process compared to in vivo models. The most common animal 
species employed in SCI research are rodents specifically; rats, mice, gerbils and 
hamsters (Kundi et al. 2013). Rat models are most frequently used as they are 
inexpensive, relatively easy to care for and can be maintained in large numbers. The 
spinal injury response of a rat has been likened to that of humans, specifically the 
occurrence of a fluid filled cyst at the site of injury (Lee and Lee 2013). Mice have been 
employed ever increasingly for SCI modelling due to large transgenic libraries available. 
However, their relative small size limits their use for in vivo studies. Also, the injury 
site begins to shrink over time and there is no fluid filled cyst at the injury site (Inman 
et al. 2002). However, mouse models offer more in terms of genetic studies and genetic 
manipulation. The use of transgenic mice species has provided valuable understanding 
of cellular and molecular aspect of SCI (Lee and Lee 2013). For example a study 
generated transgenic mice expressing multiple fluorescent proteins within neuronal 
populations, allowing detailed imaging of these multiple neuronal populations (Feng et 
al. 2000). In vitro mouse models allow the use of transgenic tissue samples and can be 
harvested so that specific interactions can be investigated in great detail.  
1.6.1 Cell culture techniques 
The major advantage with the use of in vitro models is the ability to monitor the 
progression of neuronal change following the introduction of compounds to injury, with 
the ability to assess these responses in real time. Cell culture techniques can be 
considered complex or simple. A complex cell culture contains multiple different cell 
populations interacting in one dish/well, in contrast to simple cell culture which is the 
study of a single cell type or population, or even a single cell in isolation. 
The study of SCI through cell culture has generated many in vitro models, using a range 
of different tissue sources. Cell culture can also utilise a range of different source 
material from invertebrate system to rodent models. However, cell culture can utilise 
immortalised cell lines (specifically human cell lines) for the study of specific parts of 
SCI pathology including axonal regeneration. Human cell lines allow for a more 
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translatable model for study of effectiveness of drugs and high-through put screening 
for CNS repair and regeneration.  
Simple in vitro models utilise cell lines such as PC12, an pheochromocytoma cell  
(Greene and Tischler 1976). Models have been used with particular focus on neurite 
outgrowth, with studies highlighting the effects of nerve growth factor (NGF) and its 
mechanisms on outgrowth. These studies demonstrated multiple potential mechanisms 
for NGF activity (Kumar et al. 2012) (Wang et al. 2011). Cell lines are often employed as 
a high-through put screening tool, and are used in complex in vitro models for more 
detailed studies (Allen et al. 2005).   
Using the complex culture models usually involves the incorporation of multiple cell 
types. Complex primary cell cultures can be used to study specific differentiated 
cellular functions, such as the more complex biological process myelination (Thomson et 
al. 2008). 
Previously in the Barnett lab, a complex culture system has been set up that is termed 
myelinating cultures. These cultures were devised by C Thomson & A Sørensen 
(Thomson et al. 2008) (Sorensen et al. 2008b). This culture method is a complex system 
which uses a monolayer of neurosphere-derived astrocytes on top of which a mixed 
embryonic spinal cord cell population is seeded. These cultures were modified to 
represent SCI by making a cut across layers of cells using a flat edge scalpel and shown 
to recount many of the features of SCI in vivo (Boomkamp et al. 2012).  
This culture has been used to study the formation of myelin, and the mechanisms 
involved from the perspectives of different cell types. For example, this culture method 
has highlighted the role of astrocytes in the myelination process, displaying a dual 
function of these cells, showing that the phenotypic state, whether quiescent or 
activated determines levels of myelination and this relates to factors the astrocytes 
release (Nash et al. 2011a; Nash et al. 2011b).  Moreover, using these cultures, FGF-9 
has been implicated as an astrocytic factor which inhibits myelination through the 
induction of a pro-inflammatory environment as well as inhibiting OPC maturation, 
resulting in a failure of re-myelination (Lindner et al. 2015).  In addition, this culture 
method demonstrated that OECs and not SCs promote axonal myelination in vitro 
(Lamond and Barnett 2013).  
The development of this culture system into one where injury mechanisms can be 
studied, was established in the Barnett lab (Boomkamp et al. 2012). Here, the 
mechanically induced injury (using flat edge scapel blade) in the myelinating culture 
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has many characteristics of a SCI lesion with focal demyelination, loss of neurite density 
and lack of spontaneous neurite outgrowth. Furthermore, this study demonstrated that 
astrocytes appear reactive with altered morphologies. This new injury culture model 
has been used to demonstrate the therapeutic effect of combinatorial treatment with 
well-known SCI therapeutic compounds. It has been shown that Rho-ROCK inhibitors, C3 
and the ROCK inhibitor Y23627 have a synergistic therapeutic effect, as opposed to 
either compound alone  leading to both increased myelination and promotion of neurite 
outgrowth (Boomkamp et al. 2012). Rolipram was also studied in this culture system and 
evidence of its mechanisms of action was uncovered. Furthermore, Rolipram was shown 
to be an inhibitor of the high-affinity binding site of the cAMP degradation enzyme 
PDE4, and this effect was mediated through the activation of the EPAC pathway, not 
the commonly thought PKA pathway (Boomkamp et al. 2014). This study further 
demonstrated the merit of this culture system through the dissection of individual 
mechanistic pathways following drug treatment.    
1.6.2 Limitations in current in vitro methodologies 
Although in vitro cell culture models have provided great insight into SCI pathology and 
regeneration as detailed above, they are not without their limitations. 
Primary cells are difficult to manipulate and often require specialist training and are 
very time-consuming. Furthermore, depending on the requirement, primary cells can be 
very sensitive to passage, which can lead to both altered phenotypes and senescence 
(Astashkina et al. 2012). Also, primary cells proliferate slowly and have temperamental 
metabolic capacities (Astashkina et al. 2012). However, primary cells are of more 
benefit in functional studies than cell lines. This is due to the fact that they can have 
differentiation properties which are rarely seen in immortalised cell lines, making 
primary cells more suited for toxicity studies (Ekwall 1980).  
Another limitation from in vitro techniques is due to the abnormal cellular organisation 
as the cell is removed from its normal physiological architecture, which could alter 
many cellular processes. The intricate spatial cellular position within tissue is 
fundamental to its purpose as an organ (Greek and Menache 2013). Cells in culture are 
removed from their original structure and organisation, then artificially grow on a 
substrates unlike its original microenvironment (Bhatia and Ingber 2014).  
Conventional cell culture methods have allowed for a deeper understanding of the 
mechanisms of injury and have identified key regulators in these processes. However, 
they lack the ability to precisely control the cellular microenvironment (Whitesides 
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2006). The feeding methodology for cultures are basically the standard ‘bath’ feeding 
where the cultures (whether that is cells on cover slips or tissue sections) are flooded 
with growth media. This growth media creates a molecular equilibrium where each 
individual cellular secretion becomes dispersed throughout the culture media. This does 
not reflect how factors are presented to cells in a normal physiological environment 
with concentration gradients being a feature of many tissue environments. So, to 
estimate the response of a cell in a mixed population creates problems as the in vitro 
environment is ‘contaminated’ with irregular cell communication and cross talk.    
1.6.3 Advancements in in vitro techniques 
New In vitro models of SCI have subsequently been developed with the goal of 
overcoming the limitations of current in vitro models, outlined above. Of particular 
interest are 3D cell culture and lab-on-chip device models. 
1.6.3.1   3D cell culture model of SCI 
A major caveat with in vitro models of SCI is the standard 2D platform in which cell 
culture takes places, whether that is a culture flask or a glass coverslip (Fawcett et al. 
1989). This topography is unnatural and will affect the cultured cells in unknown ways 
causing the cells to act in a way unlike what is seen physiologically. There has been an 
increasing use of 3D culture platforms in CNS in vitro modelling. The aim of 3D cultures 
is to allow the cells to be in an environment which allows a more natural 3D 
conformation of the cell, and not to be deformed by a rigid 2D surface such as glass. As 
previously described, these 2D platforms are not an accurate representation of a normal 
cellular microenvironment (Fawcett et al. 1989).  
A common approach to 3D-like cultures is through the use of basement membrane 
matrices enabling the study of proliferative abilities of differentiated neurons (Ajioka et 
al. 2011), a line of study not possible using standard 2D techniques. 3D micropillars have 
been employed to study the ensheathment by OLs, allowing a high-throughput 
compound screen to be carried out, with focus on concentric wrapping of the OL being 
the parameter measured (Mei et al. 2014).  
1.6.3.2 Lab-on-chip devices 
Lab-on-chip is the broad term for small scale investigations using miniaturised 
compartmentalised cell culture devices. The dimension and precise design of these 
devices allow for the manipulation of the fluidic microenvironment to provide a more 
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accurate representation of the fluidic physiological environment (Andersson and van den 
Berg 2003).   
Lab-on-chip technologies have been used successfully in other areas of research, 
specifically the study of HIV. Engineers at the University of New Jersey have identified a 
method of HIV testing through the development of a lab-on-chip device which uses 
miniscule quantities of expensive chemical assay compounds for identification of the 
virus, potentially reducing the cost of this expensive test (Ghodbane et al. 2015). 
Similarly, this technology could benefit many laboratories in that expensive reagents or 
potential treatments can be used in extremely small quantities. 
The study of axonal injury and regeneration has been advanced in recent years due to 
the advent of the lab-on-chip devices. These devices provide a unique resolution to the 
study of axon specific mechanisms (Taylor et al. 2005). Lab-on-chip devices allow the 
researcher to design highly specific compartmentalisation devices in which to study 
multiple cellular populations interacting or in isolation (Tharin et al. 2012) (Wang and 
Lu 2008). Additionally, they have the ability to manipulate cellular microenvironments, 
through the control of hydrostatic pressure therefore, creating a far more powerful 
technique than standard in vitro methods. Many early lab-on-chip devices overcame 
some limitations created by standard in vitro techniques such as the lack of fluidic 
control and the inability to study cells entrapped in 3D constructs. However, in the 
pursuit of a more representative in vitro model of the in vivo cellular environment an 
even more advanced version of the lab-on-chip has been developed known as organ-on-
chip (Bhatia and Ingber 2014). 
Organ-on-chip is a microfluid device which is aimed at artificially interconnecting the 
different tissue levels found in specific organs. Multiple organs have been studied in this 
fashion including heart, liver and bone (Grosberg et al. 2011; Lee et al. 2007; Zhang et 
al. 2011). Even the different cellular populations found in the spinal cord and BBB can 
be cultured in a multi-chambered device with interconnected microchannels where the 
fluid microenvironment can be manipulated to try to recapitulate the interactions in 
vivo (Booth and Kim 2012) (Achyuta et al. 2013). Theoretically, a multi-chambered 
device could be devised to have several interconnected cell seeding platforms 
containing peripheral dorsal root cells connected to endothelial cells found in the BBB 
to spinal cord cells, mimicking the PNS/CNS divide or dorsal root entry zone. This would 
allow for the investigation of therapeutics at an almost systemic level. The possibilities 
are many with the only limiting factor being the innovation of the researcher. Organ-on-
chip devices are a potentially extremely powerful tool in the study of cellular 
interactions at organ level.  
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1.7 Conclusion 
It is clear that the pathology of SCI is complex. It seems we have only scratched the 
surface of understanding spinal cord trauma and are very much in the dark concerning 
repair and regeneration. The primary and secondary injury cascades have been 
somewhat characterised and research has demonstrated how these lead to the 
formation of the glial scar. The glial scar has been at the centre of therapeutic 
intervention strategies with multiple therapies attempting to overcome the inhibitory 
environment of the glial scar. However, looking at the glial scar as being solely 
detrimental to repair is inaccurate, with studies highlighting the advantages of the glial 
scar in limiting the spread of damage. Other strategies for SCI regeneration have 
focused on many aspects of the injury such as the promotion of axonal outgrowth, 
modulation of the immune response, creation of bioscaffolds and cellular 
transplantation. However, few studies have focused on the sulphation state and the role 
of HS-mediated cell signalling during injury, which could identify HS as a target for 
therapeutic intervention for SCI. SCI research relies heavily on in vitro cell culture 
models of the pathology but current systems fail to completely mimic the injury 
process. However, novel in vitro technologies such as microfluid devices are being 
devised which may better encapsulate SCI processes and provide a greater knowledge in 
the pursuit of fully understanding SCI pathology and regeneration.  
1.8 Aims 
The overall aim of my thesis was to identify novel compounds for the treatment of SCI 
using a well-established neural cell co-culture model of SCI (SCI model). This was 
carried out by the following: 
1) Using the existing SCI model to carry out a medium-through put screen of novel 
therapeutic compounds identified for other applications. Following this, I aimed to 
identify the potential mechanisms of action for potential effective compounds.  
2) Developing a novel in vitro model of SCI where the cells are compartmentalised, 
ultimately allowing therapeutic molecules to be applied to specific groups of cells in 
isolation. This was carried out by the modification of the well-established SCI model in 
combination with a microfluidic device, where the cell bodies are separated from other 
cellular compartments e.g. the axonal compartment, so that drugs or cells could be 
directly applied to either the neuronal cell bodies or to the axonal compartment.   
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2 Materials and Methods       
2.2 Neurosphere and astrocyte culture 
Neurospheres (NS) were generated by harvesting of the striata from 1-day-old Sprague 
Dawley rat forebrains, modified from the method developed by (Reynolds and Weiss 
1996). The tissue was triturated using a glass pasture pipette in L-15 media (Invitrogen, 
Paisley, Scotland). The newly homogenised tissue was centrifuged at 1200 revolutions 
per minute (rpm) for 3 mins. The supernatant was removed and the pellet resuspended 
in 20 ml neurosphere media (NSM) containing Dulbecco's Modified Eagle Medium/F12 
(DMEM/F12, 1:1, DMEM containing 4,500 mg/L glucose), enriched with 0.105% NaHCO3, 
L-glutamine, 5,000 IU/mL penicillin, 5 µg/mL streptomycin, 5.0 mM HEPES (all from 
Invitrogen, Paisley, Scotland), 100 µg/mL apotransferrin, 25 µg/mL insulin, 60 µM 
putrescine, 20 µM progesterone, and 30 µM sodium selenite, supplemented with 20 
ng/ml of Epidermal growth factor (EGF) (Peprotech,UK). The cell suspension was 
transferred to an uncoated T753 vented flask (Greiner, Stonehouse, UK) and incubated 
at 37oC in an atmosphere of 7% CO2/93% air. The culture was fed every 2-3 days with an 
addition of 5 ml NSM and 4 µl EGF(20 ng/ml). Following 5-7 days in culture (when 
cellular spheres are visible), the suspension was triturated using a glass pasture pipette 
to produce a smaller cell sphere suspension. The cells were centrifuged at 1200 rpm for 
3 mins. Removing the supernatant and adding 10% foetal bovine serum with 2 nM l-
glutamine the cells were triturated for a final time. The suspension was transferred to 
13 mm poly-L-lysine (PLL) coated coverslips in a 24-well plate, where they were 
incubated for a further 5-7 days at 37ºC in an atmosphere of 7% CO2/93% air, until a 
confluent monolayer of cells was present.  
2.3 Myelinating spinal cord culture 
The protocol for generating the myelinating co-culture was based on, with some 
alterations, the model previously developed (Sorensen et al. 2008a). The pregnant 
female was culled using CO2 overdose followed by removal of uterus containing embryos 
via cervical dislocation. The embryos were removed from the amniotic sac and 
transferred to a dish containing L-15 media (Invitrogen, Paisley, Scotland) and the 
cranial section (5-6 mm) of the spinal cord was dissected. The cords were then 
transferred to a fresh dish containing L-15 media, the meninges were stripped and the 
exposed cord placed on ice in a vial containing 1 ml L-15 media. Four-six cords were 
placed per 1 ml vial per cell preparation. The cords were mechanically disassociated by 
trituration using glass pasture pipette, then enzymatically by incubation with trypsin 
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(100 µl of 2.5%, Invitrogen) and collagenase (100 µl of 1.33%, ICN Pharmaceuticals, 
Basingstoke, UK), for 15 min. The enzyme activity was stopped by adding 1 ml of a 
solution containing 0.52  mg/ml soybean trypsin inhibitor, 3.0 µg/ml bovine serum 
albumin and 0.04 mg/ml DNase (SD, Sigma). The cell suspension was triturated to 
ensure complete enzymatic activity was stopped, and then centrifuged for 5 mins at 800 
rpm. The pellet was re-suspended in 2 ml plating media (PM) containing  50% DMEM, 25% 
horse serum, 25% Hanks balanced salt solution (HBSS) with Ca2+ and Mg2+, and 2 mM L-
glutamine (Invitrogen). The astrocyte monolayer coverslips were removed from the 24-
well plates and transferred to a sterile 35 mm Petri dish prior to spinal cord mix being 
added. The disassociated spinal cord cells used for standard myelinating culture were 
plated onto coverslips supporting the astrocyte monolayer at 300,000 cells per 50 µl. 
The cells were left to adhere for 2 hours at 37ºC then supplemented with 300 µl PM and 
500 µl differentiation medium which contained; DMEM (4,500 mg/mL glucose), 10 ng/mL 
biotin, 0.5% hormone mixture (1 mg/mL apotransferrin, 20 mM putrescine, 4 mM 
progesterone, 6 mM selenium (formulation based on N2 mix of (Bottenstein and Sato, 
1979) 50 nM hydrocortisone), and with or without the addition of 0.5 mg/mL insulin 
known as DM+ (insulin positive) or DM- (insulin negative) (all reagents from Sigma). Each 
culture dish containing the myelinating culture was fed 3 times a week by removing 400 
µl and adding 500 µl fresh DM+ for the first 12 days, then DM- for the proceeding 12+ 
days. Cultures were sustained for 24+ days in an atmosphere of 7% CO2,
 93% air, at 37ºC.    
2.4 Injury induction 
For injury experiments, 24 day old myelinating cultures were subjected to a lesion 
created by an 11 mm single edge razor blade (WPI, Aston, UK). The culture which was 
to be injured was first removed from the culture dish and placed on a sterile blue roll. 
Then, in a guillotine-like fashion, the blade was lowered to the surface of the coverslip 
and with little pressure, the lesion occurs before finally returning the coverslip back to 
the dish.  Injured cultres were treated where appropriate, 1 day post injury (25 DIV). 
Treatment stratagies were either; 1 single treatment with two further recovery feeds 
(modified heparins) or 3 treatments administered over the course of a week (ROCK 
inhibitors). 
2.5 Oligodendrocyte progenitor cell and microglia 
culture 
Generation of Oligodendrocyte progenitor cell (OPC) and Microglia (MG) culture was 
performed by isolating the floating cell fraction of 7 day old cortical astrocyte cultures. 
The cortical-derived astrocytes were generated by dissecting the outer layers of the 
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cortex from postnatal day 1 (P1) Sprague Dawley rat pups, as previously described 
(Noble and Murray, 1984) with slight modifications. The tissue was placed in a vial 
containing L-15 media then triturated and incubated with collagenase (500 µl 1.33%) for 
20 min at 37ºC. The reaction was stopped as described previously with SD, and 
centrifuged at 1200 rpm for 3 mins. The cellular pellet was re-suspended in 10% FBS 
DMEM and cultured for 5-7 days in a PLL-coated T75 vented flask before the floating 
fraction was collected. The culture was fed 3 times a week with removal of 4 ml and 
adding 5 ml 10% FBS. The OPCs and MG were detached following controlled agitation of 
flasks, followed swiftly by plated onto a 90 mm culture dishes for 15-20 min allowing 
separation of OPCs from MG (and other glia cells) due to differential adhesion. The OPCs 
remained in the supernatant, which was removed, centrifuged at 1200 rpm 5 mins, 
resuspended in Sato media (adapted from Bottenstein and Sato, 1979) containing 0.5 
mg/ml insulin in 10 mM HCL (Sigma, UK), glutamine (100 mM; Sigma, UK, human 
transferrin (Sigma, UK) and gentamycin (100 mg/ml; Sigma, UK), supplemented with the 
growth factors; fibroblast growth factor (FGF-2) at 10 ng/ml and platelet derived 
growth factor (PDGF) at 2 ng/ml (both Peprotech, UK). The OPCs were cultured in the 
presence of the growth factors for 5 days, before incubation in Satos media alone +/- 
the required treatment for the duration of the experiment. Similarly, with the MG, the 
difference being cultured in 10% FBS containing DMEM high glucose 4.5 g/l for the 
entirety of the experiment, even at the stage of required treatment. The pure OPC and 
MG culture was then counted using a haemocytometer and seeded into a 24-well plates 
containing PLL-coated coverslips at a density of 5,000 cells in a volume of 50 µl at 37ºC 
for 15 mins to allow cells to attach. Then an additional 400 µl of Sato media or 10% FBS 
high glucose (MG) was added to each well. Both cultures were fed 3 times a week with 
the removal of 250 µl and the addition of 300 µl. 
2.6 Microfluidic device preparation 
The microfluidic device was fabricated in polydimethylsiloxane (PDMS) using soft 
lithography. A positive replica mould was produced using thin sheet silicon and two 
patterned layers of SU8 photoresist (3000 series, MicroChem, US). The first layer 
contained the positive relief patterns of the microchannels connecting the three 
chambers resulting in a thickness of 7 µm. The second layer contained the positive 
relief patterns for the cell reservoirs resulting in a final thickness of 9 µm. The positive 
silicon relief master (master) was then exposed to ultra vilot (UV) light and developed 
in a photomask (JD PhotoTools, UK) and MicroPosit EC solvent (Rohm and Haas, US). In 
addition the master was silanised by vapour deposition of 1H,1H,2H,2H-perfluoroctyl-
trichlorosilane (Sigma Aldrich, UK) for 1 hour. The PDMS (Dow Corning) was cast onto 
the master with the PDMS at a base to curing agent ratio of 10:1 at 80ºC for 3 hours. 
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After curing the PDMS was peeled off the master cut to size (approx. 24 mm by 60 mm) 
and punched out the cell reservoir chambers with 6 mm diameter biopsy punch (Stiefel, 
UK). The newly formed device and coverslip (where the device is to be mounted) was 
sterilised in 70% ethanol for 90 seconds in a sonication bath. The device assembly was 
initiated by firstly exposing the two surfaces, the coverslips and PDMS device (micro-
patterned size up) to plasma by placing them in an O2
 plasma machine, settings at 50% 
power and exposed for 6 seconds. The two surfaces are now coated in plasma and ready 
for bonding. Bonding was done by very carefully lifting the PDMS and inverting it so the 
patterned surface will meet the coverslip, then lowered the PDMS down and with slight 
pressure bonding occurred instantly. PLL coating of the devices was done by adding 100-
200 µL per well.  Coating needed to occur within 30 mins of O2 plasma exposure whilst 
the PDMS was temporarily hydrophilic (so the PLL will coat the chambers and 
microchannels), left for 1.5 hours at 37ºC. PLL solution was washed from all wells with 
dH2O, making sure not to allow the device to dry out. The devices were finally sterilised 
under UV for 45 mins. 
 
2.7 Microfluidic device cell seeding 
Prior to cell seeding, the cell reservoirs are washed with appropriate medium 
(astrocyte-10% FBS, neurons-DM- or OPC-enriched Satos medium). The devices were 
placed in individual Petri-dishes (9 cm diameter, two devices per dish). The surrounding 
area of the dish was flooded with 5-10 ml of medium (5x gentamycin concentration). 
Following the previously described astrocyte and spinal cord cell preparation (sections 
2.1 and 2.2) with only slight modification. Neurospheres were cultured, and then 
differentiated into astrocytes using 10% FBS in a T75 culture flask prior to seeding into 
the device. Astrocytes were trypsinised centrifuged at 1200 rpm for 3 mins, then re-
suspended in 1 ml of 10% FBS, and counted using a haemocytometer. Astrocytes were 
seeded at a concentration of 4*103/µl per reservoir chamber. Before seeding the 
astrocytes the resident media in the devices was removed leaving some residue, so not 
to dry out the device and the cell suspension was pipetted into the inlet reservoir. The 
cell suspension flooded into the chamber and cells attached to the PLL surface, and 
were left for 1 hour to allow full adhesion before being filled with fresh culture 
medium, 200 µL per well. Cultures were incubate and fed as instructed previously 
(section 2.1) in an atmosphere of 7% CO2
 93% air at 37ºC. Seeding of disassociated spinal 
cords cells into the devices followed the same cell preparation method as descried 
previously (section 2.2), creating a final cell concentration of 1.5x105 in each cell 
chamber  
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2.8 Nanofiber preparation  
Polycaprolactone (PCL) electrospun nanofibers (Nanofiber Solutions, Ohio USA) were PLL 
treated the same as standard glass cover slips. Both aligned and random 700 nm 
diameter fibre 24-well culture inserts and 96-well culture plates were used for OPC/OL 
myelination experiments.    
2.9 Western Blotting 
The western blotting method, involving injured cultures required three lesions per 
coverslip. Cultures were lysed using lysis buffer (Millipore, Watford, UK) and the protein 
concentration calculated using the NanoDrop spectrophotometer (Thermo Scientific, 
USA). To harvest the cell lysates, 40 µl of CellLytic M Cell Lysis Reagent was added to 
each coverslip and incubate at room temperature (RT) for 10 mins, followed by 
scrapping of the cells with a 21G needle, and transfer of lysate to an eppendorf tube 
where the cells were triturated with the same 21G needle. Protein concentrations were 
calculated using Nanodrop (Protein A280, 1 Abs=1 mg/ml). Protein samples (10 µg 
protein per lane) were prepared per well in 6 µl of 43 Laemmli sample buffer and 2.4 µl  
NUPAGE reducing agent 103 (Invitrogen) at 80ºC for 10 mins.  The samples were run on a 
NUPAGE NOVEX Tris-acetate gel (4–12%; Invitrogen) at 200 volts for 45 mins. The gel was 
then transferred to a PVDF membrane using the iBlot Western Detection system 
(Invitrogen, Paisley, UK). The membrane was incubated in blocking buffer containing 5% 
skimmed milk powder and 0.2% Triton-X100 in PBS (PBS-T) overnight at 4ºC. The 
membranes were then incubated with primary antibody (Table 2.1) diluted in blocking 
buffer for 1 hour at RT on an orbital shaker. Following three wash steps for 5 mins each 
in PBS-T, the blots were incubated with the appropriate horse radish peroxidise-
conjugated secondary antibodies for 1 hour at RT on a shaker. After three washes in 
0.2% Triton-X100 and a final wash in PBS, the membranes were treated with ECL-plus 
(1:1, Amersham, GE Healthcare, UK), and exposed to film (Amersham). The intensities 
of the protein bands were determined using densitometer Gels tool on Image J 
software. 
2.10 Immunohistochemistry 
For cell surface antigen labelling, the cultures were incubated with primary antibodies 
(diluted in relevant media) for 20 mins at RT (Table 2.1). Cells were washed in PBS and 
incubated with the appropriate secondary Alexa fluorophore-conjugated antibody 
(diluted in relevant media) (Table 2.2) for 20 mins at RT. The cells were fixed in ice-
cold methanol for 15 mins in the freezer. For co-labelling with intracellular antibodies, 
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cells were washed in PBS and incubated with primary antibodies, diluted in blocking 
buffer (containing PBS with 0.1% Triton X-100 and 0.2% porcine gelatine) for 45 mins at 
RT. The coverslips were washed with PBS and the appropriate secondary Alexa 
fluorophore-conjugated antibodies added for 45 mins at RT. The cells were washed in 
PBS followed by dH2O and mounted in Vectashield (Vector Laboratories, Peterborough, 
UK) and sealed with nail varnish or HardMount. For intracellular labelling alone, the 
cultures were fixed in 4% paraformaldehyde for 20 mins at RT followed by washes in PBS 
and permeabilization in 0.2% Triton- X100 for 15 mins at RT. The cultures were washed 
3 times in PBS. The primary antibodies were added, diluted in blocking buffer, and the 
cells incubated for 45 mins at RT. After 3 washes in PBS, the cultures were incubated 
with the appropriate secondary antibodies at RT for 45 mins. The cells were washed in 
PBS followed by dH2O, mounted in Vectashield (Vector Laboratories, Peterborough, UK) 
and sealed with nail varnish or Hardmount.   
Table 2-1 Primary Antibody List 
 
Antigen Raised in Isotype Dilution Fixation 
method 
Internal/ 
External 
Source 
AA3 
(PLP) 
Rat IgG1 1:100 4% PFA Internal Hybridoma 
SMI31 Mouse IgG1 1:1500 4% PFA Internal Abcam 
MBP Rat IgG2a 1:100 4% PFA Internal Abcam 
A2B5 Mouse IgM 1:1 Ice cold 
methanol 
External Hybridoma 
04 Mouse IgM 1:1 Ice cold 
methanol 
External Hybridoma 
NG2 Rabbit IgG 1:200 Ice cold 
methanol 
External Chemicon 
GFAP Rabbit IgG1 1:1000 4% PFA Internal DAKO 
Nestin Mouse IgG1 1:200 4% PFA Internal Abcam 
BrdU Mouse IgG1 1:20 Ice cold 
methanol 
Internal DAKO 
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Table 2-2 Secondary Antibody List 
Antibody Conjugate Dilution Source 
Goat anti-mouse IgG1 Alexa Flour: 555 
and 488 
1:600 Molecular Probes 
Goat anti-mouse IgM Alexa Flour: 555 
and 488 
1:600 Molecular Probes 
Goat anti-rat IgG Alexa Flour: 488 1:600 Molecular Probes 
Goat anti-mouse IgG2a FITC 1:100 Southern Biotech 
Goat anti-rabbit IgG Alexa Flour: 488 1:600 Molecular Probes 
 
2.11 BrdU immunohistochemistry 
For the detection of proliferating cells Bromodeoxyuridine (5-bromo-2’-deoxyuridine), 
BrdU, was employed (BD Bioscience). BrdU is incorporated into newly synthesised DNA 
or replicating cells. During S-phase replication BrdU can also be delivered to daughter 
cells therefore, tagging any cell which are in a proliferative state. Using this technique 
in our culture system, BrdU (5 µg/ml) was added to the medium and left for 18-24 
hours. The BrdU-treated cultures were washed in PBS, prior to fixing the cells in ice 
cold methanol for 10 mins at -20ºC. This was followed by mild permeableization in PBS-
T and brief fixation in 0.02% PFA for 1 min at RT. The coverslips were washed and 
incubated in fresh 0.07 M NaOH diluted in PBS-T at RT for 10 mins. In addition to 
detection of proliferating cells via antibody detection of the incorporated BrdU co-
staining can be performed, staining for any desired marker to confirm cell specific 
proliferation. Anti-BrdU (BrdU, mouse, 1:20) was added for 45 mins at RT. After another 
washing step, Goat anti-mouse (Alexa 488, 1:500) was added for 30 mins at RT. The 
coverslips were the mounted in Vectashield with DAPI (Vector Laboratories, 
Peterborough, UK).       
2.12 Microscopy and Image analysis 
Cells were imaged using Olympus BX51 or LAS AF Leica DM4000 B fluorescence 
microscopes, a Zeiss LSM 510 confocal microscope or an Etaluma Lumascope 500 
inverted fluorescent microscope. For quantitative analysis of injury; neurite density, 
myelination and neurite outgrowth, the entire lesion site was imaged adjacent (0–670 
µm from the lesion edge) to the actual injury site with each condition being blinded to 
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the experimenter. Similarly, for the non-injury quantification of neurite density and 
myelination, each condition was blinded to the experimenter and standardised random 
sampling was performed. For cell counting analysis (OPC/OL, MG and astrocyte) 20x 
magnification was used with 10 images per coverslip and the cells of interest counted 
per field of view and divided by the total number of DAPI-positive cells. For neurite 
density, myelination and neurite outgrowth studies images were taken at 10x 
magnification with 20 images per coverslip (with each experimental sample contained 
technical triplicates). 
2.13 Myelination quantification 
Firstly neurite density was quantified using CellProfiler Image Analysis software (Broad 
Institute). The pixel value for SMI-31 immunoreactivity was measured by dividing that 
pixel threshold level by the total number of pixels. We refer to all SMI-31-positive 
processes as neurites and processes ensheathed by myelin as axons. To calculate the 
percentage of myelinated axons, immunoreactivity associated with PLP (AA3) positive 
myelin sheaths was also measured using CellProfiler Image Analysis software. A pipeline 
program which tracks the myelin sheaths over axons, and the percentage of myelin 
calculated using the area obtained for the highlighted myelin divided by the area. All 
experiments were carried out at least three times using technical duplicates. For 
intensity studies specific marker staining was calculated using ImageJ software by 
measuring the integrated density of the individual colour per image and normalizing the 
value to the number of DAPI-positive nuclei. Cell size was determined using ImageJ 
software and a sample of cells were taken per image and drawn around using a define 
region of interest size, then the area calculated by threshold intensity. 
2.14 Neurite outgrowth and lesion size 
quantification 
A neurite outgrowth was defined as a SMI-31 positive projection with enters and crosses 
the lesion site. Each image was subject to scoring of each neurite which crosses the 
lesion site, any areas which appear to be uninjured they are excluded from the analysis. 
The number of neurites per images was then averaged across the lesion and given as a 
number of neurite per field of view. Using the same images the length of the lesion was 
calculated using ImageJ software. Multiple points per images were measured and 
averaged across the entire lesion per condition.  
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2.15 Statistical analysis 
Graphpad Prism software was used for data presentation and statistical testing. For 
simple comparison paired-students t-test was employed to determine statistical 
significance. For multiple condition comparisons One-way repeated measures ANOVA 
test was employed to data sets followed by Dunnett’s multi-comparison test to 
calculate potential significant difference. Asterisks are used to represent significance 
less than *p<0.05, **p<0.01, **p<0.001 and inserted onto graphed data. All errors are 
depicted as standard errors of the mean (SEM).  
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Chapter 3 
Neural co-culture model of SCI as a medium 
throughput screening tool for therapies in 
SCI repair 
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3 Introduction 
The processes underpinning SCI and regeneration are complex and it is possible that 
there are many potential therapeutic targets.  To test these compounds in vivo requires 
large numbers of animal cohorts which have ethical and practical problems. This has led 
to the development of in vitro throughput screening tools (Krishna et al. 2014), using 
primary animal tissue for the rapid assessment of therapeutic compounds for SCI 
regeneration. 
A challenge in developing an in vitro screen to identify potential regenerative 
therapeutics is the complex neurobiology underlying CNS injury, as this is not 
completely understood and cannot be completely modelled by an in vitro system 
(Fawcett and Asher 1999). However, SCI involves several global processes that can be 
encapsulated in vitro including, but not limited to, focal demyelination from OL cell 
loss, OPC proliferation/differentiation, focal neurite density loss, neurite retraction and 
lack of outgrowth (Boomkamp et al. 2012).  
Classically, compound screens involved the investigation of multiple compounds to one 
specific target or pathway. However, in this study we modified this approach by 
employing several compounds targeting different processes involved in SCI and repair in 
order to ascertain which processes were the most responsive to therapeutic 
intervention. The SCI model first described in (Boomkamp et al. 2012) can be employed 
for this purpose by providing a collection of experimental parameters; myelination, 
neurite density and neurite outgrowth. These parameters were examined following 
exposure of the culture to a set of 5, potentially therapeutic, compounds. These 
compounds were selected for this screen as they have shown therapeutic benefit even 
though not exclusively related to CNS injury. Table 3.1 provides a short description of 
the compounds that were used in the screen.  
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Table 3-1 Compounds screen candidates 
Compound 
Name 
Previous 
effects 
Provided by 
Published 
findings  
Predicted cellular 
target 
A specific ROCK 
inhibitor: 
SC336 
SC76 
SC96 
Stem cell 
survival 
Dr. J. 
Mountford 
Under 
patent 
Multiple cellular 
targets 
Olfactory 
ensheathing cell 
conditioned 
media 
Promotion of 
myelination 
Current lab 
members 
(Lamond 
and Barnett 
2013) 
OPCs and neurons 
Modified 
Polysaccharides 
(chemically 
modified 
Heparin) 
Reduction of 
Astrocytosis  
Dr. J. Turnbull 
(Higginson 
et al. 2012) 
ECM/cell surface 
 
3.1 Aims 
The primary aim of this study was to identify novel compounds in CNS repair and 
regeneration. This was be carried out by screening a diverse set of compounds at a 
range of concentrations, using the SCI model. 
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3.2 Results 
3.2.1 Novel ROCK inhibitors’ role in CNS repair and regeneration 
Rho-kinase (ROCK) is a serine/threonine kinase and a major downstream effector of the 
small GTPase Rho. Rho-GTPases are molecular switches which regulate signal 
transduction and 20 Rho-GTPases have been described. The ROCK pathway is involved in 
many cellular functions specifically controlling the actin cytoskeleton, microtubule 
dynamics and membrane transport, leading to regulation of cellular behaviour, 
proliferation, migration and morphology (Nobes and Hall 1999). The ROCK pathway is 
involved in the stabilisation of the actin cytoskeleton, through the inactivation of 
myosin light chain phosphatase, which leads to an accumulation of phosphomyosin, 
which in turn induces cytoskeletal reorganisation (Coleman et al. 2001).  Most 
importantly, the inhibition of ROCK has been associated with functional recovery in SCI 
(Chan et al. 2005).  
The diverse roles of Rho-ROCK within the cell and the plethora of dysregulations 
observed at the injury site suggest that this pathway may be implicated in the injury 
response with changes observed in both neurons and glia. In particular, it has been 
associated with increased proliferation states seen in astrocytes and OPCs (McTigue et 
al. 2001) (Bush et al. 1999), changes in cellular behaviour and migration as seen with 
microglia invasion and activation to phagocytic macrophages to the injury site (Carlson 
et al. 1998) (Rolls et al. 2008) and microtubule depolymerisation leading to neurite 
retraction and lack of neurite outgrowth.  
It is well documented that there are three injury-related myelin-associated inhibitors of 
axonal outgrowth signalling through the Rho-ROCK molecular switch; Nogo, myelin-
associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein (OMgp) (Mimura 
et al. 2006). Each have different initial activation mechanisms (Filbin 2003) but 
converge on the activation of the ROCK response to actin/microtubule rearrangement 
and subsequent lack of neurite outgrowth. Previous studies have looked to the use of 
ROCK inhibitors for therapeutic use in SCI (Fournier et al. 2003) (Chan et al. 2005). 
However, our collaborators have provided three novel ROCK inhibitors (SC76, SC96 and 
SC336), each of which show a highly specific inhibition of the ROCK pathway 
(unpublished data) compared to that of Y27632. Thus, it has been hypothesised that 
these inhibitors would be more useful in SCI treatment as they are more specific 
inhibitors of the ROCK pathway. The ROCK inhibitors used in this screen were shown to 
have high specificity targeting only the ROCKII pathway identified using a kinase array. 
The results of this kinase array are currently in preparation for publication and the 
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compounds are currently undergoing the patenting process. Therefore, the specifics and 
actual results of the kinase array and the chemical composition cannot be divulged. 
3.2.1.1 Result: ROCK inhibitor  
The SCI-myelinating culture was established as described previously (Boomkamp et al. 
2012). Briefly, the myelinating cultures were incubated until day 24 before then being 
injured using a flat edged scalpel blade. The injury created a focal decrease in neurite 
density and myelination levels adjacent to the lesion. The cultures were treated with 
the ROCK inhibitors at a range of concentrations as advised by Dr. J. Mountford – SC76: 
30 nM and 45 nM, SC96: 15 nM, 30 nM and 45 nM and SC336: 25 nM, 50 nM and 75 nM, 
from day 25 to day 31. The cultures were then fixed at day 33 and stained for the 
myelin marker, PLP, and the neurofilament marker, SMI31. The cultures were imaged 
using an Axio fluorescent microscope at a 10x magnification, adjacent to the cut site as 
described in (Boomkamp et al. 2012) for the entire lesion length. Neurite density was 
calculated based on the SMI31 pixel intensity compared to the total pixels per image. 
Myelination was quantified by calculating the percentage PLP pixel staining overlying 
the SMI31 staining but only at a uniformed longitudinal structure with predetermined 
dimensions. Neurite outgrowth was analysed by scoring the neurites that were seen 
entering and crossing the lesion site. Images were taken by focusing on the lesion site 
with each neurite which entered and crossed the lesion classified as ‘outgrowth’.  
Untreated control cultures had neurite density and myelination scores of 35.3% and 5.8% 
respectively (Fig.3.1.G and H). Treatment of the injured cultures with inhibitor SC76, 
led to increased neurite density and myelination compared to untreated controls 
(Fig.3.1. G and H). Neurite outgrowth showed a promotion at 45 nM (Fig.3.2. D) with an 
average increase of 16 neurites per field of view.  
Inhibitor SC96 promoted neurite density at 15 nM but a decrease was observed at 30 nM 
and 45 nM with density levels dropping below those of the control to 29.6% and 31.2% 
respectively (Fig.3.3.). An increase in myelination was observed at all concentrations of 
SC96 (Fig.3.3. I and J). No promotion of neurite outgrowth was observed with SC96, 
with neurite outgrowth not exceeding control levels (Fig.3.4.E).  
The ROCK inhibitor SC336 did not have any observable positive effects on neurite 
outgrowth at any concentrations tested (Fig.3.6.E). Treatment with 50 nM appeared to 
cause an increase in neurite density (Fig.3.5.B and I), however, at the same 
concentration there is a marked decrease in myelin levels (Fig.3.5 G and J). Treatment 
with the 25 nM concentration had no apparent effect on either neurite density or 
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myelination with levels similar to that of control (see Fig.3.5.B,F and I-J). SC336 at 75 
nM appears to promote myelination, however, no increase in neurite density was 
observed (Fig.3.5.I and J). 
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Figure 3.1 ROCK inhibitor SC76 promotes both neurite density and myelination following 
injury.  
The myelinating cultures were injured after 24 DIV and treated with ROCK inhibitor for a 
further 5 days. The ROCK inhibitor was used at two concentrations 30 nM and 45 nM with 
both showing a trend towards promotion of neurite density (SMI31, Red) and myelination 
(PLP, green) relative to the untreated control (A and D). SC76 at a concentration of 30 nM (B 
and E) was more potent than 45 nM as the former had greater increase of neurite density 
and myelination adjacent to the lesion (G and H) (C and F). N=2 and error bars-SEM, scale 
bar-25 µm.  
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Figure 3.2 ROCK inhibitor SC76 promotes neurite outgrowth at 45 nM concentration. 
Neurite extension was assessed by scoring the number of neurites which cross the lesion 
site, marked by dashed line and identified by a decrease in the nuclei density (DAPI, blue) 
seen down the entire cut area (A- control). SC76 at 45 nM (C and D) appears to promote 
neurite extension following a 5 day treatment course with neurite numbers above that of cut 
control. There was no recorded difference to the number of neurite (SMI31, red) which cross 
the lesion following the same treatment at 30 nM (B and D) when compared to control (A). 
N=2,  error bars-SEM, scale bars-25 µm.  
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Figure 3.3 ROCK inhibitor SC96 elevates and myelination following injury. 
Following a 5 day treatment with SC96 at a range of concentrations from 15 nM-45 nM, 
neurite density (SMI31, red) was promoted at 15 nM only (B-D and I). However myelination 
(PLP, green) was promoted at all concentrations (F-H and J).  N=2, and error bars -SEM, 
scale bar-25 µm. 
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Figure 3.4 ROCK inhibitor SC96 does not promote neurite extension at any concentration 
Treatment with SC96 at concentrations of 15 nM-45 nM did not have any effect on neurite 
outgrowth (B-D). The number of neurite scored crossing the lesion site did not surpass that 
of control (A and E). Lesion marked by dashed line and identified by a decrease in the nuclei 
density (DAPI, blue) seen down the entire cut area (A). N=2, and error bars -SEM, scale bar-
25 µm. 
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Figure 3.5 Inhibitor SC336 elevates both neurite density but myelination is unaffected. 
The myelinating cultures were lesioned at 24DIV and treated with inhibitor SC336 for a 
further 5 days. The inhibitor was used at three concentrations 25, 50 and 75 nM, with only 50 
nM having any effect. A potential promotion of neurite density (SMI31, Red) at 50 nM occurs 
(C, I) but myelination (PLP, green) was seen to decrease to levels below control (E, J). 25 nM 
and 75 nM (B and D, F and H) did not have an effect on either neurite density or myelination 
(I and J). N=2 and error bars-SEM, scale bar-25 µm. 
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Figure 3.6 Inhibitor SC336 does not promote neurite extension after injury.  
Following a 5 day treatment at no concentration used displayed any promotion in neurite 
extension (B-D, E), with number of neurites per field of view not surpassing control levels 
(A-D, E). Lesion site marked by dashed line (A) and a decrease in the nuclei density (DAPI, 
blue) observed down the entire area. N=2 and error bars, SEM, scale bar-25 µm. 
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3.2.2 Repair and regenerative properties of olfactory ensheathing 
cell conditioned media  
Glial cell transplantation is a promising approach to SCI repair. Both in vitro and in vivo 
studies have outlined various modes of function for OECs in the repair process (Kocsis et 
al. 2009). OECs are a unique glial cell type which can myelinate axons of a small 
diameter and support the growth and regeneration of olfactory neurons (Fairless and 
Barnett 2005). Although OECs have been shown to have similar characteristics 
astrocytes and Schwann cells, they appear to have advantages over these cells for CNS 
repair (Barnett and Riddell 2004). OECs have been shown to provide trophic support to 
surrounding neurons through the secretion of; NGF, BDNF, GDNF, and FGF (Lipson et al. 
2003).   Interestingly, OECs have been shown to actively migrate to the injury site. A 
study demonstrating TNF-α was secreted by reactive astrocytes which could attract 
OECs to the site of injury (Su et al. 2009). Many studies discuss the beneficial 
interaction, in terms of CNS repair, of the OECs on the surrounding neuron and glial 
populations. For example, they can intermingle with astrocytes, downregulate GFAP 
(Lakatos et al. 2003) and do not induce astrocyte hypertrophy (Lakatos et al. 2000).  
In this screen we treated injured myelinating cultures with OEC conditioned medium 
(OEC-CM) to investigate if the beneficial associated processes for repair reported in the 
formentioned study occur from an OEC secreted factor as opposed to direct cellular 
interaction. OEC-CM has been shown to be beneficial in the development of myelin in an 
in vitro model (Lamond and Barnett 2013). If a promotion in myelination, neurite 
density and outgrowth is observed following the treatment with OEC-CM, this would 
merit further investigation into the exact composition of the medium to identify 
components which may be driving the repair processes recorded.  
3.2.2.1 Result: OEC-CM promotes both neurite outgrowth and myelination 
following injury 
The SCI model was followed as described previously (Boomkamp et al. 2012). Briefly, 
the myelinating cultures were incubated until day 24 before then being injured using a 
flat edge scalpel blade. The injury created a focal decrease in neurite density and 
myelination levels adjacent to the lesion. The cultures were treated with OEC 
conditioned medium at 1:2 and 1:4 dilutions with standard DM- culture media (see 
Materials and Methods section 2.5), at day 25 until day 31, treating every other day. 
The cultures were then fixed at day 33 and stained for the myelin marker, PLP and 
neurofilament marker, SMI31. The cultures were imaged using an Axio fluorescent 
microscope at a 10x magnification, adjacent to the cut site as described in (Boomkamp 
et al. 2012) for the entire lesion length. Neurite density was calculated based on the 
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SMI31-red pixel intensity compared to the total pixels per image. Myelination was 
quantified by calculating the percentage PLP-green pixel staining overlying the SMI31-
red staining only at a uniformed longitudinal structure with predetermined dimensions. 
Neurite outgrowth was analysed by scoring the neurites that were seen entering and 
crossing the lesion site. Images were taken by focusing on the lesion site with each 
neurite which entered and crossed the lesion classified as ‘outgrowth’.  
OEC-CM treated cultures following injury promoted both myelination and neurite 
density at both 1:4 and 1:2 relative to untreated controls. The ratio of 1:4 promoted 
myelination to a greater percentage over 1:2, with myelin levels reaching 11.3% and 
6.45% respectively (see Fig.3.7 B, C and E, F). However, following treatment with OEC-
CM at 1:2, the cultures had a slightly higher neurite density percentage adjacent to the 
lesion compared to 1:4, with density levels increasing to 44.9% and 41.4% respectively.  
Following treatment with both dilutions of OEC-CM, there was a promotion of neurite 
outgrowth compared to controls (Fig.3.8. C,D)  with 1:2 and 1:4 ratios increasing the 
number of neurite per field of view to averages 12 and 18 neurites per field of view 
respectively compared to average untreated control levels of 5 (Fig.3.8. D).  
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Figure 3.7 OEC-CM promotes both myelination and neurite density following injury. 
The myelinating cultures were set up and injured after 24 DIV and treated for a further 5 DIV 
with OEC-CM at 1:2 and 1:4 ratios. Treatment with OEC-CM at both ratios showed a 
promotion of neurite density (SMI31, Red) (B and C, G) and myelination (PLP, green) (E and 
F, H). N=2 and error bars-SEM, scale bar-25 µm. 
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Figure 3.8 OEC-CM promotes neurite outgrowth following injury. 
Myelinating cultures were set up and cut with a scalpel blade after 24 DIV. Following a 5 day 
treatment with OEC-CM. A promotion in neurite outgrowth was recorded at 1:2 and 1:4, with 
number of neurites per field of view surpassing control levels (A-D). Lesion site marked by 
dashed line (A) observed down the entire area. N=2 and error bars-SEM, scale bar-25 µm.  
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3.2.3 Modified heparin as a novel approach to SCI therapy  
Following the promising repair-associated processes of the OEC-CM treated injury 
cultures, I sought to identify the factor(s) present within the OEC-CM which were pro-
repair. Following (Higginson et al. 2012), which examined the OEC-CM composition, I 
hypothesised that the degree of sulphation of HSPG may be a factor associated with the 
repair processes promoted in the OEC-CM treated cultures. In this study, the sulphation 
state of HSPG was seen to be the factor which allowed for another repair-associated 
process, astrocyte mingling, to occur which merited the investigation of HSPG 
sulphation in our injury myelinating culture system. 
Heparin has been proposed as a potential CNS therapy. A study found that proteoglycan 
accumulation and the inflammatory response in brain regions affected by senile 
dementia could be resolved by treatment with heparin. They found that this was due to 
the competitive inhibition of proteoglycan accumulation by heparin and its anti-
inflammatory activities (Ma et al. 2007). SCI also involves changes in proteoglycan 
accumulation and an inflammatory response suggesting a role for heparin as a treatment 
for repair. 
Heparin is an analogue of the HS side chain of HSPG and both are chemically and 
structurally similar (Sarrazin et al. 2011) (Xu and Dai 2010). HSPGs mediate a plethora 
of signalling pathways, and signalling dysregulation is prevalent in many CNS pathologies 
(Cui et al. 2013). It is thought that exogenous Heparin, or modified heparin, could 
mimic HSPG and mediate certain ligand-receptor binding leading to either suppressing 
detrimental or activating beneficial  HSPG-associated pathways to promote SCI repair 
(Smith et al. 2015).  
Modified heparins (mHep) are compounds which have been artificially altered, changing 
their degree of sulphation, with an emphasis on the number of sulphate and n-acetyl 
groups bound to the sugar residue. The mHeps used for the screen were previously used 
by Higginson and colleagues (Higginson et al. 2012). In this study multiple mHeps were 
generated with mHep6 (a 2-O-monosulphated heparin) having the greatest impact on 
mingling, meriting it being chosen for this study. It has been modified via desulphating 
the C2 position on the carbon chain and been shown to be more potent in reducing 
astrocyte reactivity (Higginson et al. 2012). 
The injury mechanisms following trauma are becoming more apparent with signalling 
disruptions, changes in proteoglycan accumulation and sulphated side changes 
potentially underling SCI pathology. Using these mHeps to manipulate or ‘reset’ the 
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signalling disruptions by endogenously adding these signalling co-factor mediators could 
be a suitable option in SCI therapy.  
3.2.3.1 Result: Modified Heparin polysaccharides 
The SCI cultures was incubated until day 24 then injured using a flat edge scalpel blade. 
The lesion created an initial cell free space at a length of ~300 µm. This creating a focal 
decrease in neurite density and myelination levels adjacent to the lesion. The cultures 
were treated with mHep6 at a range of 1 ng/ml to 50 ng/ml, at day 25 then allowed to 
recover for a further 8 days. The cultures were then fixed at day 33 and stained for 
appropriate myelin marker: PLP and neurofilament marker SMI31. The cultures were 
imaged using an Axio fluorescent microscope at a 10x magnification, adjacent to the cut 
site as described in (Boomkamp et al. 2012) for the entire lesion length. Neurite density 
was calculated based on the SMI31-red pixel intensity compared to the total pixels per 
image. Myelination was quantified by calculating the percentage PLP-green pixel 
staining overlying the SMI31-red staining only at a uniformed longitudinal structure with 
predetermined dimensions. Neurite outgrowth was analysed by scoring the neurites that 
were seen entering and crossing the lesion site. Images were taken by focusing on the 
lesion site with each neurite which entered and crossed the lesion classified as 
‘outgrowth’. 
Following a single treatment of mHep6 it can be seen that the 1 ng/ml concentration 
significantly promotes myelination, p-0.0353 (Fig.3.9.G and L) and neurite density, p-
0.0035 (Fig.3.9 B and K). There was no promotion in either neurite density or 
myelination with increasing concentrations of mHep 6 (10-50 ng/ml) when compared to 
the untreated control (Fig.3.9.L and K). Precise myelin and neurite density p-values can 
be seen in table 3.2 below with significant results highlighted in bold. 
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Table 3-2 mHep Myelination percentages, Neurite density and P-values 
Concentration 
ng/ml 
Myelination (%) p-value/ 
Significance  
Neurite density 
(%)  
p-value/ 
Significance  
1 9.03 0.0353/Y 64.89 0.0035/Y 
10 6.707 0.6039/N 52.67 0.1899/N 
25 6.250 0.8768/N 43.67 0.9985/N 
50 4.500 0.7360/N 40.33 0.9665/N 
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Figure 3.9 mHep 6 promotes myelination and neurite density at 1 ng/ml. 
The myelinating cultures were set up and injured after 24 DIV and treated for a further 5 DIV 
with varying concentrations of mHep 6. mHeps 6 was used at four concentrations from 1-50 
ng/ml with only 1 ng/ml showing a significant promotion of neurite density (SMI31, Red) (B 
and K) and myelination (PLP, green) (G and L). The higher concentrations of mHep6, 10-50 
ng/ml (C, D and H, I) appeared to have a negative correlation of concentration verses effect 
on both neurite density and myelination (K and L). Statistical test used was one-way ANOVA 
with post-hoc multi-comparison correction, p<0.05 represented * in graph (K and L). N=3 
and error bars-SEM, scale bar-25 µm. 
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Following mHep6 treatment there is a promotion neurite outgrowth across the lesion 
significantly at 1 and 10 ng/ml (Fig.3.10.B-C and F). mHep6 at 25-50 ng/ml 
concentrations (Fig.3.10. D-F) had no effect on the number of neurites crossing the 
lesion compared to control (Fig.3.10. A and F). Precise values can be seen in the table 
3.3 and significant concentrations in bold. 
Table 3-3 mHep6 neurite outgrowth and P-values 
Concentration 
ng/ml 
Number of 
Neurite 
outgrowth 
p-value/ 
Significance  
1 10.00 0.0098/Y 
10 11.50 0.0018/Y 
25 2.000 0.7193/N 
50 1.500 0.5323/N 
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Figure 3.10 The mHep 6 treatment promotes neurite outgrowth 
Myelinating cultures were set up and cut with a scalpel blade after 24 DIV. Following a 5 day 
treatment at 1-50 ng/ml of mHep 6. Significant neurite outgrowth was recorded at 1 ng/ml 
and 10 ng/ml with number of neurites per field of view surpassing control levels (A-C and F). 
There was no significant neurite outgrowth following treatment of mHep6 at 25 ng/ml and 50 
ng/ml (D-F). Lesion site marked by dashed lines (A). Statistical test used was one-way 
ANOVA with post-hoc multi-comparison correction, p<0.05 represented * in graph (F) N=3 
and error bars, SEM, scale bar-25 µm.  
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3.3 Discussion 
In an effort to identify potential therapeutic compounds for CNS repair, we screened a 
range of potential therapeutics on a SCI model which has key SCI experimental 
parameters to identify therapeutics for further study. 
3.3.1 Neural co-culture model of SCI compound screen 
The SCI model was used to screen 5 different compounds (See Table 3.1) at a range of 
concentrations. The culture was sensitive enough to determine effects from compounds 
at low concentrations (1 ng/ml range for mHep). In addition, certain compounds were 
seen to have effects on either myelination, neurite outgrowth or in certain case, both, 
as seen after treatment with the SC76, OEC-CM and mHeps.  
Moreover, the demand to assess large numbers of compounds for SCI therapeutic benefit 
in a cost- and time-efficient manner highlights the need for throughput assays, such as 
the compound screen used here. However, this system could be further developed to 
incorporate, high-content approaches such adapting the culture to a 96-well plate, as 
well as automated microscopy, particularly to evaluate myelination and neurite 
outgrowth. Incorporating these adaptions could advance this culture system to an even 
more high-throughput screening tool for SCI therapeutics.  
3.3.2 Highly specific ROCK inhibitor SC76 has multiple beneficial 
therapeutic effects in our in vitro model of SCI 
The ROCK pathway is involved in many aspects of cell motility, specifically cellular 
migration and processes extension and neurite outgrowth (Riento and Ridley 2003). This 
pathway becomes activated following SCI and contributes to many of the injury-related 
processes (Fujita and Yamashita 2014). Therefore, inhibiting the ROCK pathway is a 
justified target in SCI treatment (Dergham et al. 2002).  
SC76 appeared to promote myelination and neurite density and outgrowth (Fig.3.1). 
Myelination and neurite density were promoted at both concentrations tested whereas 
neurite outgrowth was only promoted at 45 nM (Fig.3.2). SC96 showed promotion of 
myelination at all concentrations tested (Fig.3.3), however, no promotion of neurite 
outgrowth was observed (Fig.3.4). Even though SC336 showed promise in aspects of 
stem cell biology (protected data, under patent, J. Mountford, University of Glasgow) it 
seems to lack any repair effect on myelination, neurite density and outgrowth (Fig.3.5-
3.6). These results were generated from two biological repeats so the data can only 
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suggest trends towards an effect. Further repeats are required for statistical analysis to 
conclusively assess the true therapeutic potential of these novel ROCK inhibitors. 
The ROCK inhibitors used in this study were more highly selective inhibitors of the ROCK 
pathway than the previously used ROCK inhibitor, Y27632, based on a kinase assay 
undertaken by J. Mountford (unpublished data).  
The SC76 inhibitor data from this screen suggests that the activation of the ROCK 
pathway following injury may have a role in the OPC/OL demyelination, which backs up 
previous data from other studies in the literature (Boomkamp et al. 2012) (Pedraza et 
al. 2014). This could be due to actin reorganisation in the OL following SCI which 
destabilises the myelin sheath (Kippert et al. 2007). 
The ROCK pathway mediates myosin light chain MLC via the accumulation of 
phosphomyosin, leading to microtubule depolymerisation and neurite retraction 
following injury. Data from this screen suggests that inhibiting the ROCK pathway solely 
following injury leads to neurite outgrowth across the injury site. This could be due to 
the inhibition of phosphomyosin accumulation and depolymerisation of microtubules. 
This potential mechanism has been implicated previously, in a study using the less 
specific Y-27632 ROCK inhibitor (Lingor et al. 2007).  
This screen does not identify the target cell(s) which receive the most therapeutic 
benefit from ROCK inhibition. However, due to the multiple beneficial effects including 
the promotion of myelination and neurite outgrowth, this suggests several cellular 
targets. 
SC96 and SC336 did not show the same effects on myelination and neurite outgrowth as 
SC76. The kinase array performed by Dr. Mountford demonstrated the same ROCK 
inhibitory effects of all three inhibitors. However, this is beyond the scope of this 
screen. Even though the ROCK inhibitor data from this screen seems promising, due to 
the similarities these novel ROCK inhibitors have compared to the well-known ROCK 
inhibitor Y27632 in term of myelination and neurite outgrowth further research using 
these compounds is potentially redundant. Therefore, no further experimentation will 
be carried out using these ROCK inhibitors.  
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3.3.3 OEC secrete a positive factor which promotes myelination 
and neurite outgrowth in our model of SCI  
A potential treatment option for SCI is cellular transplantation, with autologous OEC 
shown to be promising (Raisman 2001) (Tabakow et al. 2013). To determine if the OEC 
pro-repair element was a secreted factor, the SCI culture was treated with OEC-CM. CM 
promoted myelination and neurite outgrowth following injury, suggesting a secreted  
factor from the OEC is responsible for these repair associated processes at the injury 
site (Franssen et al. 2007). The CM contains multiple signalling mediators and trophic 
factors which could be promoting these repair-associated processes. Following the 
Higginson study, we were particularly interested in assessing the role of HSPGs in 
mediating these repair processes. HSPGs have been associated with signalling pathways 
involved in myelination and neurite outgrowth (Hantaz-Ambroise et al. 1987) (Properzi 
et al. 2008). Thus, it was hypothesised that the degree of sulphation on the expressed 
HSPGs could be playing a role in promoting myelination and neurite outgrowth in our SCI 
model.  
Therefore, the OEC-CM line of inquiry was continued using the mHeps to determine the 
role of sulphation in SCI-associated processes. Thus, using the most promising mHep 
highlighted in the Higginson experiments, mHep6, at varying concentrations we 
screened for its potential therapeutic benefit for treatment of SCI.  
3.3.4 mHeps could be a novel repair therapeutic in SCI  
Much research has been carried out relating to sulphated GAGs at the injury site, 
specifically chondroitin sulphate proteoglycans (CSPG) (Jones et al. 2003). However, 
there has been little investigation into the role of HSPG at the injury site (Properzi et 
al. 2008). mHep6 is a heparin desulphated at carbon-2 position of the uronic acid 
residue of the heparin disaccharide repeating unit. It was produced 
chemicoenzymatically altering the level of sulphation of heparin (Yates et al. 2004). 
mHep6 that was shown to promote astrocyte mingling (Higginson et al. 2012). 
Therefore, this mHep was selected as a proof-of-principle that the sulphation state of 
the injury site contributes to the repair outcome. 
In this culture system, a single treatment with mHep6 at a concentration of 1 ng/ml 
promoted myelination and neurite density, but not at higher concentrations. At 
concentrations of 1 and 10 ng/ml, mHep6 promoted neurite outgrowth.  
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Interestingly, the higher concentrations of mHep6 did not promote myelination, neurite 
density or neurite outgrowth. This could be explained by the chemical structure of 
mHep6 (Fig.4.1.C). At a certain point the low sulphation status of mHep6 becomes 
redundant with the injury site becoming saturated by sulphate groups, thus negating the 
therapeutic effects of the compound. 
3.3.5 Conclusion 
Use of the screen demonstrated that the SCI cultures can be used to evaluate effects of 
many therapeutics on CNS injury repair using the parameters; myelination, neurite 
density and neurite outgrowth. Following the identification of mHeps as a potential 
treatment for SCI, this compound was taken forward for further study. However, using 
the SCI model alone is insufficient to gain a better understanding of the potential of the 
therapeutic and the mechanism underlying this activity.   
Thus, the model has certain limitations which need to be addressed:  
1. The response of each of the individual cells present in the culture to the 
therapeutic needs to be addressed such as the proliferation and differentiation 
of OPC and the phenotypic shift of astrocytes. This is due to the complex nature 
of neuronal-glial and glial-glial cross-talk which carry out processes such as 
myelination and neurite outgrowth. This limitation needs to be addressed 
through the use of monocultures, looking at each of the key cell types in the SCI 
model to determine the effects the therapeutics have on the isolated cell 
population. 
2. In addition, with all its merits the culture does not accurately represent some 
features of the in vivo environment. It lacks defined cellular orientation, 
specifically, the neuronal cell body and neurite compartmentalisation. This 
somewhat limits our ability to study the specific mechanisms relating to neurite 
outgrowth.   
This SCI culture has identified two new avenues of study. Firstly, the prospect of a novel 
therapeutic strategy for CNS repairs and secondly, the requirement for further 
development of this model to better investigate repair-related processes such as neurite 
outgrowth 
Of the 5 compounds examined here, three have shown benefit in both promotion of 
myelination and neurite outgrowth; SC76, OEC-CM and mHep6 (both at 1 and 10 ng/ml). 
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However, due to the dual benefit of mHep6 combined with the limited reports in 
literature using heparin mimetics in SCI and repair we took this compound forward for 
further study. 
This led to the formation of the hypothesis: ‘The sulphation level of the heparin 
mimetic effects the level of myelination and neurite outgrowth following injury’ 
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Chapter 4 
 
Modified Heparin mimetics as a novel 
treatment option for SCI repair and 
regeneration 
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4 Result: Modified Heparin mimetics as a novel 
treatment for SCI repair and regeneration 
4.1 Introduction 
GAGs, HSPGs and heparin could potentially provide a novel opportunity for the 
development of carbohydrate-based therapeutics for many pathologies, including SCI. 
Advancements in our understanding of GAG interactions has enabled the generation of 
GAG mimetics with desirable chemical properties, ones which allow for highly 
controlled interventions of certain pathological mechanisms.  
4.1.1 Heparin treatment 
Heparin is a well-known potent anticoagulation and antithrombotic drug (Damus et al. 
1973). It was first described in 1916, commercial manufacture started in the 1920s, and 
improved purification methods led to animal studies and the first clinical trials in the 
1930s (Barrowcliffe 2012). Through intense structural and interaction studies it was 
found that the thrombin affinity occurred through binding to only one third of the 
heparin chains (Hirsh 2001). Further studies into the structural functions of Heparin 
identified two prominent forms of Heparin; Low- dose Heparin, used for prevention of 
deep vein thrombosis (DVT) (McCarthy et al. 1977), and low-molecular-weight heparin 
used in anticoagulation treatments (Weitz 1997) demonstrating that Heparin has been 
modified to best suit certain biological activities.  
Heparin, like heparan sulphates (HS), exerts its effects on a variety of biological 
processes through interactions with growth factors, cytokines, adhesion molecules and 
extracellular matrix enzymes (Capila and Linhardt 2002) (Powell et al. 2004). Heparin 
treatment has also been associated with having tissue repair properties, for example, 
heparin has been investigated as an anti-inflammatory agent with its use as a treatment 
for burns (Ferreira Chacon et al. 2010) and for smoke inhalation damage (Miller et al. 
2009).  Heparin mediates its effects through competitive binding to release growth 
factors tethered to the ECM, allowing the growth factors to participate in tissue repair 
processes (Pike et al. 2006). These studies demonstrate that heparin has many potential 
therapeutic benefits. However, the potent anticoagulation and antithrombotic effects 
of heparin could potentially result in an undesirable side effect when developing 
towards other therapeutic possibilities.  
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4.1.2 Heparin mimetics 
‘Heparin mimetics’ is a term for a class of chemically modified HS GAGs and heparin.  
Numerous diverse heparin mimetics have been designed which are structurally distinct 
from naturally occurring sulphated GAGs. There is high structural and chemical 
similarity between Heparin, GAG chains of HSPGs and heparin mimetics. Therefore, 
heparin mimetics have been used as a tool to help understand the role of GAGs/HSPGs 
in multitudes of biological processes in both physiology and pathology (Freeman et al. 
2005).   
Heparin mimetics are classified based on their starting compound and the type of 
modifications they have undergone. A high proportion of heparin mimetics are 
carbohydrates, whether that is oligosaccharide (between 2-10 monosaccharide residues) 
or polysaccharide (>10 to several hundred monosaccharide residues). There is also a 
growing number of non-carbohydrate based mimetics which are adding to this ever 
expanding class of therapeutics (Coombe and Kett 2012). 
There are many structural features which add to the diversity of the mimetics. The size 
and molecular weight of the starting molecule is a common chemical modification 
target with investigators normally reducing the size of the polysaccharide in the pursuit 
of increased specificity and effectiveness. However, this can potentially impact the 
compound’s effect, as alterations to size also alters the overall sulphation state and 
final molecular conformation (Lindahl 2007). The degree and orientation of sulphation is 
also a critical target for modification (Wessel et al. 2005). Due to the limitation and 
inconsistency of the sulphation and desulphation techniques, typically a heterogeneous 
population of products is formed, potentially leading to highly variable results.  
Each modification, however complex, is limited by the ability to produce the mimetic 
on an industrial scale. Each of these potential drugs has to be commercially viable and 
translate to clinical relevance in the form of mass production (Lord and Whitelock 
2014). There are few heparin mimetics in clinic (Table 4-1), however, this appears to be 
changing with many mimetics now entering clinical trials 
4.1.3 Heparin mimetics as a therapeutic strategy  
Heparin mimetics have been developed to broaden the therapeutic potential. Heparin 
modifications aim to increase the potency of interactions between the mimetic and the 
target protein.   
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Table 4-1: To date seven heparin mimetics have been approved for clinical use, 
compounds adapted from (Barrowcliffe 2012). These include: 
Trademark Name Chemical Name Structure and 
composition 
Treatment 
Sucralfate® sucrose octasulphate sulphate sucrose 
derivative and aluminium 
hydroxide  
Gastric and duodenal 
ulcers 
SP54®, Elmiron® pentosan 
polysulphate 
a derivative of Pentosan 
Polysulfate 
Interstitial cystitis 
Dextran sulphate dextran sulphate sodium or potassium 
dextran sulphate 
derivative 
Inhibition of peptic 
ulcers 
Hirudoid® oversulphated 
heparin 
mucopolysaccharide 
polysulfuric acid 
Thrombophlebitis 
Soft tissue injuries 
Macugen®  
 
pegaptanib sodium twenty-eight 
oligonucleotide modified 
with 
nucleotidesmonomethoxy 
polyethylene glycol (PEG) 
Neovascular age-
related macular 
degeneration  
Suramin® Sodium sulfonate 6-sodium sulfonate   Onchocerciasis and 
sleeping sickness 
Cacipliq20® Heparan sulfate 
analogues 
Heparan sulfate 
analogues-poly glucose 
backbone 
Diabetic ulcers and 
chronic wounds 
 
 
 
It is clear that the design and modification of heparin-like compounds and their use 
extend beyond just the anti-coagulation field. Therefore, the modifications need to 
overcome the apparent innate anti-coagulation of heparin activity whilst maintaining 
and strengthening their other, less well defined, biochemical activities (Wall et al. 
2001) (Lapierre et al. 1996). 
A number of studies suggest the use of chemically modified heparins as a potential drug 
treatment strategy. A large amount of research in the field of oncology evaluates the 
use of chemically modified heparin as an anti-metastatic and anti-angiogenic therapy 
(Casu et al. 2010) (Casu et al. 2004). Heparin mimetics have been shown to be an 
effective inhibitor of heparanase (Naggi et al. 2005). Heparanase has been shown to 
play a role in tumour cell proliferation, metastasis and neovascularisation, making the 
targeting of heparanase a promising treatment strategy (Nadir and Brenner 2014). The 
heparin mimetic sulphation positions, specifically: 2-O-sulphate and 3-O-sulphate have 
been shown to be key in inhibiting heparanase and also decreases the anti-coagulant 
side effect of the mimetic (Lapierre et al. 1996). This study suggests that at least one 
negatively charged sulphate group is required to inhibit the heparanase enzyme. This 
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study has also highlighted that the placement and orientation of the sulphate groups on 
the heparin moiety is crucial in understanding the interaction of the mimetic with a 
target protein.  
4.1.4 Heparin and heparin mimetics in neuroscience 
It is known that heparin and its related GAGs are involved in the pathomechanism of the 
neurodegenerative disorders, Alzheimer’s disease and also in CNS trauma (Snow et al. 
1989) (Snow et al. 1987). Additionally, GAGs have been recently shown to be 
neuroprotective in animal studies suggesting an entirely new avenue in the treatment of 
neurodegenerative diseases and neurological trauma (Dudas and Semeniken 2012). 
Heparin could potentially be exerting its effects through the heparin-binding region of 
neural cell adhesion molecule (NCAM) (Cole et al. 1986) suggesting heparin mimetics 
can mediate specific neurological processes. 
A study using a panel of selectively desulphated heparin compound to demonstrate the 
role of FGF signalling in astrocyte and SC/OEC boundary formation, a measure of 
astrocyte reactivity, which could have implications for glial cell transplantation in CNS 
injury (Higginson et al. 2012). The same selective desulphated heparin panel has been 
used in a study of selective inhibition of Alzheimer’s β-secretase 1 (BACE-1), an enzyme 
which cleaves the amyloid precursor protein and a key protein in Alzheimer pathology. 
Here one of the heparin mimetics, which contained N-acetyl, 2-O- and 6-O-sulfates, was 
effective in the BACE-1 inhibition (Patey et al. 2006). Additionally, heparin has recently 
been suggested as a treatment for limiting neurological injury that follows subarachnoid 
haemorrhage (Simard et al. 2010). Promising studies have also demonstrated a role for 
heparin and GAGs in the suppression of apoptotic processes through regulation of the 
death receptor ligands and their receptors (Belmiro et al. 2009). This has implications in 
SCI and suggests a potential treatment approach in repair and regeneration. 
It has been suggested that heparin mimetics could exert their therapeutic benefit by 
regulating ligand-receptor binding and signalling activation. With signalling 
dysregulation a feature of many neurological disorders and trauma, mimetics could be 
introduced to intercede and provide therapeutic benefit. Studies have demonstrated 
the role of HSPGs as co-factors for several key pathways, including the neurite 
outgrowth and myelination associated Wnt and FGF pathway (Wade et al. 2014). 
Is has become apparent that activation of Wnt signalling in the injured CNS could be 
important in the regenerative process which may be in part due to Wnt being able to 
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activate other signalling pathways (Gonzalez et al. 2012). The initiation of the canonical 
pathway begins with the binding of the ligand with its receptor Frizzled (Fz). Wnt 
proteins are lipid-modified glycoproteins which are reliant on the HSs on the cell 
surface and in the ECM to stabilize the ligand (Fuerer et al. 2010), maintain the 
solubility of the ligand, distribute the ligands along the morphogenic gradients and 
initiate the signalling cascade (Ai et al. 2003). Wnt signalling could potentially have 
protective roles in neurogenesis and blood brain barrier restructuring (Briona et al. 
2015) (Stenman et al. 2008) (Liebner et al. 2008). Moreover, there is evidence to 
suggest that following SCI there is a down regulation of the mRNAs for many Wnt 
ligands, suggesting Wnt signalling is largely repressed after injury (Gonzalez-Fernandez 
et al. 2014). This suggests that a potential treatment which could mediate or even 
activate Wnt signalling could aid regeneration.   
The stabilisation and/or activation of the Wnt pathway as a treatment would re-
establish the signalling cascade which has been demonstrated to be down regulated 
following injury. Studies have alluded to the activation of the canonical Wnt pathways 
as a potential treatment in CNS regeneration specifically for neurite outgrowth, with 
focus on the stabilisation of the β-catenin messenger molecule or inhibition of β-catenin 
degrading molecule GSK3-β (Cuzzocrea et al. 2006). Wnt signalling has been shown to 
be a mediator of axonal guidance with several Wnt proteins being shown to stimulate 
the extension of axons through controlled gradients which attract the axons towards the 
brain once they cross the midline from the dorsal spinal cord (Lyuksyutova et al. 2003). 
However, Wnt signalling activation may have differential effects depending upon the 
cell type involved. A study has been reported showing that if the Wnt pathway is 
repressed in OPCs through exon targeted knockdown, it leads to decreased OPC 
proliferation following trauma, with an increase in neurite outgrowth observed 
(Rodriguez et al. 2014). This study highlights that this specific pathway may not have a 
global benefit in the injury response. It is clear that Wnt play important roles in injury 
and repair-associated processes, but many of the precise mechanisms are unknown. 
Therefore, employing modified heparins (mHeps) in the treatment of SCI could allow for 
the elucidation of the exact mechanism of Wnt in SCI and repair. 
 
FGF signalling has been implicated in SCI but has been recorded to have both beneficial 
and pathological roles (Koshinaga et al. 1993). FGF signalling has been shown to 
decrease astrocytosis and promote neurogenesis by inducing glial progenitor-like 
phenotypes which are supportive of axonal regeneration (Goldshmit et al. 2014). The 
majority of research has focus specifically on FGF2 and it’s role in SCI pathology and 
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regeneration (Adeeb and Mortazavi 2014).  Similarly, other studies have suggested a 
neurotrophic effect of FGF2 and subsequent upregulation promoting regeneration.  
However, there is a recorded increase in FGF2 after spinal cord injury contusion, which 
suggests that FGF signalling could have a neuroprotective role (Mocchetti et al. 1996). 
However, this suggests that even though upregulation of FGF2 is recorded after SCI, 
FGF2 appears to have little regenerative potential, beyond the limited innate 
regenerative capacity of the spinal cord. In addition, FGF signalling has been shown to 
promote OPC proliferation and could potentially attribute to the lack of OL 
differentiation and subsequent myelination adjacent to the lesion. FGF signalling and 
OPC proliferation and OL differentiation is a complex interaction, with the 
developmental stage of the OPC/OL dictating the effect the FGF signalling has, this is 
due to the change in receptor prolife as the cell matures (Bansal et al. 1996).   
FGF signalling has a long history which goes hand in hand with HSPG. HSPG are well 
characterised co-factors which initiate FGF signalling, through the specific sulphation 
moieties found on the GAG chain. Therefore, using selectively desulphated mimetics the 
injury response could be beneficially altered and provide more understanding of the 
role of FGF2 signalling in repair and regeneration.    
It is clear that heparin and it’s analogues interact with a wide variety of biological 
mechanisms and highlighting a place for heparin mimetics in CNS injury and treatment. 
Using the modified heparin (mHep) panel utilised in the Higginson and Patey 
experiments we can evaluate the use of mHeps as a treatment for SCI (Higginson et al. 
2012; Patey et al. 2006). 
  
4.2 Aims  
o To utilise the selectively desulphated mHep panel and ascertain effects 
on:  
 myelination and neurite outgrowth following injury 
 the maintenance of myelination 
o To understand the mHep mechanism of action. 
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4.3 Results: Effects of odified Heparin panel on 
promotion of myelination and neurite outgrowth 
To date, heparin mimetics have not been studied in SCI and repair. The SCI myelinating 
cultures were employed as a tool to study the effects of variably desulphated mHeps on 
myelination and neurite outgrowth following injury to establish the therapeutic 
potential of these mHeps, and to study the role of heparan sulphation at the injury site.  
The mHeps used here were provided by Dr. E.A. Yates, and in collaboration with Dr. J. 
Turnbull University of Liverpool, UK. The compounds were produced by a semisynthetic, 
selective desulphation of the commercial available heparin. Each modified version of 
heparin was structurally distinct and therefore, had different biochemical capabilities. 
Each mHep and the chemical modification it underwent are described in Table 4.2 and 
Fig 4.1. 
Table 4-2: Selectively desulphated mHeps panel with chemical modification. (Adapted from 
Patey et al., 2006) 
 
 
 
 
 
 
 
 
 
 
  
Modified 
Heparin 
Chemical modification No:SO3- 
mHep1  No modifications. Complete iduronate 2-O,  
glucosamine 6-O-sulphation and N-sulphation 
3 
mHep5 Selective removal of iduronate 2-O-sulfate. 
(concomitant modification in the small number 
of N- and 3-O-sulfated glucosamine units) 
1 
mHep6 Selective removal of glucosamine 6-O-sulfate 
and N-sulphate 
1 
mHep7 Complete removal of O-sulphates (achieved 
using solvolytic de-sulfation) 
1 
mHep8 Complete desulphation of 
iduronate/glucosamine O-sulphates and N-
sulphates with N-acetylation 
0 
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Figure 4.1 Heparin Disaccharide unit and modifications 
Commercial heparin was selectively desulphated at three possible positions: 2-O-iduronic acid 
(IdoA), 6-O and N-glucoasmine (Glc/NAc), marked dashed red circle (A).  mHep5 sulphation 
profile, 6-O-sulphated (B), mHep6 sulphation profile, 2-O-sulphated (C), mHep7 sulphation 
profile N-sulphated (D) and mHep8 total desulphated (E) each desulphated positions marked 
black dashed circle and list of modifications tabled below each disaccharide unit. 
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4.3.1 mHep effect on neurite density and myelination following 
injury 
To investigate the effects of the mHeps on neurite density and myelination following 
injury, myelinating cultures were carried out a previously described (Section 2.2). 
Cultures were incubated until day 24 at which time a cut was made across the cultures 
using a flat edge scalpel blade. The lesion created a focal (650 µm) decrease in neurite 
density and myelination levels adjacent to the lesion (Boomkamp et al. 2012). The 
cultures were treated with each mHep compound (for chemical structure, Fig 4.1) at a 
concentration of 1 ng/ml for a single treatment at day 25 before being allowed to 
recover for a further 5 days with no treatment applied.  
The cultures were then fixed and stained for SMI31 for axons and an anti-PLP antibody 
was used to visualise mature myelin. The cultures were imaged at 10x magnification 
adjacent to the cut site for the entire length of the lesion (region of focal effect). 
Neurite density was calculated based on the red pixel intensity (red, SMI31/neurite) 
compared to the total pixels per image. Myelination was quantified as described 
previously (2.2) by calculating the percentage of green pixels (AA3/myelin) over laying 
red pixels (SMI31/axon) only at a uniformed longitudinal structure with define 
dimensions.  
Neurite density was significantly promoted after treatment with 2-O-sulphate mHep6 
compared to the untreated control (Fig.4.2. D and H). The other desulphated forms of 
mHep5,7 and 8 had no significant effect on promoting neurite density with values not 
exceeding 48%, 54% and 52% respectively (Fig.4.2. G). Normal heparin (mHep1) had no 
effect on neurite density (56%), with no statistically significant difference compared to 
the untreated control (44%) (Fig.4.2.G).  
mHeps 6-8 significantly promoted myelination compared to control (Fig. 4.2.D-F and H). 
Partially desulphated mHep5 did not affect myelination levels, with levels not 
exceeding 5% (Fig. 4.2.C and H). mHep1 significantly decreased the level of myelination 
compared to the control with 2.6% myelination compared to 5% (Fig.4.2. H). 
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Figure 4.2 The Desulphated forms of mHep have positive effects on myelination and neurite 
density following a single treatment. 
mHep6 promoted neurite density (SMI31, red) following treatment at 1ng/ml (D and G). With 
no other mimetic having any statistical effect on neurite density. mHep 6-8 significantly 
promoted myelination adjacent to the lesion following a single treatment, with percentages 
raising above 9%-mHep6, 10%-mHep7 and 10%-mHep8 compared to the control 5% (.H). mHep5 
did not statistically promote myelination with levels reaching slightly greater than 5% (H). 
mHep1 significantly decreased the levels of myelination with percentages of 2.5% (H). Statistical 
test used was one-way ANOVA with post-hoc Dunnett’s multi-comparison correction, *p<0.05, 
**p<0.01 represented in graph (G and H). N=6 and error bars SEM, scale bar, 25 µm. 
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4.3.2 Desulphated mHeps promote neurite outgrowth following a 
single treatment 
Injury was achieved using a flat edge scalpel blade which created an initial cell free 
space with very low numbers of neurites, average of three, crossing the lesion. 
Following the same treatment plan and time course as previously described, cultures 
were fixed and stained for the axonal marker SMI31 and DAPI for nuclei. Neurites which 
entered and extended across the entire cut site were counted and determined to be 
neurite outgrowth. 
Desulphated forms of the mHep 5-8, all significantly promoted neurite outgrowth across 
the lesion compared to the untreated control (Fig.4.3. C-F and graph G). mHep5 and 
mHep7 were the most effective promoters of neurite outgrowth with the number of 
neurites per field of view increasing to,  on average, 14 per field of view, compared to 3 
neurites in control cultures. mHep6 and mHep8 both promoted neurite outgrowth but to 
lower levels,  averaging 10 neurites per field of view each (Fig.4.3. G). mHep1 did not 
promote neurite outgrowth following the same treatment course with neurite numbers 
not rising about 2-3 neurites per field of view (Fig.4.3. B and G).  
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Figure 4.3 The mHep5, 6, 7 and 8 all significantly promote neurite outgrowth following a 
single treatment. 
Lesion site marked by dashed line and a decrease in the nuclei density (DAPI, blue) 
observed down the entire area. Significant neurite outgrowth across the lesion was seen 
with mHep5-8 with numbers of neurites per field of view surpassing control levels (C-F and 
G). There was no effect on neurite outgrowth with mHep1 following a single treatment 
course (L). Statistical test used was one-way ANOVA with post-hoc Dunnetts multi-
comparison correction, *p<0.05, **p<0.01, ***p<0.001 represented in graph (L) N=3 and error 
bars-SEM, scale bar-25 µm. 
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4.3.3 Highly sulphated mHep increases the size of the lesion site 
Following injury, the lesion site was initially a cell free space about 400 µm across. The 
lesion size was defined as the area lacking nuclei and neurites. 10 images were taken 
for each condition. The size of the lesion was calculated using ImageJ LineTool, by 
drawing a line from one edge of the lesion to another which was then converted to the 
actual size in µm.  
Highly sulphated mHep1 significantly increased the lesion size to 564 ± 27.47 µm 
compared to the untreated control of 400 ± 20.04 µm (Fig.4.4.G). The desulphated 
mHeps, mHep5-8, did not have any statistically significant effect on the lesion size 
(Fig.4.4.D), with average lesion sizes being 380 ± 18 µm (mHep5), 315.16 ± 46.8 µm 
(mHep6), 405 ± 48.65 µm (mHep7) and 316.6 ± 56.22 µm (mHep8).  
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Figure 4.4 High levels of sulphate significantly exasurbates the lesion size following a single 
treatment. 
The lesion edge was marked and 10 measurements were taken per image at even spaced 
intervals.  Significant increase in lesion size was observed with Heparin (mHep1) (B and D) 
with the average lesion size reaching 564.5 µm, when compared to control lesion 400 µm. 
Desulphated mHep 6-8 did not have any effect on the lesion size with no statistical 
difference (D). Statistical test used was one-way ANOVA with post-hoc Dunnett’s multi-
comparison correction, p<0.05, * represented in graph (D) N=3 and error bars-SEM, scale 
bar-25 µm. 
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4.3.4 Desulphated forms of mHep cause an increase in the active 
astrocytic marker nestin 
Following injury the lesion site is invaded by astrocytes which have an altered 
morphology and reactive phenotype. For astrocytosis experiments, western blotting was 
carried out on protein lysates extracted. Protein level comparisons were performed 
using semi-quantitative densitometry analysis using imaging software, ImageJ.  
mHep1 significantly increased GFAP protein levels following injury (Fig.4.5.A and D) 
whereas the desulphated forms, mHep6 and mHep7, did not significantly alter the GFAP 
levels (Fig.4.5.A,C and D). There was no statistically significant change in nestin levels 
following treatment with mHep1 (Fig.4.5.B and E). However, both desulphated mHep6 
and mHep7 induced a statistically significant increase in Nestin protein levels compared 
to the untreated control (Fig.4.5.B and E).  
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Figure 4.5 Desulphated forms of mHeps cause an increase in the active astrocytic marker 
nestin following a single treatment 
GFAP was significantly increased following mHep1 treatment (A) and Nestin was significantly 
increased following mHep6 treatment (B) Loading control being GAPDH which is expressed 
ubiquitously (C). There was no significant change in GFAP levels following treatment with 
mHep6 or 7 (A and D). However, mHep1 significantly increase GFAP (A and D, *). There was a 
significant increase in Nestin levels following treatment with mHep6 and mHep7 compared to 
control (B and E, **). There was no change in the nestin levels following treatment with 
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mHep1 (B and E). Statistical test used was one-way ANOVA with post-hoc Dunnett’s multi-
comparison correction, p<0.001 represented ** in graph (E) N=3 and error bars, SEM.  
 
4.3.5 Desulphated mHeps cause a decrease in OPC proliferation  
In order to assess the effects of the mHeps on OPCs, OPCs were seeded at a 
concentration of 500 cells/µl in Bottenstein Sato (BS) media containing PDGFα and FGF2 
and maintained for 5 days. The BS enriched media was then switched to BS media with 
or without mHeps at a concentration of 1 ng/ml. Cultures were used for proliferation, 
morphology and differentiation assays.  
For proliferation studies the cultures were co-incubated with BrdU at the same time as 
the mHeps for 12 hours before being subjected to fixation and staining. Controls for this 
experiment were cultures incubated with BS alone to show basal proliferation and 
cultures incubated with BS plus PDGFα and FGF2 as a positive control for proliferation. 
Following fixation the cultures were co-stained for BrdU and the appropriate 
differentiation marker; either immature OL marker (04) or myelin marker (PLP) and 
DAPI (nuclei).  The cultures were blinded to the experimenter and each culture was 
imaged at 10x magnification in a random sampling fashion. Quantification was 
performed using a CellProfiler pipeline which simultaneously counts the total number of 
nuclei and the BrdU positive cells producing a ratio of proliferating cells (BrdU+) verse 
total number of cells. BS control was used to compare each treatment and is the 
baseline level of proliferation.      
The BS only control had an average of 32% proliferating cells (Fig.4.6.B and E). mHep1 
promoted proliferation of OPC with the average percentage of 53% (Fig.4.6.A and E). 
Desulphated mHep6, 7 and mHep8 decreased the number of proliferating OPCs with the 
average percentage number of BrdU+ cells falling to 29% (Fig.4.6.B-E).  
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Figure 4.6 Desulphated mHeps causes a decrease in OPC proliferation 
The cultures were co-stained for BrdU (green) and nuclei-DAPI (blue). PDGF and FGF 
positive control (A). Each treatment was compared to SATO control (B), desulphated 
mHep6-8 (C and D mHep6 and 7 respectively, E) reducing proliferation of OPCs with mHep1 
promoting OPC proliferation (E). N=1, scale bar-25 µm. 
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4.3.6 OL numbers are rescued adjacent to the lesion following 
treatment with desulphated mHeps 
Following treatment of the injured myelinating cultures with mHeps, the cultures were 
fixed and stained with SMI31 for axons and AA3 for mature OLs. The cultures were 
blinded and imaged at 10x magnification adjacent to the cut site for the entire length 
of the lesion (region of focal effect), 10 images per coverslip. OL number were 
quantified directly adjacent to the lesion site, using a CellProfiler plugin, which counts 
the number of green (PLP+) circles over laying blue (DAPI+) circles per image. Mature 
OLs were defined as PLP+ cell bodies. 
mHep1 displayed a significant decrease in OL number adjacent to the lesion compared 
to the untreated control (Fig.4.7.C). mHep5 and mHep6 did not significantly promote 
OL number adjacent to the lesion with PLP+ cells not exceeding control numbers 
(Fig.4.8). However, desulphated mHep6, 7 and 8 did significantly promote/rescue the 
number of OLs adjacent to the lesion site with mHep8 having the greatest impact on OL 
number (Fig.4.8.C).  
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Figure 4.7 The Desulphated forms of mHep promote the number of OL adjacent to the lesion 
OL quantification was performed using CellProfiler pipeline which calculate green spherical 
objects (B) at a set dimension each mHep treatment was compared to control OL number 
(A). As the sulphation level decreases mHep1-8 we see an increase in the number of OL 
adjacent to the lesion. Highly sulphated mHep1 significantly decrease the number of OL 
compared to control levels (C). Desulphated mHep6, 7 and 8 both significantly promote the 
number of OL adjacent to the lesion with number reaching 85, 78 and 109 respectively (C). 
Statistical test used was one-way ANOVA with post-hoc Dunnett’s multi-comparison 
correction, p<0.05, p<0.001 and p<0.0001 represented *, **, *** in graph (C). N=3 and error 
bars-SEM, scale bar- 25 µm. 
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4.3.7 mHep6 and 8 promote myelin sheath length and mHep 7 
increases OL size   
OPCs were seeded onto PLL coated nanofiber culture inserts (Nanofiber Solutions TM) at 
a concentration of 500 cells/µl in a volume of 50 µl, then made to a final volume of 
250µl in BS media containing PDGFα and FGF2 for 5 days. The OPC media was then 
switched to BS media with mHep treatment at 1 ng/ml for 7 days. Controls (BS only, 
growth factor BS) were also maintained for 7 days. The cultures were co-stained with 
the appropriate OPC/OL markers; either immature OL marker (04) or mature myelin 
marker (PLP) and nuclei (DAPI).  The cultures were blinded to the experimenter and 
each culture was imaged at 10x and 40x magnification 10 per coverslip, in a random 
sampling fashion. Sheath length was quantified by measuring a single internode (PLP+ 
process) per cell, from cell body to outmost internode using the imaging software 
ImageJ LineTool and Measure function. Cell area was quantified using the imaging 
software ImageJ. The cell size was defined by the green (PLP+) pixel threshold 
compared to the total pixel intensity and individual cells were marked with region of 
interest (ROI) tool to allow single cell analysis. 
The OL sheath length of the untreated control (BS only) averaged 166.6 ± 20.37 µm with 
the growth factor control sheath size only reaching 87.3 ± 31.24 µm (Fig. 4.8.A). mHep1 
had no significant effect on the sheath length with the average length reaching 150.6 ± 
57.94 µm. Similarly, the desulphated mHep 7, had no significant effect on the sheath 
length with average lengths measuring 196.9 ± 60.18 µm (Fig.4.8.E and G). Desulphated 
mHep6 and 8 significantly promoted the OL sheath length compared to control with an 
average length 298.64 ± 84.31 µm and 317.4 ± 66.7 µm respectively (Fig.4.8.D, F and 
G).  
The cell size of OLs was significantly increased following treatment with mHep7, 289.17 
± 49.75 µm2 compared to control, 139 ± 16.9 µm2 (Fig.4.8.B,E and H). mHep, 6 and 8 did 
not show any statistically significant difference on cell size (157.87 ± 41.9 and 141.9 ± 
36.86 µm2, respectively) (Fig.4.8.D, F and H). However, mHep1 significantly decreased 
the overall cell size, 79.65 ± 8.31 µm2 (Fig.4.8.C and H).  
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Figure 4.8 Promotion of myelination by Desulphated mHep maybe due to process 
stabilisation and increased cell size   
Desulphated mHep7 caused a statistical increase in the OL cell size following treatment, 
with an increase of 170 µm compared to control (E and H). mHep6 and 8 statistically 
promoted sheath length compared to control (D, F and G). Statistical test used was one-way 
ANOVA with post-hoc Dunnett’s multi-comparison correction, p<0.05 * p<0.001 **and 
p<0.0001 *** represented in graph (A-B) N=4 and scale bars-25 µm error bar-SEM. 
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4.3.8 2-O-sulphated mimetic inhibits OPC proliferation by binding 
FGF2 ligand but not the FGFR 
To determine whether mHeps inhibit FGF2 signalling by binding to the FGF2 ligand but 
not presenting the ligand to the receptor, monocultures of OPCs were treated with 
FGF2 (a known activator of proliferation) and with mHeps to assess whether the 
mimetics blocks FGF2 activity. 
OPCs were seeded on to PLL-coated coverslips at a concentration of 500 cells/µm2 in 
500µl of BS media containing; PDGFα and FGF2 and maintained for 5 days. The OPC 
media was then switched to BS media containing a combination of mHeps (1 ng/ml) plus 
FGF2 (50 ng/ml).  
Treatment with FGF2 alone induced OPC proliferation compared to BS control, with an 
average of 61% proliferation versus 41% (Fig.4.9.E). FGF2-mHep6 co-treatment reduced 
the mitogenic activity of FGF2 alone, with levels decreasing to 21% (Fig.4.9.C-E). 
Treatment with FGF2 plus mHep1 enhanced OPC proliferation compared to FGF2 alone, 
with an average percentage of BrdU incorporation increases to 70% (Fig.4.9.E).  
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Figure 4.9 2-O-sulphation (mHep6) can immobilise FGF2 ligand and inhibit signalling 
activation leading to a decrease in OPC proliferation 
OL ensheathment experiments the cultures were treated with each mHep compounds at 1 
ng/ml for 7 days. The cultures were co-stained with appropriate OPC/OL markers either 
immature OL marker (04, red) or myelin marker (PLP, green) and DAPI (nuclei, blue). FGF2 
treatment alone promotes 60% OPC proliferation an increase on Sato alone 41% (A-B and E, 
marked black dashed box). mHep6/FGF2 co-treatment removes the proliferative effect of 
FGF2 to 23% which is similar to mHep6 alone 26% proliferation (C-E, marked black dashed 
box). mHep1/FGF2 co-treatment slightly enhances the FGF2 proliferative effect compared to 
mHep1 but increase dramatically compared to Sato control (E). N=1 and scale bars-25 µm. 
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4.3.9 N-sulphation position (mHep7) has demyelinating effects in 
established myelinating cultures  
For myelin maintenance experiments, the uninjured myelination cultures were treated 
with each mHep compound at 1 ng/ml for a single treatment at day 25 for 5 days at 
which point cultures were fixed, stained and analysed. 
No significant effect was recorded on neurite density following with any mHep 
treatment (Fig.4.10. A-E). Highly sulphated mHep 1 significantly decreased the levels of 
myelination with myelin percentages falling to 5.3 ± 2.3% compared to control 12.5 ± 
2.25% (Fig.4.10 B and F). Desulphated mHep7 had similar effects on the level of myelin, 
with 7.2 ± 0.9% average myelination, mHep6 and mHep8 had no statistically significant 
effect on myelin values; 10.7 ± 2.5% and 10.3 ± 2.9% (Fig.4.10.F).  
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Figure 4.10 Desulphated mHep7 and sulphated mHep1 have demyelinating effects on 
healthy cultures following a single treatment. 
No effect was seen on neurite density (SMI31, red) following treatment with any mimetic (E). 
mHep 1 (B) and mHep7 (D) significantly decreasing myelination following a single treatment, 
compared to control (A and F). mHep6/8 did not statistically promote myelination with levels 
reaching slightly greater than 10% (C [representative of 10% myelination] and F). Statistical 
test used was one-way ANOVA with post-hoc Dunnett’s multi-comparison correction, 
p<0.001 represented ** in graph (F). N=6 and error bars-SEM, scale bar-25 µm. 
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4.3.10 N-sulphation and 2-O-sulphation could be promoting 
myelination through the activation of the canonical Wnt 
pathway. 
The myelinating cultures were incubated until day 24 then a cut was made across the 
cultures using a flat edge scalpel blade. The lesion created a focal (650 µm) decrease in 
neurite density and myelination levels adjacent to the lesion. Cultures were subject to 
a single treatment on day 25 with mHep6 and 7 at a concentration of 1 ng/ml. 
Mechanisms by which the mHeps might work was investigated by treating the cultures 
with mimetics plus a specific signalling pathway inhibitor. XAV inhibitor (blocks the 
canonical Wnt pathway by inhibiting β-catenin) was used at a concentration of 200 nM. 
Following treatment, cultures were incubated for 5 days before being fixed, stained and 
analysed for neurite density and myelination. 
There was no significant effect on neurite density after co-treatment with mimetics and 
XAV inhibitor compared to mHeps alone and control (Fig.4.11.G). 
As seen in Results: 4.3.1, mHep6 and 7 can promote myelination following injury to the 
myelinating culture. The promotion in myelination observed with mHep6 was removed 
following co-treatment with XAV (Fig.4.11.C-D and H) and significantly decreased when 
compared to mHep6 alone (4.11.F). mHep7 co-treatment with XAV significantly 
decreased myelination compared to mHep7 alone and was similar to that of the control 
level (Fig.4.11.D and F). XAV treatment alone decreased myelination but not 
significantly when compared to controls (Fig.4.11.B and F). 
  
 
 
114 
 
 
Figure 4.11 Canonical Wnt signalling pathway activation could be in part involved in mHep6 
and mHep7 promotion of myelination. 
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XAV inhibitor alone (B) was not significant compared to control (A) There is a significant 
reduction in the mHep6 (C) and 7 (E) effect on myelination following the inhibition of β-
catenin mHep6+XAV (D) and mHep7+XAV (F), graphed in H. There is no statistical change in 
the neurite density effects following the same treatment course on neurite density (G). 
Statistical test used was one-way ANOVA with post-hoc Dunnett’s multi-comparison 
correction, p<0.01 represented ** in graph (H). N=6 and error bars SEM, scale bar- 25 µm. 
 
4.3.11 mHep7 promotion of neurite outgrowth is mediated 
through the Wnt pathway. 
Injury to the cultures results in an initial cell free space with very low numbers with 
averages of 3 neurite acrossing the lesion. The cultures were co-treated with mHep6 
and or 7 at 1 ng/ml and XAV inhibitor at 200 nM on day 25, then allowed to recover for 
a further 5 days at which point cultures were fixed, stained and assessed for neurite 
outgrowth across the lesion.  
Desulphated mimetics mHep6 and 7 significantly promoted neurite outgrowth across a 
lesion compared to the untreated control (Fig.4.12.C,E and G). XAV inhibitor alone 
promoted the number of neurites per field of view to 17 compared to the untreated 
control with 4 (Fig.4.12.A-B and G). 
XAV inhibitor-mHep6 co-treatment did not remove the promotion of neurite outgrowth 
created by mHep6 alone with number of neurites per field of view averaging at 15 
compared to 13 in mHep6 alone (Fig.4.12.C-D and G) 
Following mHep7- XAV co-treatment there was a significant decrease in neurite 
outgrowth compared to treatment with Hep7 alone (Fig.4.12.E-G). However, neurite 
outgrowth of the co-treatment was still significantly increased compared to the 
untreated control (Fig.4.12.F-G).  
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Figure 4.12 Canonical Wnt signalling pathway activation could be in part involved in mHep6 
and mHep7 promotion of neurite outgrowth. 
XAV inhibitor alone cause a significant increase in neurite outgrowth compared to control 
(A-B and G). mHep6/XAV co-treatment did not result in a removal of neurite outgrowth 
activity (C-D and G). Whereas, mHep7/XAV co-treatment saw a significant reduction in 
neurite outgrowth compared to mHep7 alone (E-G). However, mHep7/XAV co-treatment 
increased neurite outgrowth number is significant compared to control (A, F-E). Statistical 
test used was one-way ANOVA with post-hoc Dunnett’s multi-comparison correction, 
p<0.01** and p<0.001*** represented in graph (H). N=6 and error bars-SEM, scale bar-25 µm. 
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4.4 Discussion 
It has been shown that Heparin and its mimetic derivatives have many binding targets 
(Coombe and Kett 2012). It has been suggested that modulation of certain factors 
(mimetic-binding-proteins) within an injury site could have therapeutic benefit. For 
these reasons, several heparin mimetics were created in the pursuit of tissue repair 
properties heparin may possess.  
This has led to the investigation and hypothesis that the introduction of desulphated 
heparin mimetics can have multiple therapeutic benefits and used for the treatment 
and understanding of SCI.  
Four heparin mimetics, mHep6 (2-O-sulphated), mHep7 (N-sulphated), mHep8 (total 
desulphated/N-acetylated) and mHep1 (commercial heparin), were examined for their 
capacity to promote myelination and neurite outgrowth following injury in a complex in 
vitro CNS injury model. This type of assay, where multiple cells types are interacting to 
create a complex CNS myelinating culture which can be injured which then mimics 
many key features of SCI, is a powerful screening tool for potential therapeutics 
(Boomkamp et al. 2014; Boomkamp et al. 2012). 
mHep6 and mHep7 have been shown in this study to have potential therapeutic benefit, 
both showing promotion in both myelination and neurite outgrowth. However, with 
continued investigation the mimetic with N-sulphation (mHep7) demonstrated 
demyelinating effects on healthy established cultures suggesting a duality in effect; 
beneficial in injury and detrimental in steady state. This potentially has far-reaching 
effects in that off-target effects of mHep7 could undermine benefits and be potentially 
catastrophic to SCI patients.     
Following the recorded promotion in myelination and neurite outgrowth, the successful 
mimetics were carried forward for more detailed investigation. This entailed looking 
further with the SCI model and monocultures of individual cell types contained in the 
culture. 
Turning to monoculture experiments, it was shown by two different methods that 
mHep6 and mHep7 even though thet had myelin promoting properties, their effects on 
OPCs and OLs were quite different. However, the experimental options available for 
detailed neurite outgrowth investigation are limited.  
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In this study we suggested a novel therapeutic approach in the form of mHeps for SCI 
repair. The principle finding of this study was; partially and fully desulphated heparin 
mimetics promote neurite density, myelination and neurite outgrowth following a single 
treatment after injury. From this finding, a secondary hypothesis was formed that the 
mHeps act by altering the availability and thus change activity of certain signalling 
pathways. This was investigated using commercially available receptor blockers to 
identify specific pathways involved during mimetic treatment.  
By understanding the individual mHep mechanisms and cellular responses, we can in 
turn further suggest how to best modify the mHep compounds to increase treatment 
potency and potentially further promote the beneficial effects associated with a given 
mHep.  
4.4.1 mHeps’ effects on myelination   
This study recorded an increase in myelination adjacent to the lesion following a single 
treatment of mHeps 6, 7 and 8, at 1 ng/ml concentration 1 day post injury (4.3.1). The 
complex nature of the culture makes identifying the specific cells and mechanisms 
involved very difficult. Therefore, OPC/OL monocultures were used to assess the effects 
of the mHeps on these cells which directly involved in myelination, investigating, 
proliferation, differentiation and OL; ensheathment and internode length (4.3.5 and 
4.3.7).  
4.4.2 mHeps and myelinating glia 
The recorded promotion of myelination by mHeps 6, 7, 8 and the reduction in 
myelination by mHep1 (Fig.4.2) resulted in the investigation of the mimetics on OPCs 
and OLs as these are the specialised cells responsible for myelin sheath formation and 
axonal ensheathment.  
It was found that treatment with desulphated mimetics, mHep 6 and 7, in an OPC 
monoculture decreased OPC proliferation, suggesting the inverse response of 
differentiation. These observations implicate 2-O-sulphate and N-sulphate positions 
(mHep6 and 7 respectively) as key mediators of certain signalling pathways resulting in 
OPC proliferation and differentiation (Fig.4.6). However, mHep8 which lacks both of 
these sulphate moieties (Fig.4.1.D) also yields increases in myelination. This result, 
coupled with the results from the mHep6 and 7 experiments, suggests that introduction 
of desulphated mimetics is more beneficial than their more sulphated counterpart; 
mHep1. 
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The shift to OPC differentiation was supported by counting the number of OLs adjacent 
to the lesion in the complex culture, with an increase in OLs compared to untreated 
control following treatment with desulphated mHeps 6, 7 and 8 (Fig.4.7). This suggests 
that the increase in myelination following treatment with desulphated mimetics on 
injured cultures could be in part due to the inhibition of proliferation and the induction 
of OPC differentiation and maturation. Thus, increase OL number corresponds to the 
mimetic inducing OPC differentiation and inhibition of OPC proliferation.   
Similar observations have been made relating to neural cell proliferation in the 
developing brain and in an in vitro study of spinal cord neural precursor proliferation. 
These studies concluded that, sulphation is crucial in the proliferative state of a cell, 
demonstrated by treatment with sodium chlorate which inhibits sulphation of the HSPG, 
thus, leading to a disruption in proliferation of a cell line (Ford-Perriss et al. 2003) 
(Karus et al. 2012). Therefore, by introducing desulphated mHeps into the injured 
culture we are disrupting the proliferative state of the OPCs and could be inducing 
differentiation to myelinating oligodendrocytes which would allow for promotion of 
myelination of spared axons. 
Inversely, treatment with a highly sulphated mimetic (mHep1) lead to an enhancement 
of OPC proliferation. A similar observation was made by Becker-Catania and colleagues, 
but here they suggest that heparin potentiates OPC proliferation through the mitogenic 
factor such as FGFa (Becker-Catania et al. 2011). OL number adjacent to the lesion was 
also reduced following mHep1 treatment suggesting that OPC proliferation (potentially 
even increased) is maintained at the injury site. These responses to mHep1 treatment 
could potentially lead to a reduction in myelination following injury. Heparin has also 
been shown to have proliferative effects on non-neuronal cells, specifically smooth 
muscle cells. This study concluded that the proliferation relates to the level and 
position of the sulphate groups on the heparin polysaccharide. It was shown that 
substitutions of O- and N-sulfo groups relates to the heparin anti- proliferative activity 
(Garg et al. 2008). The data using the SCI in vitro model also recorded an anti-
proliferative activity on OPCs by the desulphated mHeps (4.3.5).  
The variations in the chemical composition of each of the mimetics could lead to 
different ligand/receptor interactions within the injury environment. For instance, 
mHep6 (desulphated at C6, sulphated at C2, Fig.4.1.C) may be mimicking the sulphation 
state of the endogenous OPC HS-GAG sulphation pattern which has a similar chemical 
structure to mHep6. Properzi and colleagues observed an increase in HS sulphated at C2 
following injury to the CNS. They concluded that OPCs have increased 2-O-sulphated HS 
GAG chains compared to OL suggesting an immaturity and an inability to bind certain 
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growth factors which would otherwise elicit proliferation (Properzi et al. 2008). 
Therefore, treatment with exogenous soluble heparin mimetics which are 2-O-sulphated 
could be indirectly competing for the ligands/receptors which would otherwise bind to 
the OPC cell surface HS and elicit a proliferative injury response.  
Both in vivo and in vitro studies have demonstrated that there is a loss of myelination 
adjacent to and at the site of injury even though OPCs are present. However, these OPC 
do not differentiate into mature myelin forming OL. Mimetic treatment induces OPC 
differentiation and OL myelination of the spared axons. The data generated in this study 
suggests that the OPCs at the site of injury have the capacity to mature and form 
myelin-producing OL but the injury microenvironment is not permissive to elicit this 
process. Therefore, the mimetics counteract the injury microenvironment and promote 
the recovery of myelination.  
The desulphated mimetics create an environment permissive for myelination to occur. 
Evidence has been provided suggesting that the mimetics directly impact the OPC/OL 
state at the site of injury.  The exact mechanism in which the mimetics are acting still 
remains elusive, however, looking to the potential role of mimetic acting as a co-factor 
for cell signalling may provide an answer. 
4.4.2.1 Mimetic promotion in myelination potentially through ligand 
immobilisation and signalling deactivation 
It has been known for some time that heparan sulphates act as a co-factor for FGF 
signalling. Using biochemical techniques it has been shown that the sulphate moieties 
on the GAG chain specifically the 2-O and 6-O carbon position on the iduronic acid and 
glucosamine residues are crucial for ligand binding (2-O-sulphate) and receptor 
activation (6-O-sulphate). With this knowledge we hypothesised that the mimetic 
treatment may be interfering with FGF signalling, and FGF signalling has also been well 
known to dictate OPC proliferation. Therefore, it was theorised that mHep6 could be 
acting as a ‘sponge’ or blocker for the ligand and inhibiting FGF signalling, as it lacks 
the appropriate sulphate moiety required to bind to and activate the receptor 
(Fig.4.1.C). Therefore, endogenous mHep6 (sulphated at only C2) blocked FGF signalling 
and caused OL differentiation leading to increased myelination.  This appeared to be 
the case, following OPC co-treatment with mHep6 and FGF2 ligand (Fig.4.9). FGF2 has 
been shown to induce OPC proliferation (it is actually a part of the BS DMEM enriched 
media required for OPC culture). Here, it is evident that FGF2 ceased to induce OPC 
proliferation when it was co-treated with mHep6, suggesting that mHep6 is mopping up 
the FGF2 ligand, and due to mHep6 lacking 6-O-sulphated moiety it cannot form the 
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FGF-HS-FGFR complex leading to silencing of FGF signalling and in turn OPC 
proliferation. As a proof of principle FGFR blocker SU5402 was introduced to the OPC 
culture which led to similar observation on OPC proliferation generated by mHep6 
(Fig.4.9.E). 
Under the same hypothesis, treatment with mHep1 or heparin which has both 2-O and 
6-O-sulphates, would therefore, promote OPC proliferation. Increased OPC proliferation 
was observed in monoculture and enhanced proliferation in the presence of 
mHep1/FGF2 co-treatment, when compared to BS-Sato control and to mHep6 
(Fig.4.9.E). Therefore, this suggests that mHep1 did not promote myelination following 
injury due to its role in enhancing OPC proliferation, preventing OL differentiation and 
subsequent myelination of spared axons. 
FGF signalling is one of many cell signalling pathways which mediate their signalling 
through the sulphated HSPGs. Therefore, other pathways were considered, which have 
been shown to play a role in myelination which signal via HSPG involvement. This has 
led to the use of specific signalling inhibitors.  
These FGF2 co-treatment experiments were a proof of principle experiment testing the 
hypothesis of ligand immobilisation (or ligand ‘sponge’). The mimetic mode of action 
has by no means been uncovered, what has been demonstrated here is that mimetics 
which lack certain sulphated moieties can bind to but not act as co-factors for certain 
signalling complex activation. There are many more signalling ligands and receptors in 
which our mimetics are interacting with but it has been demonstrated that interceding 
in injury mediated signalling disruption can be an effective approach to SCI therapy. 
4.4.2.2 Promotion in myelination by mHeps and activation of Wnt signalling 
In parallel with identifying the cellular target of the mHeps, an investigation was 
carried out into the role of mHeps and signalling activation. Data presented here 
suggested that the desulphated mHep6 and 7 may have a role promoting the canonical 
Wnt signalling pathway. Wnt signalling, specifically the canonical pathway, has been 
implicated in the activation of myelin genes and formation of compact myelin (Tawk et 
al. 2011). Using the commercially available β-catenin inhibitor, the role of the canonical 
Wnt signalling pathway was assessed in its activation following treatment with the 
mHeps. 
 
 
122 
 
Here it was shown that following the co-treatment with mHep6 and 7 and the β-catenin 
inhibitor, XAV, the promotion of myelination was abolished (Fig.4.11.H), suggesting that 
mHep6 and 7 are activating the canonical Wnt pathway.  
It has previously been shown that the 2-O-sulphate in HS GAG chain is required for the 
activation of the canonical Wnt pathway (Cadwalader et al. 2012). Wnt signalling has 
long been implicated in OL myelination. β-catenin has been shown to be present in the 
OLs and active in both a developmental and lesioned CNS (Fancy et al 2009). However, 
its involvement and dysregulation in demyelination and remyelination still remains 
unclear. A study identified Wnt/β-catenin as an essential promotor of myelin-associated 
gene expression. This study also showed that blocking Wnt signalling reduces PLP 
(myelin) in OL but activating Wnt1 ligand increases the expression of  myelin-associated 
genes through the promotion of β-catenin binding to T-cell factor/lymphoid-enhancer 
factor transcription factor (Tawk et al 2011). Another study demonstrated that a 
continuous activation of Wnt signalling in OPCs displays a hypomyelination phenotype in 
β-catenin dominant-active transgenic mice (Fancy et al 2009).  This observation could 
potentially explain the data gathered in our study specifically relating to the treatment 
strategy employed; a single treatment followed by recovery. This suggests that β-
catenin could be initially upregulated by mHep7 then in the subsequent days the same 
pathway in no longer being activated, therefore, ‘resetting’ the pathway transiently 
leading to a beneficial effect. 
OPC differentiation to OLs and a change in the microenvironment, such as through 
injury, involves intermediate cellular phenotypes or a ‘spectrum of cells’ which will 
have different receptors and ligand profiles which control the differentiation process. 
This suggests that signal manipulation by the mimetics can have the same biochemical 
effects on the ligand/receptor but the presentation or immobilisation of a signalling 
pathway depends upon the presence of the ligand/receptor on a cell.  
FGF2 activation was investigated to demonstrate the function of the mimetics as a 
ligand ‘sponge’, specifically mHep6 which is 2-O-sulphated. However, due to the 
promiscuous nature of HS binding many other signalling pathways could also be 
influenced by the mimetics. One such signalling pathway which requires the loss of 6-O-
sulphation of the cell surface HSPG for activation is Wnt signalling (Ai et al. 2003). This 
is due to 6-O-sulphate binding Wnt with high affinity and competing with the ligand for 
the Frizzled receptor. So through the introduction of mimetics lacking the 6-O-sulphate 
moiety, Wnt signalling could be initiated indirectly through none-active competition for 
the ligand (Dhoot et al. 2001). Thus, evidence was provided in this study that mHep6 
does initiate Wnt signalling, leading to promotion in myelin following injury. This was 
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tested experimentally by, mHep6 and -catenin inhibitor co-treatment, which 
demonstrated that the activation of the canonical Wnt pathway via the non-competitive 
binding of the ligand by mHep6 can be removed to 4.5% (Fig.4.11.H) through the 
inhibition of -catenin. This was tested in the complex injury setting to demonstrate the 
mimetic effect in an injury environment and that Wnt signalling activation was taking 
place. This provides a more transferable demonstration of the mechanistic role of 
mHep6 in an injury setting which is difficult to recapitulate in a monoculture. 
The culture used in this study identified mHep6 and 7 as a mediator of the Wnt/ β-
catenin signalling pathway. The specific cellular target for Wnt/β-catenin in the SCI 
model remains unknown. Many studies have focused on OPCs/OLs, however there are 
multiple cell populations which could impose a Wnt signalling effect on the OPCs/OLs.  
It has been shown that 2-O and 6-O sulphation positions are required for both the 
immobilisation and activation of FGF and Wnt signalling (4.3.8 and 4.11). Through the 
introduction of a mimetic which has 2-O-sulphation and 6-O-desulphation, it was 
demonstrated that both the inhibition and activation of FGF and Wnt signalling 
respectively is possible (Fig.4.9 and Fig.4.11). Previous studies have conferred with 
some of the observations made here specifically the biochemical interactions of mHep6 
(Higginson et al. 2012). However, what was shown in this study is that N-sulphation 
(mHep7) can also initiate Wnt signalling, however, very little known about the role of N-
sulphation and Wnt signalling activation. N-sulphation has been shown to be crucial in 
PDGF-B activation (Abramsson et al. 2007) and interestingly PDGF-B has been implicated 
in reductions in secondary damages after SCI.  
What these experiments demonstrate is that the different mimetics have a diverse set 
of signalling modulation abilities. I have only scratched the surface of the exact 
mechanism of action. However, evidence has been provided implicating two signalling 
pathway interactions, the immobilisation of FGF signalling leading to the inhibition of 
OPC proliferation and subsequent OL differentiation and promotion in myelination and 
the activation of Wnt signalling and myelination. Continued study is required to provide 
a more detailed signalling profile picture of SCI and their manipulation by the mimetics. 
However, it can be clearly seen that there is great promise for heparin mimetics as a 
treatment strategy for SCI. 
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4.4.3 mHeps’ effects on neurite outgrowth 
This study recorded an increase in neurite outgrowth across the lesion following a single 
treatment of mHep5, 6, 7 and 8, at a concentration of 1 ng/ml 1 day post injury 
(Fig.4.3.G).  
These mHeps could be directly affecting neurite outgrowth, rescuing the disrupted 
interaction of a the GAG chains of the resident HSPG or through artificially mimicking 
their interaction with the growing neurite (Lander et al. 1982). Or indirectly by altering 
surrounding cellular behaviour which then creates a permissive environment for 
outgrowth.  
The introduction of single desulphated mHeps, mHep6, 7 and fully desulphated mHep8, 
resulted in the promotion neurite outgrowth across a lesion. Similar data has been 
generated by Karumbaiah and colleagues targeting CSPGs sulphation levels. In this 
study, siRNA knockdown of the astrocytic sulfotransferase enzyme (sulphates C4 and C6) 
led to the promotion of neurite outgrowth (Karumbaiah et al. 2011). This provides 
further evidence that the sulphation levels of heparin or resident GAGs, specifically a 
more desulphated environment, is permissive to neurite outgrowth.  
It has been suggested in this study that the specific sulphation position on the 
disaccharide unit could be crucial. The specific sulphation pattern could dictate which 
signalling pathway is initiated. Data generated here has shown that 2-O-sulphation and 
N-sulphation occurring in isolation support neurite outgrowth. Other studies have 
observed similar results, mutants having defects is the Hst-2 gene which encodes the 
enzymatic activity of the 2-O-sulphation of the glucosamine on the HS display axonal 
patterning defects (Kinnunen et al. 2004). Suggesting that 2-O-sulphate is involved with 
neurite outgrowth and pathfinding. However, mHep8 which lacks any sulphated moiety 
in the three modification positions yet also promotes neurite outgrowth. This suggests 
that the overall level of sulphation may be in part the reason for the outgrowth 
observed. 
Desulphated heparin mimetics have been shown in this study to promote neurite 
outgrowth (4.3). Once again the different sulphation patterns of the mHeps could be 
crucial in identifying their specific mode of function. For example, mHep6 mimics the 
sulphation pattern of syndecan, an HSPG, in that they both have 2-O-sulfation of the 
iduronic acid residue. Interestingly, syndecan has been implicated in what has been 
termed ligand ‘shuttling’ which presents ligands to the neuron and triggers outgrowth. 
Additionally, syndecan has been shown to be able to bind and present Wnt ligands to 
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neurons (Beller and Snow 2014) (Tkachenko et al. 2005). Therefore, treatment with 
mHep6 could be providing the neurite with growth factors which then initiates 
outgrowth. 
An additional mimetic was shown to have neurite outgrowth benefit; one which did not 
have positive myelination properties – mHep5. However, criteria was set which  states 
that only a mimetic which displays both promotion of myelination and neurite 
outgrowth will be subject to further study. For this reason mHep5 was not carried 
forward for more detailed study. However, mHep5 data has demonstrated that each of 
the three modification sites individually has neurite outgrowth activating potential. 
However, 6-O-sulphate position on the glucosamine along with 2-O-sulphate on the 
iduronic acid and N-sulphation on the glucosamine can initiate neurite outgrowth but 
when each of these sulphate positions are simultaneously sulphated there is no 
promotion of neurite outgrowth as seen with mHep1. This suggests that to increase 
potency of the effect, combinations of all sulphated sites is not the answer. This is 
valuable information for future mimetic designs and sulphated modification 
combinations. However, it is not known if dual sulphation for example 2-O-sulphation 
and N-sulphation, lacking 6-O-sulphation could increase neurite outgrowth, we do not 
know but is a logic next step in the pursuit of neurite outgrowth potency. 
4.4.3.1 Desulphated mHeps promote neurite outgrowth partially through the 
activation of the Wnt pathway  
The canonical Wnt pathway has been well documented. It acts via the presentation of 
ligands in a gradient manner, suggesting a strong link between neurite outgrowth and 
axonal pathfinding (Salinas 2012).  
Data from this study suggests that β-catenin may play a role in neurite outgrowth and 
possibly a partial target for mHep7 following treatment. In co-treatment of mHep7 with 
β-catenin inhibitor, we saw a partial removal of the mHep7 effect on neurite 
outgrowth; less than that of mHep7 alone but still a statistically significant promotion of 
neurite outgrowth compared to untreated controls. These data suggest that mHep7 is in 
part acting via the activation of the Wnt pathway and that neurite outgrowth activation 
requires multiple signalling pathways, specifically ones provided by mHep7 and N-
sulphation interactions.  
The role of β-catenin in neurite outgrowth remains unclear (Endo and Rubin 2007; Zou 
2004). Several studies provide conflicting observations but this could be related to the 
use of non-neuronal cells in their studies. Whether our treatment is ‘resetting’ the Wnt 
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signalling or stabilising -catenin, we are unsure. However, evidence has been provided 
previously implicating Wnt in myelination so it is follows that the mimetic is interacting 
with the canonical Wnt pathway but in neurite outgrowth process.  
My data suggests promiscuity in the heparin mimetic interactions in the culture with an 
interaction of the mimetics with the Wnt signalling pathway. The mimetic neurite 
outgrowth mechanistic story still remains elusive. A potential (partial) mechanism has 
been shown for mHep7 via the Wnt pathway. However, the inability to study the 
neurons-neurites in monoculture or in a structured organised fashion makes uncovering 
the exact mechanism very difficult. There are many cofounding factors in the complex 
culture with many cell types potentially involved in the outgrowth process. So it cannot 
be shown here if the mimetics are directly or indirectly acting on neurite. This problem 
is what generated the development of a novel model in which to study neurites isolated 
from their cell bodies. 
4.4.4 mHeps’ effects on astrocytes 
Treatment with desulphated heparin mimetics showed multiple beneficial outcomes 
following treatment by promoting myelination, neurite density, neurite outgrowth and 
decreasing lesion size. This suggests either multiple cellular targets or the targeting of a 
cell which interacts with several different cellular processes. Astrocytes have been 
shown to mediate between many cellular populations and cellular interactions. 
The glial scar is a major feature of SCI pathology; astrocytosis occurs following injury 
which is characterised by an alteration in astrocyte phenotype to a more reactive state 
(Faulkner et al. 2004). This shift in phenotype has been linked with contributing to 
pathology creating an environment non-permissive to axonal regeneration and 
remyelination. GFAP and Nestin are upregulated in astrocytes following trauma and are 
well established markers of astrocytosis. Following SCI there is a focal increase in 
nestin, by astrocytes which, however, has been suggested to be potentially 
neuroprotective.  
The mimetics used in this study were previously used as a tool to assess the role of 
differentially sulphated heparan sulphates on cell-cell interactions, specifically OECs 
and SCs with astrocytes in a confrontational assay (Higginson et al. 2012). This study 
was the premise behind their use in this SCI model. The major finding from the 
Higginson study was that desulphated heparins do not induce a (negative) boundary 
between the cell populations and suggesting a role for sulfatases in the formation of the 
boundary.  
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What this study and the SCI model have in common is the astrocyte. Astrocytes have 
been implicated in a plethora of pathologies including SCI and the glial scar, which is a 
characteristic of this SCI model. The observations in this study, specifically neurite 
outgrowth, lesion size and myelination, have strong links with and are potentially 
mediated by the astrocyte. This led to our prediction that the heparin mimetics, 
specifically the desulphated versions, have beneficial effects on astrocytes which 
results in the beneficial effects on the cells which are mediated by the astrocyte, such 
as the OPC/OL and the neurites.  
However, we did not see any beneficial effect on two common reactive astrocytic 
markers; nestin and GFAP. These two markers have been shown in numerous studies to 
be increased following damage to the astrocyte and suggestive of a negative phenotype. 
GFAP was not affected at all and nestin was actually increased following treatment with 
the desulphated mimetics. Interestingly, a study has shown that an increase in GFAP in 
astrocytes can promote myelination through the increased expression of CNTF (Nash et 
al. 2011a).   
Astrocytes have been implicated with an increased expression of HSPG following injury 
to the cord (Properzi et al. 2008). They showed a strong upregulation in Glypican-1 (a 
HSPG) and an increase of the detrimental highly sulphated GAGs that are 2-O-sulphated 
on the astrocyte surface. A similar increase seen of 2-O-sulphation on OPC HSPG 
suggested that treatment with the 2-O-sulphate mimetic mHep6 could indirectly 
compete for the FGF ligand and nullify the signalling initiation and negative response to 
injury. However, this competitive blocking of ligand binding does not alter the reactive 
astrocyte phenotype as there is no change in the levels of common reactive marker 
protein levels following treatment. 
Due to the beneficial effects observed with the desulphated mimetics and the diverse 
effects (both promotion in myelination and neurite outgrowth) it was hypothesised that 
these compounds may be mediating a change in the reactive astrocyte. However, there 
was no change in levels of GFAP and nestin levels actually increased following 
treatment with mHep6 and 7. 
This could be potentially related to the low number of astrocytes migrating into the 
lesion site, with decreased density of seeding and migratory cells in vitro being shown 
to upregulate Nestin. Also Nestin has been shown to be activated by certain growth 
factors, such as NGF, FGF and CNTF. All of these growth factors are in part mediated by 
HSPG by acting as co-factors for signalling activation. This suggests that the treatment 
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with mHeps could be mediating the activation of nestin expression through the 
presentation of these growth factors to the astrocytes. 
The Nestin positive cells have also been linked with reverting to a more 
immature/progenitor-like state (Lin et al. 1995). Another study linked low sulphated 
HSPGs and restriction of embryonic stem cell neural differentiation suggesting a crucial 
ratio of HSPGs and FGF4 ligand is required to be present for stem cells to undergo 
differentiation and even enabling the cells to survive (Forsberg et al. 2012). This study 
suggests that low sulphated heparin could maintain a more immature phenotype or 
developmental state. If desulphated mimetics establish an environment similar to early 
developmental stages around the injury site, this could be why there is repair and 
regeneration after trauma in this injury model. Evidence has arisen which suggests that 
successful regeneration after SCI needs to be accompanied by a developmental state 
which can aid in neural pathfinding and circuit-refining mechanisms (Harel and 
Strittmatter 2006). However, astrocytes are not the only cells within this mixed 
population of glia and neurons in the CNS which express nestin. Radial glia cells also 
express Nestin and have been highlighted as a potential cell of interest in CNS repair, 
being linked with creating a more favourable developmental-like environment. 
Incidentally, mature astrocytes can de-differentiate to a radial glia phenotype, 
providing a scaffold for neurons to extend processes (Leavitt et al. 1999). This cellular 
shift could be responsible for the effects observed following treatment with 
desulphated mimetic. Radial glia have not been explored in this study, however, with 
this new evidence that nestin levels are increased following mHep treatment, these 
cells require further investigation. 
4.4.5 Treatment strategy 
The treatment strategy used (single treatment then recovery) could also be affecting 
the outcomes we recorded. Previous treatment strategies using this model as published 
in Boomkamp 2012 and 2014, employ a continuous presence of the compound with 
administration occurring from DIV25 every other day until DIV31. However, this method 
was detrimental to the cultures during the preliminary stages of the study. This lead to 
both a reduction in the concentration of the compound but also to the number of times 
the compound was administrated following injury, and this method of treatment was 
then subsequently applied to the beneficial desulphated mimetics. 
The treatment method used here could be a crucial factor in the promotion of 
myelination. The desulphated heparin mimetic effect on OPC/OL could be a balancing 
act between proliferation and differentiation. Rosenberg and Chan use the phrase 
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‘Timing is everything’ and following injury to the culture the single treatment as 
opposed to repeated treatments could be a factor in the promotion of myelination. 
Potentially, a sustained treatment could have yielded a different result. As alluded to 
earlier, persistent activation of a signalling factor could actually hinder the repair 
process. A study highlighted that overexpression of -catenin can be detrimental to 
microtubule/actin organization (Ligon et al. 2001), therefore indicating that persistent 
activation of the signalling pathway targeted by the mHeps could potentially be 
detrimental to the both myelination and neurite outgrowth. 
4.5 Conclusion 
Selective desulphation of heparin has shown potential as a treatment for SCI using this 
in vitro SCI myelinating culture. The results gathered in this study demonstrate a role 
for sulphation in injury, in the form of exogenous desulphated mHeps inducing 
beneficial effects in the form of promotion of myelination and neurite outgrowth.  
There is a possibility that the different biochemical structures of each heparin mimetic 
could be mediating different or multiple signalling ligands and receptors. Therefore, 
each mimetic could have different mechanisms of action, which could initiate different, 
potentially beneficial, recovery mechanisms following injury.  
The mimetics could be potentially acting as a sponge and clearing the availability of a 
detrimental ligand removing the hyperactivity of the negative signalling pathway, or 
enabling the activation of a beneficial pathway. It seems that both may be the case. 
The promiscuity of the mimetics may be the combinational treatment approach that SCI 
needs but in the form of a single orchestrator molecule.  
There are other factors which have not been addressed in this study relating to other 
structural features of the heparin molecule, such as the size of the carbohydrate. The 
size of the polysaccharide could alter the effect observed either negatively or 
potentially beneficially adding to the benefits and repair strength of the molecule. 
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Chapter 5 
 
Development of a novel microfluidic device 
to study CNS injury and regeneration  
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5 Result: Development of a novel Microfluidic 
device to study SCI and regeneration 
It is now apparent that conventional in vitro models are inadequate for the study of the 
CNS specifically, the highly specialised neuronal cells. Neuronal cells are specialised 
cells which extend processes over substantial distances and encounter many differing 
microenvironments. Conventional in vitro models do not provide control of the neuronal 
microenvironments and also they are inadequate in the study of the individual sections 
of the neuron such as the axon, dendrite or soma. Therefore, it is difficult to study 
molecular and cellular changes that occur during different states such as, during 
development or following injury.  For this reason compartmentalisation devices have 
been developed which allow for controlled isolation of the different parts of the 
neuron. The first devised technique for neuronal cell compartmentalisation was the 
Campenot chamber, which allowed for the study of axons independently from their cell 
body (Campenot 1977). Campenot chambers were primarily used for the study of 
peripheral nerve injury and regeneration processes (MacInnis and Campenot 2002).   
 
The next stage in CNS study has led to micro-scaled compartmentalisation devices and 
methodologies. The subject of micro scaled technologies was introduced previously 
(section 1.6.3.2). Lab-on-chip technology has been applied to cell biology and has 
created a powerful arsenal of tools for the study of neuronal-glial interactions and the 
targeted study of axons. Microfluidic technology is at the forefront of the in vitro 
revolution and has pushed boundaries, not only in cell biology, but, in fields such as 
protein crystallography, drug discovery and microbiology (Maeki et al. 2016) (Chi et al. 
2016) (Probst et al. 2013) (Saleh-Lakha and Trevors 2010). 
The microfluidic platform provides a means of not only compartmentalisation but also 
control of the fluidic microenvironment. This is due to the physical phenomena that 
intercedes at sub-millimetre dimensions within the devices. Microfluidic devices (MFD) 
take advantage of the change in forces that dominate within the devices. These 
include, creation of laminar flow, fluidic resistance and surface tension (Beebe et al. 
2002). Conventional in vitro models are dominated by turbulent flow, whereas, 
microfluidic devices are dominated by laminar flow. These two fluid regimes differ in 
that laminar is controlled directional particle fluid flow and turbulent is chaotic/ 
unpredictable (Beebe et al. 2002). The fluid dynamics of a system is defined by 
Reynolds number (Re). This number is calculated using the fluid density, velocity of the 
fluid, viscosity and hydraulic diameter (of the microchannels). Any device using 
microchannels almost always involves laminar flow (White.F. 1991). Therefore, a Re < 
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2300 indicates laminar flow whereas, >2300 indicates signs of turbulent flow. The 
creation of laminar flow can lead to the creation and manipulation of particle diffusion 
within the device (Dertinger et al. 2001). Thus, creating an in vitro model (as it more 
accurately represents the fluid dynamics in vivo), which allows the movement of 
extracellular fluid carrying secreted molecules, which can create diffusion gradients 
within in a microenvironment.  
Microfluid devices are economically viable as the ‘master mould’ from which a 
particular microfluidic device can be cast, can be repeatedly used. The device is casted 
in Polydimethylsiloxane (PDMS) which is a relatively cheap elastomer (Peterson et al. 
2005). The concepts of microenvironment manipulation and regulation of diffusion 
gradients make microfluidics a promising prospect for the study of SCI and neuroscience 
in general. 
Neuroscience, like other areas of biological sciences, can exploit the benefits of 
microfluidics. This experimental tool allows for a multifaceted approach to the study 
neuroscience. For example, the study of genetically manipulated cells and their 
responses to various potential therapeutic treatments can be investigated using a 
microfluidic platform. This enables individual neurons and their axonal/dendritic 
processes to be studied in isolation allowing genetic diseases such as Parkinson’s disease 
and Alzheimer’s disease and their responses to be mapped in greater detail than 
compared to standard in vitro cultures (Song et al. 2014) (Seidi et al. 2011).  
Electrophysiology can be performed within the device using patch clamping so the 
electrical functionality of individual neurons can be assessed. In addition, the study of 
localised physiology of isolated cellular projections such as axons can allow for 
comparison between the axonal and somal proteome and gene expression patterns 
(Taylor and Jeon 2010). Even the investigation of neurological behaviour is possible,a 
device has been created which again exploits the microfluidic technology but this time 
focusing on the multicellular organism C.Elegans (Chronis 2010). Here, the device was 
used to study locomotion and olfactory sensing in a precisely controlled manner by 
controlling the diffusion gradient. This enabled visualisation of whole organism neural 
activity, which is not possible using a standard non-compartmental and fluidically 
control in vitro system. The examples discussed have utilised the many benefits of 
microfluidics, but for the purpose of my study the salient quality of the microfluidic 
technology is the compartmentalisation of neuronal and glial cells and the introduction 
of targeted injury in a closed system. This enables the investigation of neurite 
outgrowth and myelination in a primary spinal cord cell culture in a manner not possible 
with our previous model or any published model.  
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The standard myelinating culture and the SCI model have a number of limitations when 
it comes to the study of axonal outgrowth and understanding the mechanisms of repair. 
The neuronal organisation in the myelinating culture is not representative of the in vivo 
physiology, specifically the neurons are not aligned, which results in neurites and 
neuronal cell bodies being proximal to each other. In the case of injury this creates an 
injury environment which is not seen in vivo, and potentially generating inaccurate 
responses in repair and regeneration processes. Furthermore, due to the lack of defined 
neuronal orientation, injury induction can be inconsistent between cultures making the 
targeted study of axons and other neurites very difficult. Finally, there is no 
compartmentalisation and isolation of cellular populations so focused treatment is not 
possible. Addressing all of these factors is crucial to gaining a better understanding of 
CNS repair and regeneration. 
5.1 Aims 
To overcome the limitations of the standard myelinating culture, the aims were 
 Use commercially available culture isolation devices to compartmentalise the 
CNS populations of cells of the myelinating culture. 
 Develop a novel microfluidic device for the study of axonal injury and repair. 
 
5.2 Result: Using Ibidi® culture inserts to 
compartmentalise CNS cells for injury and 
regeneration 
Our primary investigation into the compartmentalisation of neuronal cell bodies from 
their projections involved the use of commercially available culture inserts, Ibidi® 
Culture Inserts. These inserts are composed of two chambers aligned side by side, into 
which cells or molecules can be placed, after which the insert can be removed to allow 
the interactions of the components of the both chambers to be analysed (Fig.5.1.Ai). 
These products have been used previously for studying cell migration, wound healing 
and cell invasion (Chang et al. 2015) (Tolg et al. 2014) (Shih et al. 2012) (Higginson et 
al. 2012).   
We aimed to use the Ibidi® insert, to compartmentalise neuronal cell bodies from the 
neurite projections. Figure 5.1 visually demonstrates the conceptual parameters of the 
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insert design of the method we employed, including the specific seeding arrangement 
and orientation. 
5.2.1 Establishment of the seeding protocol for Ibidi® culture 
inserts as a means of isolating different cellular populations 
A single Ibidi ® culture insert was placed on top of a standard 13 mm PLL-coated 
coverslip and adhesion occurred with light pressure applied to the insert. These were 
then inserted into a 24 well culture plate. The chambers of the insert will be referred 
to as insert chamber 1 and 2 with left chamber being 1 and right chamber being 2 (See 
Fig.5.1. ii-iii).  
The astrocyte seeding protocol was performed as described previously in (Higginson et 
al. 2012) with some minor modifications. Neurospheres were first differentiated into 
astrocytes, then trypsinised and counted, using a cell density of 2-3 x 104 cells in 70 µl 
in chambers 1+2 (Fig.5.1. iv). Astrocyte confluencey was achieved in each chamber 
prior to the seeding of spinal cord cells.  
Dissociated rat mixed spinal cord cells were generated as previously described (section 
2.3) with slight modifications. Insert chambers 1 and 2 were emptied of all media prior 
to the addition of the spinal cord cell mix. Spinal cord cells were seeded 15 x 104 cells 
in 70 l PM/DM+ (neuronal cell media) to chamber 1 and 70 l PM/DM+ only in chamber 
2 (Fig.5.1.v). The spinal cord mix was left to adhere for 2 hours before the culture 
insert was removed, with each chamber being emptied prior to insert removal to 
prevent unadhered cells from washing over to the neighbouring chamber. The entire 
well containing the culture was flooded with 500 l of PM/DM+ and maintained 
according to the previously described myelinating culture method (section 2.8).  
Following the removal of the insert, we hypothesised that the neurites should extend 
across the insert interface to the neural-free chamber, creating an area for targeted 
neurite injury investigation (Fig.5.1.vi-vii).  
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Figure 5.1 Myelinating culture compartmentalisation using Ibidi ® culture inserts. 
The Ibidi ® insert was placed on a standard glass cover slip (ii and iii) Astrocytes were 
seeded in chambers 1 and 2 and allowed to become confluent taking ~4 days (iv), then 
disasociated spinal cord cells were seeded into chamber 1 only (v). Neurite extended from 
the seeding chamber out over the astrocyte space (vi) and injury induction applied to 
neurite which extend over to chamber 2-the astrocyte only side (vii). 
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5.2.2 Astrocytes in both chambers migrate into the cell free space 
created by the insert joining both populations 
To assess the astrocyte response when placed in the culture inserts, astrocytes were 
cultured in the absence of the spinal cord cells.  
Following astrocyte seeding, the cells became confluent at 3-5 DIV, then the insert was 
removed (Fig.5.2.Ai). Astrocyte migration into the cell free space created insert can be 
seen 2 days following the removal of the insert (Fig.5.2.A). Both astrocyte populations 
show cellular elongation and migration into the cell free space; whether that is the 
space between the chambers or the space surrounding the entire insert. The astrocytes 
migrated into the cell free space created by the insert at day 3 post insert removal.  
The original cell free space can be located as the cellular morphology of the astrocyte 
in this space is more process bearing and elongated compared to the flat, ‘cobble stone’ 
morphology of the astrocytes in the seeding chamber (Fig.5.2.B). However, these cells 
are successful in forming a confluent monolayer between the two chambers, which is 
necessary for neurons to project neurites in culture.  
These data support the use of these inserts, as the cells appear viable and can migrate 
into the cell free space and create a confluent monolayer connecting the two chambers. 
The cultures were fixed and stained using the same protocol described previously 
(section 2.10). 
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Figure 5.2 Astrocyte response to insert seeding and removal. 
(A) Phase contrast images of the cell free space (depicted by dashed lines) taken at days 1-4 
following insert removal. (B) Astrocytes stained with GFAP (green) following insert removal. 
Scale bar-25 µm. 
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5.2.3 Spinal cord cells have no defined directionality and neurite 
extension is too low to allow targeted injury of neurites 
Following the investigation of astrocyte response to the culture insert system, we next 
assessed the properties of the dissociated rat spinal cord cells when added to chamber 1 
of the inserts.  
Following the formation of the astrocyte monolayers generated in chambers 1 and 2, 
spinal cord cell mix was added to chamber 1. These cultures were fixed and stained for 
-tubulin to identify neurons and neurites, to map the progress of the neuronal 
processes. 
The neuronal migratory response to the removal of the insert appears to be tied in with 
the astrocyte response. The neuronal cells moving into the cell free space with the 
astrocytes likened to ‘riding a wave’ (Fig.3-3.B). Neurites follow no apparent direction 
with neurite projecting in any given direction. -tubulin staining was present in the 
neuronal free area after removal of insert (A), so prior to insert removal the wells are 
emptied and washed with fresh media to remove any unadhered cells.  
Additionally, the identification of the neuronal cell body-free area, the area which is to 
be subjected to the injury was difficult to find, by eye, making accurate injury site 
induction difficult.  
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Figure 5.3 Seeding of spinal cord cells into the culture insert. 
Spinal cord cells were seeded on top the astrocyte (green) monolayer in chamber 1. (A) β-
tubulin (red) neurite staining in chamber 1 and (Ai) wash over of neurites in chamber 2. (B) 
Demonstrates the neurite ‘wave’ migration into the cell free space. Scale bar-25 µm.  
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5.2.4 Single Ibidi ® culture insert - Conclusion 
The aim of this section was to compartmentalise the neuronal cell bodies from the 
neurite processes, using a commercially available culture insert. The insert allowed for 
the successful seeding of both astrocytes and spinal cord cells into the chambers. 
Astrocytes successfully migrated into the cell free space created by the removal of the 
insert. However, the extension of the neurites from the spinal cord cell mix seeded in 
chamber 1 into the adjacent compartment was unsuccessful.    
The astrocytes were able to adhere and migrate into the cell free space created by the 
insert, forming a monolayer of cells. This was crucial as primary immature rat neurons 
and neurites require both physical and trophic support from a confluent monolayer of 
astrocytes to develop. Therefore, if a cell free space was maintained between the two 
chambers, the neurites would not be able to extend across into the soma-free space. 
The original purpose of this design was to isolate the neuronal cell bodies from the 
processes so that injury could be targeted to the neurites alone, a more accurate 
representation of the in vivo injury state. Isolation of the cell bodies was partially 
achieved; they were seen to reside in the primary chamber site in which they were first 
seeded, however, there was no consistent neurite orientation towards the cell body 
free space which was required for targeted injury induction. The random orientation 
may be related to the lack of guidance cue gradients of certain neurotrophic factors 
(Kennedy et al. 2006) (Guan and Rao 2003), which would provide a neurite orientation 
to a defined location. Potentially, the neurotrophic factors are lost in the surrounding 
media, a product of turbulent flow, making neurite orientation seemingly random, but 
in fact just a product of the lack of definitive diffusion gradients.  
Optimisation for this design would involve overcoming the lack of aligned neurite 
extension. This could be done by increasing the number of spinal cord cells seeded, to 
increase the number of neurites we see in the soma-free space. However, this idea is 
potentially detrimental, with increased cell number and density, so does the chance of 
the culture being lost from sloughing off the coverslip.  
Furthermore, surface topographical cues could be used to promote alignment of the 
neurites. This idea was investigated by using aligned fibrillary collagen matrix to align 
white matter neurons using Ibidi® inserts (Lanfer et al. 2010). This approach however, 
may not be appropriate in this culture system as the astrocyte monolayer may mask the 
alignment potential of the collagen. However, astrocytic alignment has been shown to 
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increase neuronal growth and alignment in culture (East et al. 2010). This suggests that 
astrocyte alignment could increase the number of neurites seen in the soma-free space.  
Another way to promote neurite extension would be to modify the insert design. The 
addition of a second culture insert directly adjacent to the first would allow for an 
additional spinal cord cell seeding chamber. Therefore, this could increase the number 
of neurites in the soma-free chamber. This new design may also help promote an 
increase in neurites due to the guidance cues secreted from the adjacent neuronal 
populations. In addition, this design would allow for easier identification of the soma-
free area for precise injury induction. 
To gain a deeper insight into the axonal response to injury there is need for the 
development of a model which allows for neurite compartmentalisation. However, as it 
is this culture design does not enable the investigation of neurites separate from their 
soma. 
5.3 Result: Development of a dual insert 
compartmentalised co-culture model of CNS injury 
and regeneration 
The single culture insert design investigated in the previous results section was limited 
in its capacity to provide adequate neurite numbers for injury analysis. This could be 
due to the number of initial spinal cord cells seeded or due to lack of neurite guidance. 
Furthermore, the identification of the potential injury area was difficult. 
The subsequent compartmentalisation design accommodated two culture inserts. Figure 
5.4 visually demonstrates the method employed, including the specific seeding 
arrangement of astrocytes and spinal cord cells and orientation of the inserts. Larger 
coverslips were required to accommodate the two inserts which were placed in 6 -well 
culture plates. This method created a second, much larger cell free space between the 
two individual inserts when the inserts were removed. This design also helped to 
identify the area which is subjected to injury, this is because a clear central cell area 
will be easily identifiable by eye. In this following section, the seeding wells are 
denoted as chambers when the insert is still in place and are denoted as cell areas once 
the insert is removed.  
It was hypothesised that this set up would overcome the problems with neurite 
outgrowth the problem accompanying the single insert design. The aim of this was to 
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develop further the compartmentalisation design to increase the neurite number for 
injury induction.  
 
 
Figure 5.4 Dual insert compartmentalisation method 
Two Ibidi® culture inserts were placed next to each other on a 30 mm coverslip. Astrocytes 
were seeded into all chambers. A cell free space was formed between chamber 1 and 2 but 
also between inserts so between chamber 2 and 3. Spinal cord cells were seeded into 
chamber 1 and 3. 
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5.3.1 Astrocytes seeded in chambers 2 and 3 do not migrate and 
fully close the cell free space created following insert-insert 
removal 
To assess the astrocyte response in this new dual insert method, observations were 
made on astrocyte culture in the absence of spinal cord cells. 
The seeding protocol was similar to that described above, with the addition of seeding 
astrocytes into chamber 3. The final cell seeding volume was 70 l per insert at a cell 
density of 2-3 x 104 cells. Both culture inserts were removed from the coverslip after 3-
5 DIV, creating two cell free spaces with the cell free space between the two inserts 
being larger than the cell free space between the two chambers of an individual insert. 
The cell free space created by the insert-insert arrangement ranged from 1000 m at 
the edges to 950 m at the centre. The astrocytes failed to migrate fully into this cell 
free space resulting in a cell free space devoid of astrocytes (Fig.5.6.B-Bi). Astrocytes 
originating from chambers 2 and 3 both extended processes and displayed an elongated 
morphology in the cell free space but failed to form a confluent monolayer following 9 
DIV. The cell free space created by the insert alone between chambers 1 and 2 was fully 
populated by cells as observed in (Fig.5.6.A). However, the closure time of this space 
was increased from 2-3 DIV to 4-6 DIV. The cultures were fixed and stained for 
astrocytes for GFAP to map the progress of the cells. As neurites require a confluent 
monolayer to support their extension, this design is not suitable for investigating 
neurite-specific injury.  
5.3.2 Additional spinal cord cell seeding does not increase the 
observed number of neurites in the central area 
Spinal cord cells were added to chamber 1 and chamber 3 following confluence of the 
astrocyte monolayer, at a concentration of 1.5 x 105 per 70 l. The cells were allowed 
to adhere for 2 hours before each well was emptied of all media and washed with fresh 
media. Each insert was removed, followed by flooding of the cells with 1 ml of PM/DM+ 
media. The cultures were fixed and stained using the same protocol described above; 
neurons and neurites stained with B-tub and SMI31 depending on the maturity of the 
culture to map the progress of the neuronal processes, nuclei with DAPI.  
Following the seeding protocol for spinal cord cells, few neurites projected from area 1 
into the central area, which was observably no more than with the single insert design 
(Fig.5.A1). Due to the lack of cellular closure of the insert to insert cell free space, the 
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neurites from area 3 did not populate the central area and increase the observable 
neurite number. Furthermore, the astrocyte migration seemed to be additionally 
hindered in the presence of the spinal cord cells. Neurite trajectory was similar to that 
seen in the single insert experiment with no defined orientation (Fig.5.Bi)   
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Figure 5.5 Astrocytes do not migrate and close the area between the two inserts leading to 
no improved neurite number in the central area. 
Astrocytes were seeded into all chambers. Following 4 DIV spinal cord cells were seeded 
into chamber 1 and 3. (A) Astrocytes (GFAP, green) migrating and closing the cell free 
space created within the insert. (Ai) neurites seen extending from area 1 into soma-free 
space. (B) Astrocytes (GFAP, green) can be seen migrating into the space created between 
the two inserts, failing to form confluency. (Bii) neurites (β-tubulin, red) can be seen 
migrating as far as the leading astrocyte but no farther. (C) Is a schematic of the positions 
of the fluorescent images (A-Bi). Scale bar 25-µm. 
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5.3.3 Dual culture insert as a means of increasing targeted injury 
Even though initial observations indicated that there were few neurites extending into 
the central area, neurites projected sporadically from area 1 into the central area are 
were then subjected to injury. The central area was more easily identified in the dual 
insert system than in the single insert system, which was why this was used for injury 
experimentation. 
Following astrocyte and spinal cord cell seeding into the appropriate chambers, the 
central area was easily identified by eye. The cultures were matured for 14 days, then 
subjected to injury, using a single flat edge blade. However, due to the lack of neurites 
in the central area, the injury was induced at a site closer to area 1 and 2 rather than in 
the centre of area 2. Injury was induced directly proximal to area 1 which would allow 
for the greatest likelihood of neurite injury. The injury cultures were then visualised to 
determine the injury response, they were fixed and stained, for neurites using SMI31, 
nuclei with DAPI and myelin with PLP. 
The central area was easily identified and injury was induced. The astrocyte response to 
injury was similar as seen previously within this thesis and published observations 
(Boomkamp et al. 2012), with an initial cell free space being invaded by astrocytes 
which have a reactive morphology (Fig.5.6.B). The limited number of neurites which 
had migrated into this area were severed and no neurites were observed entering the 
lesion site (Fig.5.6.B). 
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Figure 5.6  Dual insert lesion 
Injury was performed by targeting the site between area 1 and 2 to increase chance of 
neurite injury. (A) Shows injury induction schematic. (B) Shows the lesion attempt, white 
dashed lines highlights lesion site, neurites (red) and astrocyte (green) and the few neurites 
growing out into the lesion site. Scale bar 25-µm. 
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5.3.4 Conclusion 
The development of a dual insert design failed to meet the desired criteria set out at 
the start of this section, namely the separation of neurte projections from the soma. 
The design only overcome the pitfalls created with the single insert method, which was 
the lack of identification of the central area. Many of the limitations of the single insert 
method apply to the dual insert method as discussed in section 5.2.4. The first problem 
arose with the inability of the astrocytes to migrate and close the insert to insert cell 
free space. The lack of astrocytic migration, subsequently led to a lack of neurite 
presence in the central area, therefore failing to increase the number of neurites in the 
injury site.  
There was no observable indirect promotion of neurites in the central area due to the 
addition of another neuronal population and a potential increase in guidance cues by 
the opposing neuronal populations. This failure could be again due to the lack of 
controlled diffusion of guidance cues in the culture dish as discussed previously with the 
single insert design. Any neuronal guidance factors released by the cells in the culture, 
such as those in the Netrin family (Kennedy et al. 1994) and slit proteins (Bashaw and 
Goodman 1999), diffuse uniformly through the entire culture due to turbulent flow, 
leading to a lack of defined growth and guidance of the neurites. Additionally, the lack 
of neurite extension could be related to the inability of any cell, including astrocytes, in 
a 2D environment to adequately form the ECM where the guidance cues would 
otherwise direct the growing neurites. It has been known for many years that the 2D in 
vitro models have limitations in the study CNS ECM-related function (Cullen et al. 2011) 
(Fawcett et al. 1989). However, decellularisation techniques could be employed to 
quantify ligands or guidance cues which are bound in the ECM of these cultures (Gao et 
al. 2013). This would test whether the 2D ECM of these cultures is capable of interacting 
and mediating neurite guidance in this system and would provide evidence whether the 
lack of guidance is not solely related to lack of fluidic diffusion gradients, but a lack of 
ECM to ‘house’ and sequester the guidance factors.    
This dual insert design did allow for focused injury induction. The symmetry created by 
the two inserts allowed for easy identification of the central chamber, which was not 
possible with the single insert design. Injury to this area showed similar visual 
similarities to the previous cutting technique used in the myelinating cultures 
(Fig.5.6.B).  Furthermore, neurites were severed and the underlying astrocyte 
monolayer was damaged, with the astrocytes responding as previously described 
(Boomkamp et al. 2014; Boomkamp et al. 2012) and observed elsewhere (Etienne-
Manneville and Hall 2001). 
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Due to the lack of astrocyte closure at the insert-insert space there was no neurite 
extension across the cell free space to the central area. This process of astrocytic 
guidance has been observed elsewhere; in vitro models have demonstrated the need for 
astrocytes to support overlying neurons (Sorensen et al. 2008a) (Recknor et al. 2004), 
also during development neurons rely on astrocytic tracts to guide the neurons to their 
desired locations where they can mature and function (Lois et al. 1996). For this reason 
the lesion was created at a site closer to chamber 1 and 2, rather than at a more 
central position, so the neurites which extended into the central space were injured.  
Logical progression from this design would be a new insert culture device which has a 
triple chamber design with a uniform space between chambers 1-2 and 2-3, to 
overcome the lack astrocyte migration seen in our dual insert design.   
5.4 Novel Microfluidic device to study SCI and 
Regeneration 
The culture insert techniques provided valuable preliminary results, specifically the 
requirement of multiple neuronal populations converging on a central area; which 
would allow for direct analysis of the effects of injury and treatment on neurites in the 
absence of any neuronal cell bodies. Also, the two designs highlighted the need for 
manipulation of the cellular microenvironment, through controlled diffusion gradient 
across the entire culture, if we aim to create a more accurate representation of the in 
vivo environment (Whitesides 2006). However, the culture insert designs hit major 
obstacles, specifically; the lack of design freedom to add or rearrange the chamber 
positions, the difficulty in neurite separation from cell body, inadequate neurite 
number and finally the inability to manipulate the microenvironment. 
With these new criteria plus the formation of a new collaboration with Dr. M. Zagnoni at 
the University of Strathclyde, it was possible to develop a novel microfluidic device to 
study spinal cord injury which should meet all the criteria highlighted from the previous 
experiments. 
A novel microfluidic platform to study axonal biology 
Microfluidic technology has been shown to be a powerful in vitro tool, due to its ability 
to precisely control, monitor and manipulate cellular microenvironments. This is 
achieved by controlling volume differences between to culture chambers connected by 
microchannels. Microfluidics technology has been used in the study of localised 
physiology of isolated cellular projections such as axons (Taylor and Jeon 2011). These 
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microchannels are hijacked by growing neurite which enter and extend down the 
microchannel exiting in the adjacent chamber, where soma cannot. Therefore, allowing 
compartmentalisation of the neuronal cell body from the neurite (Gross et al. 2007; 
Taylor et al. 2005). Here we are adopting this technology and applying it to the study of 
axons.  
Microfluidic technology has been accepted with open arms in the study of axonal 
biology. Device design freedom allows for complex biological interactions to be studied 
in greater detail than ever before. There is a lot of design freedom with a wide range of 
designs possible using the fabrication technique known as soft lithography (Whitesides 
et al. 2001). Soft lithography refers to the creation of a master mould which has the 
device design including seeding chambers and microchannels, which then can be 
stamped onto a material to create the device. Devices are fabricated from 
polydimethylsiloxane (PDMS), a plastic polymer which has useful characteristics such as 
elasticity, durability, biocompatibility and optical transparency (McDonald et al. 2000). 
PDMS-based microfluidic devices have several useful characteristics such as elasticity, 
durability, biocompatibility, optical transparency, gas permeability, no toxicity, and low 
electrical conductivity (McDonald et al. 2000). This system uses computer-aided design 
software for designing the compartment/chambers and microchannels, that are etched 
etched on to a photoresist material so that an inverse master mould is formed. PDMS is 
then cast on the mould creating a device which has the desired compartmentalised 
chambers and microchannels.  
Axonal guidance cues have been studied in detail and many factors have been described 
in both repulsion and attraction (Dickson and Senti 2002). Microfluidic devices have 
been designed to study these factors in greater detail, (Joanne Wang et al. 2008) using 
a novel microfluidic device showing that the ECM bound molecule, laminin, plays an 
intricate role in the response of the axonal growth cone to brain-derived neurotrophic 
factor (BDNF). This observation was not possible using standard in vitro methods. These 
designs have capitalised on the physical microchannel guidance and axonal targeting 
towards a desired repulsion or attraction factor.  
Microfluidic technology has also been used in the study of microglia-axonal interactions, 
specifically the response of microglia to health and injured/degenerating axons 
(Hosmane et al. 2010). A novel spherical multi-chambered device was created, which 
observed the migration of microglia along the axon with higher numbers being found 
around the injured axon (Hosmane et al. 2010). This study allowed the tracking of glial 
cells with individual and bundles of axons providing a far more detailed study of the 
interaction occurring along the axons. Microfluidic technology can allow for comparison 
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between the axonal and somal proteome and gene expression patterns (Taylor and Jeon 
2011) and also the targeted injury of axons through compression and stretching 
techniques (Hosmane et al. 2011) (Yap et al. 2014).  
For the purposes of this study, the most important quality of the microfluidic 
technology is the compartmentalisation of neuronal and glial cells which allows for the 
introduction of targeted injury in a closed system. This quality enabled the investigation 
of axonal outgrowth and myelination in primary spinal cord cell culture in a controlled 
manner not possible with our previous model or any published model. This technology 
has become available to this lab through collaborations with Michelle Zagnoni and 
Trevor Bushell at the University of Strathclyde, who provided help in designing the novel 
SCI-microfluidic device (SCI-MFD). 
Controlling the media volumes in the seeding chamber and the central chamber can 
allow for the manipulation of diffusion gradients within the device by a process known 
as hydrostatic pressure-caused laminar flow. This property allows for isolated treatment 
of each of the chambers so that treatment in chamber 1 will not cross into the adjacent 
chambers. This allows for the study of targeted treatment of different neuronal 
populations and different sections of individual neurons, such as treating the injured 
axons and studying the knock on effects on the cell bodies, or vis-versa. This will allow 
for a more in vivo-like treatment strategy as treatment of the injury site through 
injection may not directly affect the neuronal cell bodies associated with injury site. 
 
5.4.1 Microfluidic devices to study axonal injury 
In collaboration with the University of Strathclyde we designed the first SCI-MFD. 
Fig.5.8.A shows the novel MFD; the SCI-MFD has a detailed micro-pattern which 
comprises the 2x inlet and outlet ports, 2x seeding chambers and 2 sets of 
microchannels 500 µm in length that converge onto a single central seeding chamber. 
The device is symmetrical down the central vertical axis, which enabled manipulation of 
diffusion gradients. Two variations on the device design were tested, differing only in 
width of the microchannel; 40 µm and 20 µm (Fig.5.7.B). Following device fabrication 
and assembly (see Materials and Methods 2.5) each compartment was PLL coated (4 
g/ml) for 1 hour. The cell seeding method is detailed in section 2.5; astrocytes were 
differentiated from neurospheres in a T75 flask for 4 days in 10% FBS and these 
astrocytes were seeded into chambers 1, 2 and 3 at a density of 5 x 104 in 5 µl for 15 
mins then a further 115 µl added to each chamber. Neurospheres which were not 
differentiated were also seeded into the chamber to investigate if they could 
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differentiate into astrocytes and form a confluent monolayer. Disassociated spinal cord 
cells was then introduced into chamber 1 and 3 at a density of 3.5 x 105. The MFD was 
visualised live using phase contrast microscopy. The devices were fixed and stained 
using the protocol described in section 2.9. The cultures were stained for appropriate 
neuronal markers, β-tubulin and SMI31 depending on the maturity of the culture, 
astrocytes were stained using marker-GFAP, myelin was stained using marker PLP and 
nuclei were stained using DAPI and Axio Fluorescent microscopy.   
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Figure 5.7 Spinal cord injury microfluidic device (SCI-MFD) 
The SCI-MFD (A) which comprises of the 2x inlet and outlet ports, 2x seeding chambers and 
2 sets of microchannels that converge onto a single central seeding chamber. The device is 
completely symmetrical down the central vertical axis. The schematic can be seen in (A) 
and an enlarged section depicting the seeding protocol for neurons and astrocytes and the 
axonal migration down the microchannel (Ai). (B) shows the widths of the microchannels 20 
µm and 40 µm. (C) photograph of the device.  
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5.4.2 Astrocyte monolayer confluency was only observed in SCI-
MFD with differentiated astrocytes 
Astrocyte confluency was achieved after 3 DIV (Fig.5.8.B and D) in the microfluidic 
device by seeding differentiated astrocytes at a density of 3.5 x 105 per 5 µl volume into 
the inlet port of chamber 1 and 3 and directly into chamber 2. Following 15 minutes 145 
µl of 10% FBS was added to each seeding chamber creating a final volume of 150 µl. 
Seeding with neurospheres did not allow for the formation of an astrocyte monolayer in 
chamber 1 and 3 (Fig.5.8.E), the closed seeding chambers.  
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Figure 5.8 Astrocyte seeding in the MFD 
Astrocytes were firstly differentiated from neurospheres in a T75 flask and seeded in the 
device at 3.5*105 at 5 µl volume. (A) number the chambers which are seeded with 
astrocytes/ (B) a representative phase images of the seeding chambers, (C-D) 
immmuocytochemisty images stained for GFAP (Green) and DAPI (Blue) for Chamber 1 and 
2. (E) Neurosphere seeding into chamber 2. All immunostainings images were taken 3DIV, 
Scale bar-25µm. 
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5.4.3 Cellular invasion down the microchannel 
From phase microscopy cellular components were seen down the microchannels which 
appear more in the injury device with 40 µm-wide microchannels not the 20 µm-wide 
channels (Fig.5.9. A+B).  
To investigate the cellular invasion of the microchannels, immunohistochemistry was 
used to identify possible cells migrating down the microchannels. Initially, nuclei 
staining alone with DAPI showed massive infiltration of nuclei down the entire 
microchannel (see Fig.5.9.C). Upon further investigation the device design with 40 µm-
wide channels had vastly more nuclei infiltration than the 20 µm-wide device (see Fig 9 
A [40 µm] and C [20 µm]). Manipulation of the hydrostatic pressure across the 
microchannels resulted in a drastic decrease in the number of nuclei seen in the 
microchannels of both channel widths (Fig.5.9.F). Manipulation of hydrostatic pressure 
was achieved by maintaining identical volumes of media 50 µl in both central chamber 
and the adjacent chamber at the moment of seeding, (section 5.5.2). The 20 µm-wide 
device was taken forward for further experimentation. 
 
 
157 
 
 
Figure 5.9 Nuclei seen in microchannels in the 20 µm and 40 µm wide microchannel devices 
A and B show phase images of the channels with cellular intrusion .DAPI (blue) positive 
nuclei can be seen in the microchannel in both 20 µm 40 µm wide channels. 40 µm (C) have 
vastly more and down the entire channel length as compared to 20 µm (D). It is not known 
which cells types they are and if the nuclei presence is due to cellular migration or 
hydrostatic force acting upon the cells. Controlling volumes in the adjacent seeding 
chamber can remove nuclei present in the channel 20 µm (F) and 40 µm (E). Scale bar-25 
µm. 
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5.4.4 Neuronal and astrocyte processes extend down the 
microchannels. 
As the initial data showed that we could generate a confluent monolayer of astrocytes 
in each chamber, this gave us impetus to try the full, complex myelinating culture. 
Dissociated rat mixed spinal cord cells were generated as previously described from 
E15.5 Sprague Dawley rat embryos (Section 2.3). The seeding protocol was followed as 
previously described with slight modifications to the final seeding volume and cell 
density, so that 5 l of 5 x 104 spinal cord mix cells was added to chamber 1 and 
chamber 2. 
For optimal cell loading, all chambers were emptied of media prior to the addition of 
spinal cord cells. The spinal cord cell mix was added to chambers 1 and 3, and then the 
media DM+/10% FBS to chamber 2. Cells were observed by phase microscopy to 
determine if more or less media was needed to be added to the central chamber to 
adjust the hydrostatic pressure and manipulate the final position of the cells near the 
microchannels. The spinal cord mix was left to adhere for 2 hours then flooded with 145 
l of appropriate media to create a final volume of 150 l in each chamber. 
Following fixation, neurites were immunolabelled with β-tub and SMI31 depending on 
the maturity of the culture to map the progress of the neuronal processes in the 
chamber and microchannels. GFAP and DAPI were used to identify the astrocyte 
positions throughout the device.  
Fig.5.10.A-B shows astrocyte processes entering the microchannels and extending up to 
100 m after 3 DIV. In these experiments it appears that the astrocyte nuclei do not 
follow the processes, with no GFAP+ nuclei present in the microchannel at the distances 
the processes were observed. 
In addition to astrocyte processes, neurites (Fig.5.10.C-F) can be seen extending down 
the microchannels after 6 DIV and even exiting the channel into the open access 
chamber following a further 4 days in culture (see Fig.5.10.F).  
This data suggests that the device is capable of fulfilling the criteria of neuronal cell 
compartmentalisation with neuronal cell bodies remaining in the seeding chamber and 
neurites entering and exiting into the central chamber. Astrocyte process can be seen in 
the channels but do not appear to hinder the neurite entry. 
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Figure 5.10 Neurite and Astrocyte processes can be seen to migrate into and along the 
microchannels.  
Astrocytes (GFAP, green) were seeded into the device and following monolayer formation 
processes can be seen extending into the microchannels (A and B). Spinal cord cells were 
seeded and after 6 DIV neurites (β-Tubulin) can be seen in the microchannels (C-F). Scale 
bar; 15 µm (A-B and E-F) and 25 µm (C-D).  
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5.4.5 Antibody diffusion controlled by volumetric differences 
between chambers 
Manipulation of diffusion gradients can occur between two chambers which are 
connected by microchannels. The diffusion site can be seen in Fig.5.11.B-D. This allows 
for fluidic isolation of a particular treatment, or in this case a fluorescent antibody. 
Differentiated astrocytes were seeded in chambers 1 and 3 as previously described 
(Section 5.5.2). GFAP staining was used in each chamber but three different secondary 
antibodies were applied to each chamber. The device was fixed and immunolabelled as 
described in Material and Methods: 2.7. Chamber 1 contained anti-rabbit Alexa Fluor® 
488, chamber 2 containing anti-rabbit Alexa Fluor® 555 and chamber 3 anti-rabbit Alexa 
Fluor® 350, all targeting Anti-GFAP. Diffusion gradients can be seen between the 
chambers, with certain individual cells being co-stained with two different secondary 
antibodies without overlap (Fig.5.11.B-D). This dual staining is caused by the controlled 
diffusion gradient between the two chambers, making it so that the media solutions in 
each chamber do not mix. This creates a site where the two media solutions meet but 
do not overlap.  
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Figure 5.11 Antibody diffusion control within the SCI-MFD 
Astrocytes were seeded into the device and allowed to become confluent. The diffusion 
gradient created by media volume differences in chamber 1 and 2 can be seen A-B. Each 
chamber was stained for GFAP, chamber 1 GFAP-red (C), chamber 2 GFAP-green (B) and 
chamber 3 GFAP-blue (D). Scale bar-15 µm. 
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5.4.6 Injury Induction to the open access chamber resulted in no 
spontaneous axonal outgrowth. 
The device was seeded with astrocytes and spinal cord cells as previously described and 
cultured for 16 days to allow axonal migration down the microchannels. Injury to the 
open access chamber was performed using a P200 pipette tip, as the flat edge blade 
used in previous experimentation was too large. The culture was fixed and stained for 
axons (SMI31) and nuclei (DAPI) to identify the lesion site. The injury created a cell free 
space, which was subsequently closed by migrating astrocytes (Fig.5.12.B) and no 
spontaneous axonal outgrowth was observed, with no SMI31 positive processes in the 
lesion site (Fig.5.12.C).  
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Figure 5.12 Injury to open access chamber, shows no spontaneous axonal outgrowth 
Astrocyte confluency was achieved in all chamber then spinal cord cells were seeded into 
chamber 1 and 3. The cultures were matured for 16 days then subjected to injury, the injury 
position is marked with a line on the schematic (A). The cultures were fixed and stained 5 
days later, (B) for astrocytes (GFAP-green) which migrate and close the lesion and for 
axons (SMI31-red) no axons can be seen in the lesion site. White dashed line marks injury 
site (B-C). Scale bar 25 µm (B) and 15 µm (C). 
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5.4.7 Discussion 
This microfluidic culture device provides a novel method to align, isolate, lesion and 
analyse primary CNS axons and their glial interactions (Kim et al. 2009) (Park et al. 
2009b). The technique is reproducible due to the use of soft lithography and computer 
aided design machine to create the master mould of the device, leading to consistent 
device reproducibility (Wittig et al. 2005). This design of a SCI-MFD has to meet the 
desired criteria of neuronal compartmentalization, accessibility for injury induction and 
diffusionally controllable compartments. 
This novel SCI-MFD utilises the microchannels which generate the fluidic dynamics and 
diffusion gradients, but also allows for the compartmentalisation of the soma from the 
axons. This occurs as the axons can enter the microchannels but the neuronal cell 
bodies cannot.  
There are several prominent findings within this study:  
1. Axonal growth down the microchannels 
It appears the primary aim of this study to compartmentalise the soma from neurites 
was achieved. This was accomplished by the minimal diameter of the microchannels 
inhibiting the neuronal cell body from moving into the open access chamber, whilst 
being big enough to allow for neurite projection down the microchannels. 
Neurites/axons can and been seen to enter, travel down and exit the microchannels.  
However, optimisation is required to promote the number of axons entering the central 
chamber. This could be achieved by the addition of neurotrophic factors into the 
central chamber to attract axons, in a similar way to that which was discussed 
previously (section 5.3.2). A study has shown that neurites can respond and alter their 
growth pattern through the interaction with ECM molecules and guidance cues in a MFD 
(Joanne Wang et al. 2008). However, the use of neurotrophic factors may alter the 
response of the cells within the chamber as neurotrophic factors have also been shown 
to promote and affect the response of cells (Jordan-Sciutto et al. 2001). Therefore, the 
addition of neurotrophic factors could alter the culture conditions and in turn the 
response of the cells to injury, potentially confounding the results, making the use of 
chemical guidance cues a poor option for promoting axons in the central chamber. 
Additionally, more neurites/axons could be persuaded to enter the microchannels 
through manipulating the hydrostatic pressure so that the neurites are physically pulled 
into and down the microchannel.  
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Work by Gu and colleagues utilised the hydrostatic pressure aspect of the device, using 
the physical flow of the media on axonal mechano-sensing (Gu et al. 2014). Their novel 
device, using microsyringe pumps, showed an effective approach in directing axonal 
growth, in the absence of any biochemical guidance cues. This approach was novel in 
that the actual hydrostatic pressure and physical flow was shown to be a factor in the 
axonal guidance. 
The device design ensured that only axons not dendrites entered the central chamber. 
This was achieved by controlling the length of microchannels between the seeding 
chamber and the central chamber, a channel length of 500 µm was used to ensure there 
was no dendritic contamination of the central chamber. However, other studies have 
concluded that 200 µm was sufficient to isolate dendrites (Park et al. 2009b). Modifying 
our device to reduce the size may be an interesting option as this could potentially 
increase the number of axons in the central chamber. 
2. OPC/OL microchannel migration? 
An unexpected finding was nuclei in the microchannels seen in the astrocyte monolayer 
culture. Data has yet to be collected to ascertain which cell types they are and which 
chamber they came from by immunostaining. There are many potential theories to 
explain why these cells are in the channels but two will be discussed as these can be 
approached experimentally in future studies:  
1) Cellular migration down the channels.  
2) Hydrostatic pressure caused the cells to be forced down the channel. 
Both potential theories could be investigated through a single strategy. Controlling the 
hydrostatic pressure would lead to 1) the removal of any migratory signals which will 
cause the cells to enter and migrate down the channel and 2) volumetrically identical 
chambers prior to seeding so that no hydrostatic pressure is physically forcing the cells 
down the microchannels.  
However, if the cells are in fact OPCs then their presence down the microchannel could 
open up potential axonal myelination studies including the investigation of injury and 
repair in mature myelinated axons. Myelination has been studied previously with a 
microfluidic platform using a co-culture of OLs and axons (Park et al. 2009a). However, 
the SCI-MFD offers the chance to study myelination following mechanical induced 
injury, whereas the microfluidic platform in the previous study did not.  
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3. Fluidic isolation 
Microfluidic technology offers the ability to control diffusion gradient across a cell 
culture environment. Previous studies have demonstrated diffusion control, through the 
use of analytical methods and visual colourmetic methods to demonstrate fluid isolation 
(Robertson et al. 2014) (Park et al. 2009b). However, the demonstration of the diffusion 
gradients within the SCI-MFD was performed though preferential co-staining of 
individual cells in the chamber at the site of the diffusion gradient (see section 5.5.5). 
Here, two different secondary antibodies targeting the same primary antibody (GFAP) 
were able to stain the same cell without overlapping. This highlighted the potential 
scope of this device in terms of diffusion isolation and treatment options for different 
cell populations, specifically injured axons. This ability to control and manipulate 
diffusion gradients can avoid problems arising in standard in vitro model studies such as 
off-target effects of treatment due to the turbulent flow, which could confound 
observations and results. The co-staining result better represents the diffusion 
manipulation capacity of a device than previously demonstrated colorimetric methods 
because we showed that large macromolecules such proteins (IgG antibodies) can be 
precisely manipulated. Therefore, this demonstrates that treatments with 
macromolecules, such as antibodies, which is a popular treatment strategy in SCI, 
specifically, anti-NOGO (Freund et al. 2007) and anti-LINGO (Mi et al. 2005) can be 
precisely controlled within this device.   
4. Axonal injury 
The novel design feature of this MFD was the open access chamber which allowed for 
targeted injury of axons. This compartment housed a confluent monolayer of astrocytes 
and axons, which entered from the adjacent chambers. The preliminary results for 
injury using this device suggested that there was no spontaneous axonal regeneration 
following injury, which is a similar axonal response in vivo (Yiu and He 2006). 
Furthermore, this experiment lays the foundation for the study of treatments, such as 
desulphated mHeps, for the regeneration of injured axons in the absence of soma. 
Alternatively, treatments can be applied to the somal compartment only and the effects 
on the injured axons in the central compartment studied, providing the optimal target 
for a particular treatment. 
 Limitation 
A potential limitation in this study is the time frame for device fabrication and 
preparation. The device preparation is very time consuming with on average 20 devices 
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being made each day (based on a single photoresist mould) versus being able to PLL 
coat hundreds of coverslip per day as in the standard myelinating culture. It may be an 
unfair comparison as the SCI myelinating culture is a basic in vitro system with no 
complex use of technology which a limitation of the system. However, what I propose is 
using both techniques employing the SCI myelinating culture as a screen before then 
taking the findings to the MFD for more advanced detailed study of the axonal 
injury/repair process.  
 Further Investigation 
Further investigation is required to characterise the injury response of axons by looking 
at key injury markers to determine what factors are involved at the immediate injury 
site, when only axons and astrocytes are present. This could be achieved using the 
parameter employed by (Boomkamp et al. 2012), specifically, but not limited to, the 
astrocytic upregulation of GFAP and CSPG. More detailed investigations will be carried 
out looking at the differences in axonal-related injury and regeneration markers such as 
GAP-43 (Bomze et al. 2001), a known regenerative marker, between the axons and the 
isolated cell body.  
Optimisation is needed to increase the number of axons crossing the channel to increase 
our experimental material (axons) in the open access chamber. This could be achieved 
by manipulating the hydrostatic pressure by altering the volumes of media between the 
compartments to provide physical guidance cues to the neurites.  
Finally, to validate this SCI-MFD in context of SCI treatment, we could employ 
previously published compounds of repair, which have shown promise in neurite 
outgrowth such as Chondroitinase ABC and Rho pathway targeted treatments (Bradbury 
et al. 2002) (Dergham et al. 2002). Obtaining similar data to that published in these 
studies would endorse our SCI-MFD model as being a suitable platform to study SCI as it 
is reflective of the in vivo environment.  
5.5 Conclusion 
The aim of this chapter was to develop a compartmentalisation device to study neurite 
outgrowth and repair. The first step to address this aim was the use of the commercially 
available Ibidi® culture inserts. These culture inserts highlighted the need for a 
multiple chamber device, with more neuronal populations converging on a single open 
access chamber from distances no more than 800 µm. The insert experiments were only 
brief investigations into the cellular growth and migration within the inserts. Each 
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experiment was a stepping stone which led to the next design, each addressing a 
limitation of the last. Throughout this study it became apparent that for 
compartmentalisation to be achieved there was a requirement to provide artificial 
guidance to the neurites and control of the fluid microenvironment around the cells in 
culture. Both of these criteria could be met through the use of microfluidic technology.  
The Ibidi® culture insert was a valuable starting point, and these experiments provided 
the preliminary data which led to the development of the final MFD designs. This device 
enabled compartmentalisation of the axons from the soma in a neuronal-glia co-culture 
through providing artificial guidance to the neurites, provided by the microchannels and 
through the control of the fluid microenvironment. Together, these culminated in being 
able to injure axons independently from the soma. Although no spontaneous axonal 
regeneration was observed, this model could provide the means to investigate the 
effects of treatments on axons specifically by adding these treatments to the central 
compartment.  
This novel SCI-MFD presented here describes an innovative approach to the study of 
axonal injury and regeneration. This device offers the chance to overcome several 
major limitations in the study of axonal biology such as the study of axonal response to 
injury and treatment in a complex multi-cultured system.  
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6 Discussion 
The overall aims of this PhD were to identify novel compounds to support repair and 
regeneration after SCI using a medium throughput screen and to develop a 
compartmentalised culture model of SCI to study targeted axonal injury. 
There are two principle findings of this thesis: 1) the identification of a subset of novel 
compounds, desulphated heparin mimetics, for SCI repair and their proposed mechanism 
of action and, 2) the development of a novel microfluidic culture platform to study 
axonal injury. 
 
6.1 Use of SCI model as a medium throughput screen 
Using the injured myelinating culture, and monocultures I was able to suggest a new 
therapeutic family of compounds for SCI relating to neurite outgrowth and myelination, 
namely heparin mimetics. It is well known that a successful intervention for SCI would 
be a combinatorial therapeutic approach including targeting the aberrant immune 
response, promotion and reconnection of damaged axons, manipulation of intracellular 
signalling and implementation of artificial scaffolds (Thuret et al. 2006). What has been 
suggested in this study is that a compound which in itself has multiple repair properties 
(promotion of myelination and neurite outgrowth) could remove the need for several 
different or multiple combinations of treatments for SCI. However, this can only be 
substantiated through the use of in vivo model of SCI, models such as the contusion 
impactors and clip compression (Alluin et al. 2011) (Krishna et al. 2013). Using these 
injury models and looking at parameters such as axonal outgrowth and myelination in 
and around the site of injury would determine if multiple therapeutic benefits are seen 
in vivo after treatment with mHeps.  
High throughput screening of potential drug targets has now adopted microfluidic 
technology. The MF platform has the properties of low cost, able to handle nanolitre-
volumes, low sample requirements and ability to accommodate cell culture (Yin and 
Marshall 2012). Taking the MF technology and its proven use in high throughput 
screening, potential therapeutic compounds can be assessed for SCI repair and 
regenerative properties. Chung and colleagues created a MFD which enables assessment 
of thousands of single cells and their response to kinetic and chemical stimuli (Chung et 
al. 2011). Such techniques could be adopted and the response of glial cells to potential 
therapeutic compounds such as mHeps could be assessed, and compound targets 
identified using single cell screens could be further investigated in the complex SCI-MFD 
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and SCI model. Utilising many methodologies could potentially lead to a ‘production 
line’ of models to identify potential therapeutic targets. 
The heparin mimetic panel was a set of specific modifications of the commercially 
available Heparin. Each compound was modified relating to the level or position of the 
sulphate group(s) on the heparin polysaccharide (Yates et al. 2004). In this study it was 
observed that the mimetics may be involved in the mediation of FGF and Wnt signalling 
pathways, that appear to be dysregulated or disrupted following injury. Data presented 
here corroborate the results of other studies using oligosaccharide heparin mimetics, 
looking to understand the dysregulation of HSPG production with FGF signalling in 
certain diseases such as cancer. In a study it was demonstrated that GAG mimetics can 
interact with FGF-2 and mediate signalling through FGFR4 (Saxena et al. 2010). 
Similarly, a study using mHeps as a tool to understand astrocytes and transplantation 
candidates concluded that the mimetics mediate FGF signalling (Higginson et al. 2012). 
The Saxena and Higginson studies used the mimetics as a tool for understanding the 
dysregulation of the FGF pathway, however, the work also showed the potential 
benefits of a heparin mimetic as a FGF2 signalling agonist as a treatment. 
In this thesis I show evidence that the sulphation state of the heparin mimetic is crucial 
in the promotion of both neurite outgrowth and of myelination following injury. Using 
the SCI model, desulphated mHep6, 7 and 8 had a positive effect on neurite density, 
myelination and neurite outgrowth (Fig.4.2-4.3), whereas, highly sulphated mHeps had 
adverse effects including the reduction in myelination and no increase in neurite 
outgrowth and exasperated the injury response (Fig.4.4). To identify the signalling 
mechanisms involved following treatment with mHeps, commercially available, 
signalling pathway inhibitors were used to selectively inhibit Wnt and FGF signalling 
(results:4.3.8 and 4.3.10-11). Evidence was provided that suggests canonical Wnt and 
FGF2 signalling pathways could be involved and targets for the heparin mimetics 
(Fig.4.9, 4.11-4.12). Similar observations were recorded in (Higginson et al. 2012), 
which also demonstrated FGF being mediated by heparin mimetics. However, the cell 
type(s) and the exact signalling target(s) of the effective mHeps still remain unclear. To 
identify cell populations that could be responsible for the response of the mixed 
complex culture, monocultures of OPC/OLs were used to investigate the cells 
responsible for myelin formation in isolation. This enabled the identification of mHep 
manipulation of OPC proliferation and OL sheath size (Fig.4.3.5 and 4.3.7). However, a 
monoculture of primary rat spinal neuronal cells was not possible using the standard 
methods available in our lab. Therefore, targeted neurite outgrowth study required the 
development of a new culture technique. 
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This study did provide an unexpected result in that there was no effect of the mono and 
desulphated mHeps 6, 7 and 8, on the reactive phenotype of the astrocyte specifically 
GFAP (Fig.4.5.D). Following treatment with the monosulphated mimetics there was no 
decrease in GFAP and Nestin, two common reactivity markers (4.3.4). This was 
unexpected as astrocyte reactivity is central in SCI and is targeted for reduction by 
regenerative therapies (Schwab and Bartholdi 1996) (Dergham et al. 2002) (Bradbury et 
al. 2002). However, this thesis has implicated Nestin as a potential marker for a repair 
phenotype as its upregulation occurred in conjunction with promotion in myelination 
and neurite outgrowth (Fig.4.5.E and discussed in 4.4.4).  
6.2 Selective desulphated mHeps as a treatment for SCI 
Heparin mimetics are potentially a valuable treatment for SCI. The modification of 
commercially available Heparin to create different isoforms which have different levels 
and positions of sulphate moieties is a novel approach for SCI treatment (Higginson et 
al. 2012). The molecular size of the mHeps is roughly around 10,000 kDa which 
translates to 20-24 disaccharides in length. The composition of the mHep polysaccharide 
consists of a repeating chain of iduronic acid and glucosamine which have sulphate 
moieties at either C2, C6 or N positions (Patey et al. 2006; Yates et al. 2004). This 
thesis highlighted two specific sulphate positions which were shown to have greatest 
therapeutic effect in this SCI model, 2-O-sulphated (mHep6) and N-sulphated (mHep7). 
Application of mHep6 and mHep7 demonstrated both promotion of neurite outgrowth 
and myelination following a single treatment of our SCI model at a concentration of 1 
ng/ml (Fig.4.1-2).   
Heparin is routinely used during SCI treatment, LMWH is an administered within 72 
hours following SCI to help minimise vascular complications such as DVT (Christie et al. 
2011). Following the identification of mHeps with therapeutic properties these mHeps 
could be administered alongside the LMWH and the other acute treatment options. 
Moreover, the mHeps have been shown to have no anti-thrombotic properties so their 
presence will not cause any complications for surgical procedures allowing their 
administration to continue if required.  
An important set of results which could have far reaching implications for the routine 
treatment of SCI are the effect of mHep1 (Heparin) following injury to the neural cell 
co-culture. Discussed previously, LMWH is used as prophylaxis and treatment of DVT 
within 72 hours following SCI (Kulkarni et al. 1992) (Christie et al. 2011). Within this 72 
hour time period the BBB is still disrupted (Hay et al. 2015) (Whetstone et al. 2003), 
therefore, molecules which may not be able to breach an intact BBB will have access to 
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the spinal cord. However, this study has implicated mHep1 as detrimental for CNS 
repair and regeneration. mHep1 was observed to significantly exacerbate the lesion size 
(Fig.4.4), increase GFAP a marker for reactive astrocytosis (Fig.4.5), decrease 
myelination and OL number adjacent to the lesion (Fig.4.2), decrease OL cell size 
(Fig.4.10), and finally decrease myelination in a healthy culture (Fig.4.10). However, 
these multiple negative effects were observed using the commercial Heparin but not 
with the clinically used LMWH, the difference being LMWH is a fraction of heparin with 
a mean molecular weight below 10 kDa (Nurmohamed et al. 1992). LMWH is a potent 
modified version of Heparin itself. As LMWH is in clinical use and different from mHep1 
it would be interesting to investigate LMWH on the SCI model and assay its effects on 
myelination, neurite outgrowth, astrocytosis and OPC/OL proliferation/differentiation. 
This would clarify if heparin (LMWH) administration during SCI treatment could have, 
similar to mHep1 negative effects on regeneration and repair. 
An obstacle with any potential treatment is that it has to breach the BBB. Even though 
the permeability of the BBB is disrupted following SCI which does allow drugs to reach 
their target (Popovich et al. 1996), over time the BBB reforms and will, therefore, 
reduce the effectiveness of long term treatment of the damaged cord of drugs that are 
not inherently BBB permeable (Koziara et al. 2006) (Tamai and Tsuji 1996). The mHeps 
have been shown to be able to pass the BBB, with other heparin derived mimetics 
(ultra-low molecular weight heparin fragment C3) also been shown to do the same and 
elicit their effects on CNS targets (Ma et al. 2002). MA and colleagues used C3, a 
mixture of heparin oligosaccharides which can penetrate the BBB which was 
demonstrated using radiolabelled C3 and detected in the CSF following intravenous 
injection. Furthermore, demonstrating C3 can enter and exhort anti-protease properties 
and inhibitory effect on activated factor X, providing potential attenuation of Alzheimer 
symptoms  (Ma et al. 2002) (Passeri and Cucinotta 1989) (Leveugle et al. 1998).  
Of the other major naturally occurring GAGs, chondroitin sulphates have been 
highlighted as major components of the inhibitory environment of the glial scar (Rolls et 
al. 2008). However, as this thesis has highlighted that varying the degree of sulphation 
at the injury site could present a new therapeutic avenue in SCI, could targeting not 
only HS but CS also enhance the repair and regeneration of the spinal cord? CS have 
been shown to both attract and repel neuronal processes (Brittis et al. 1992; Dou and 
Levine 1995; Nadanaka et al. 1998), suggesting they could be harnessed to induce 
axonal outgrowth.   
Work by Tully and colleagues synthesised and assessed the effects of varying sulphation 
of CS on neuronal growth. They found that sulphated tetrasaccharide and not the 
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desulphated saccharides promoted outgrowth (Tully et al. 2004). These observations are 
the opposite of the sulphation requirements of the mHeps promotion of outgrowth. Such 
studies suggest that CS should not only be seen as a factor which needs to be removed 
or overcome, but a target with beneficial repair and regenerative properties. 
Furthermore, opening up our research, using the SCI model to assess effects of other 
GAGs present at the site of injury and the creation/ modification of these GAGs could 
generate new therapeutic compounds for the treatment for SCI.  
Having heparin-derived mimetics in the clinic, which have been shown to transverse an 
intact BBB and have therapeutic properties (Passeri and Cucinotta 1989) (Cornelli 1996), 
adds to the mHeps as a more desirable treatment option in other neurological disease 
such as SCI. Moreover, not only as a treatment option in the acute phase, but also 
potentially as a long term therapy.   
 
6.3 Off-target effects of mHeps 
An advantage of the mHeps as a treatment option in the context of SCI has been the 
multiple beneficial effects observed: promotion of myelination and neurite outgrowth. 
The data shows that the heparin mimetics are in part mediating their effects on these 
processes through the Wnt and FGF signalling pathways (Fig.4.9, 11-12). Furthermore, 
the heparin mimetics have multiple cellular targets with the culture system. This 
suggests that the heparin mimetics probably have other cellular and signalling targets 
which are as of yet undiscovered. However, the in vitro SCI model used in this study 
does not encapsulate fully the in vivo environment: for instance there is no peripheral 
immune component. Previous studies have shown that HS mimetics can modulate 
chemokine activity, thus, altering the inflammatory cascade (Sheng et al. 2013) (Casu 
et al. 2010). Therefore, the multiple effects being observed in the in vitro model used 
could be amplified in an in vivo setting. It was observed that, mHep 7 in a healthy 
culture resulted in loss of myelination. This is an important consideration for the use of 
mHep7 in an in vivo model of SCI which could interact with both injured and uninjured 
regions of the CNS (Stieger and Gao 2015). The differential effect of mHep 7 between 
the states of pathology/steady state suggests the heparin mimetics can have different 
effects in a given microenvironment where different cells are more active (Douglas et 
al. 2009).  
The control of off-target effects is a common focus following compound screens. The 
identification of such targets has been aided through the use of gene microarrays to 
identify changes in gene expression patterns following exposure to compounds 
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(MacDonald et al. 2006). These gene expression fingerprints may be cell specific but 
could point towards specific cellular mechanisms and cellular populations which could 
be vulnerable to a drug’s mechanisms. Using the in vitro models in combination with 
another methodology, such as microarray analysis would enable greater confidence in 
targets identified. In addition to a gene centered study, a high-content cellular analysis 
of changes in protein-protein interactions using protein-fragment complementary assay 
(PFCA) strategies could strengthen the pursuit of potential off-targeted candidates 
(MacDonald et al. 2006). The PFCA analysis allows for a high throughput study of the 
structure-function relationship of a given drug with protein targets (MacDonald et al. 
2006). This technique could be used to understand the specific binding targets of the 
mHeps to relay this data back to any potential cellular ‘hot-spots’ where the mHeps 
may have off-target effects. The use of both experimental approaches, microarray and 
PCA analysis, could elucidate undetermined targets of the heparin mimetics.  
Ma and colleagues tracked the accumulation of the heparin-derived mimetic following 
intravenous injection. Their study concluded that the high accumulation was the brain, 
with the kidney having the second highest mimetic levels (Ma et al. 2002). This suggests 
that the mHeps could have other target sites around the body.  
Off-target effects have been seen with other treatments for SCI. The first proven 
pharmacological treatment for SCI was high dose steroid methyl-prednisolone (MPSS). A 
cohort of clinical studies showed reduced disability when MPSS was given in the early 
hours following injury (Bracken et al. 1990). This drug, like the mHeps, has multiple 
effects, such as reduction in swelling and inflammation (Bracken et al. 1997). However, 
MPSS is a controversial treatment choice as complications and off-target effects such as 
gastric bleeding and wound infections have been reported (Hurlbert 2000).  
The identification of off-target effects and the underlying mechanisms can be valuable. 
Understanding these would allow for further modifications to be made to the mimetics 
so as to remove the unwanted off-target interactions (MacDonald et al. 2006), 
therefore, increasing the therapeutic potential of heparin mimetics in SCI repair.  
 
6.4 Microfluidics 
The MFD technology used here could be an extremely useful tool for the study of axonal 
biology (Siddique and Thakor 2014; Taylor et al. 2005). The design of this device creates 
a better representation of some of the structural aspects of the spinal cord compared to 
the myelinating co-culture (Sorensen et al. 2008a) (Boomkamp et al. 2012). Specifically, 
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the compartmentalisation of the neuronal cell bodies from the neuronal processes and 
the organisation of isolated populations of neurons (Fig.5.8) are more reflective of 
certain aspects of the in vivo environment compared to the random seeding and 
undetermined neurite outgrowth of the SCI model. Additionally, the MFD allows for the 
targeted injury and study of axonal outgrowth verses neurite outgrowth, due to the size 
of the microchannels (500 µm) which only allows axons (not dendrites) to enter the 
central chamber (Fig.5.7). This allows for the investigation of compound effect on 
axonal outgrowth which is a key regenerative target following injury.  
The SCI-MFD used in this thesis is the next generation SCI-MFD. It is built on the work 
specifically by Taylor and colleagues, who devised a novel MFD to isolate and lesion 
axons (Taylor et al. 2005). However, their simple device does not allow for immediate 
access to the axons. The SCI-MFD used in this thesis has an open access central chamber 
(Fig.5.7) which allows for direct and controlled injury and treatment of the axons 
insolation (Fig.5.12).  
The MFD developed in this study can be used to investigate SCI in more depth. The 
device’s cell seeding protocol can be adapted to accommodate many cellular 
populations aiming to help understand the injury process and repair mechanisms 
(Fig.5.7.A). For example, this specific device can be used to help understand the role of 
immune cells in SCI with the possibility of seeding immune cells into any of the 
chambers. Such an investigation could enable the characterisation of certain 
chemotactic factors released at the injury site by recording the migration to the injury 
site (Li et al. 2012b) (Cho et al. 2013). This could potentially aid the identification of a 
therapeutic intervention pertaining to immune cell migration, with subsequent 
investigation into the effects of the mimetics on this process (Sheng et al. 2013). Also, 
the device can be used to study the BBB as this structure plays a pivotal role in drug 
delivery success (Bicker et al. 2014) (Prabhakarpandian et al. 2013). The device could 
be used to investigate the mimetics’ effects on the penetration and the cellular 
populations of the BBB (Gumbleton and Audus 2001). For example, the device could be 
seeded with the endothelial cells which are a component of the BBB, lining the 
microchannels and the mimetics could be introduced into the adjacent chambers and 
effects recorded.  
A characterisation requirement for the MFD, which will strengthen the validity of the 
regenerative potential of compounds tested, would be to characterise the exact 
neuronal age within the device. This can be done by first identifying the time point in 
which no further neuronal cell division takes place, by staining the culture for NeuN 
(soma marker) and a proliferation stain (BrdU) or loss of PC3 gene expression of 
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(Iacopetti et al. 1994). This will allow for the exact neural age to be calculated, and the 
inclusion of neuronal age as a factor in the regenerative process and response to certain 
compounds such as mHeps. 
The use of microfluidic platform in life science studies has drastically increased in the 
recent years with vast numbers of publications and patents relating to the use of this 
technology (Mark et al. 2010). The MF platform used in the lab for understanding basic 
biological processes and use in targeted study of axonal injury appears to be of great 
benefit (Siddique and Thakor 2014) (Taylor et al. 2005). MFD could be one of many 
technologies used in the early stages of compound development used to help guide 
towards drug mechanism and further the understanding of a complex biological process. 
Evidence provided herein supports a role for microfluidic technology allowing for the 
investigation of targeted axonal injury and treatment.   
 
6.5 The experimental design 
To critically analyse any study there are two focuses 1) the data retrieved and how this 
related to literature and future experimentation and 2) returning to assess the actual 
experimental design and the methodologies used. In this section I will focus on (2) and 
attempt to discuss the methodology used and how it can be improved. 
A potential caveat of this study was the emphasis on a single culture method with no 
deviation from the cellular source material. The compounds have not been validated in 
other model organisms, therefore, there is a lack of interspecies toxicity/effectiveness 
correlation. This could hinder the progression of the mimetics to clinical level 
(Astashkina et al. 2012).  
This culture system uses embryonic tissue as source material, so the responses to 
treatment and injury could potentially not representation of the effects in a mature 
system. The embryonic or immature cell will respond differently to extracellular stimuli 
compared to mature/terminally differentiated cells counter parts. However, the main 
reason why embryonic tissues are used is due to the comparative ease of culturing when 
compared to primary differentiated cells. Embryonic cells have a higher growth capacity 
and adapt more easily to deviations in external factors such as culture flasks and 
coverslips (Sato and Yasumura 1966). Additionally, the current scientific community’s 
drive for reduction, replacement and refinement (3R’s principle) of animal use in 
scientific experimentation places emphasis on sustainable or embryonic samples. 
Embryonic samples can be amplified readily in culture, thus, maximising sample outputs 
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from small tissue sources. This reduction in the beginnings of a pursuit for a compound 
will limit the number of in vivo models required at later stages for compound 
development. 
For these reasons I advocate the use of embryonic CNS tissue but strongly suggest future 
work to accompany this culture with: both complex cultures varying in their source 
material (ones more translatable to human; i.e. human cell lines) and in vivo model 
systems (only following an exhaustive in vitro approach) but also simple and even 
biochemical assays which can both validate and strengthen our findings with our current 
in vitro models. 
 
6.6 Future work 
Previously in the discussion I have alluded to work which could strengthen the data 
which has already been generated, such as experimentation including the use other 
source material such as human cell lines for toxicology studies, and alternative models 
such as mouse transgenic strains. These will provide further validation of the 
compounds and the microfluid device used in this thesis. 
The data and evidence generated in this study also hold promise in other neurological 
diseases; ones concerned with signalling dysregulation and alterations in the sulphation 
state at the area of trauma. This study has focused on the CNS but these compounds 
could have benefit in the peripheral nervous system (PNS). Current attempts at 
identifying a role for mimetics in PNS injury and remyelination are underway in our lab; 
a recent study highlighted heparin as a promotor in Schwann cell myelination. This begs 
the question which sulphate position and signalling pathway is responsible and these 
questions can be pursued using the mHep library.  
There are a multitude of demyelinating diseases which may benefit from the 
desulphated mimetics’ effects (modulation of disrupted signalling) on OPC proliferation 
and OL differentiation (Levine et al. 2001)  (Rodgers et al. 2013). Multiple sclerosis (MS) 
is a chronic demyelinating disease which can be studied experimentally using a modified 
version of the myelinating culture model used in this study (Lindner et al. 2015). This 
offers a readily available tool to investigate the role of the mHeps in demyelinating 
conditions and a potential role for mHeps in the treatment of MS.   
If we switch the focus slightly looking to our treatment with the heparin mimetics as a 
substitute for loss of function or presence of resident HSPG, we could approach 
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disorders which have shown reductions in the levels of HSPG. Autism is one such disease 
which could potentially benefit from our heparin mimetic compounds, especially as 
there are strong rodent models which have alterations in N-sulphated heparan sulphate 
(Meyza et al. 2012). Therefore, potentially demonstrating a multi-disease benefit of the 
mHeps and increasing the pharma/economical prospect of the mHeps.   
Mentioned previously in the discussion, more experimentation is required to fully 
understand the signalling pathways such as Wnt and FGF involved in (this culture’s) 
development to maturity and following injury. Given more time, focus would be applied 
to this characterisation as it will not only add to the strength of the culture system but 
most importantly, help to understand in greater detail any other potential compound’s 
mechanism of function pertaining to these pathways. 
The next logical avenue of research is to take the mHeps to the SCI-MFD. It was 
hypothesised that the mHeps could act similarly to their HSPG relatives and in part 
perform co-factor functions creating morphogenic gradients for signalling activation or 
competitively binding ligands leading to deactivation (Fuerer et al. 2010) (Yan and Lin 
2009). However, the SCI model used in the mHep investigation is limited in the study of 
targeted treatment and diffusion (morphogenic) gradients. Thus, investigating whether 
the presence of diffusion gradients will impact the effects of the mHeps is not possible 
in the SCI model system. Furthermore, the SCI-MFD is capable of creating and 
manipulating diffusion gradients (Fig.5.11). Therefore, using the SCI-MFD in which a 
lesion is induced followed by treatment with mHep6 and mHep7, would allow data to be 
gathered on how the mHeps act in the presence of diffusion gradients. This would 
provide data on mHeps in a more in vivo like environment. 
 
6.7 Overall Conclusion 
SCI is a devastating condition with limited effective therapies available. The consensus 
is that a combinational approach is needed to overcome the complex pathology of SCI. 
Though research presented in this thesis suggests promise, there is need for clarity into 
the exact mechanisms of function for the mHeps and the impact these compounds have 
on targeted axonal injury. In this study I have identified a novel therapeutic compound 
and focused on understanding the specific biochemical component responsible for the 
therapeutic benefit. Moreover, I have also isolated a cellular target in which the 
compounds are acting and even dissected individual differences between related 
desulphated mimetics effects on these cells. I have provided evidence suggesting that 
targeting the OPC proliferation status and forcing OL differentiation can increase 
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myelination adjacent to the lesion site. Additionally, neurite outgrowth was promoted 
but using the established SCI injury model was not sufficient to delve deeper into the 
exact mechanism of effect. For this reason a novel microfluidic model was developed, 
with the aim for creating a more in vivo-like environment in which to study axonal 
outgrowth. This new model would also prove invaluable in the study of the mimetic 
compounds. We hypothesised that the mimetics would act similarly to their HSPG 
relatives which mediate cell signalling through ligand/morphogenic gradients but the 
established SCI model does not encompass the fluid dynamics of the in vivo 
microenvironment rendering these gradients potentially non-existent. However, the 
microfluid device can create and even allow manipulation of such gradients, resulting in 
a model that not only allows for targeted axonal study but also an environment in which 
the mimetics will exhort their greatest impact as signalling pathway manipulators. To 
end, this study has provided a foundation for two novel avenues of future study 1) 
heparin mimetics as a treatment for SCI and 2) a compartmentalised open access injury 
microfluidic device for vastly more detailed study of SCI. It is my hope that these two 
advancements may provide future improvement of treatment options for this 
devastating condition.      
  
 
 
181 
 
7 References 
2002. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 
50:S63-72. 
Abbott NJ, Ronnback L, Hansson E. 2006. Astrocyte-endothelial interactions at the 
blood-brain barrier. Nat Rev Neurosci 7:41-53. 
Abe N, Cavalli V. 2008. Nerve injury signaling. Current Opinion in Neurobiology 18:276-
283. 
Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, Stenzel D, 
Sauvaget D, Ledin J, Ringvall M and others. 2007. Defective N-sulfation of 
heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment 
in vascular development. Genes Dev 21:316-31. 
Achyuta AK, Conway AJ, Crouse RB, Bannister EC, Lee RN, Katnik CP, Behensky AA, 
Cuevas J, Sundaram SS. 2013. A modular approach to create a neurovascular 
unit-on-a-chip. Lab Chip 13:542-53. 
Adeeb N, Mortazavi MM. 2014. The role of FGF2 in spinal cord trauma and regeneration 
research. Brain Behav 4:105-7. 
Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP, Jr. 2003. QSulf1 
remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans 
to promote Wnt signaling. J Cell Biol 162:341-51. 
Ajioka I, Ichinose S, Nakajima K, Mizusawa H. 2011. Basement membrane-like matrix 
sponge for the three-dimensional proliferation culture of differentiated retinal 
horizontal interneurons. Biomaterials 32:5765-72. 
Alberts B, Johnson A, Lewis J. 2002. Molecular Biology of the Cell. 4th edition. New 
York: Garland Science. 
Allen A. 1911. Surgery of experimental lesion of spinal cord equivalent to crush injury of 
fracture dislocation of spinal column: A preliminary report. Journal of the 
American Medical Association LVII:878-880. 
Allen DD, Caviedes R, Cardenas AM, Shimahara T, Segura-Aguilar J, Caviedes PA. 2005. 
Cell lines as in vitro models for drug screening and toxicity studies. Drug Dev Ind 
Pharm 31:757-68. 
Alluin O, Karimi-Abdolrezaee S, Delivet-Mongrain H, Leblond H, Fehlings MG, Rossignol 
S. 2011. Kinematic study of locomotor recovery after spinal cord clip 
compression injury in rats. J Neurotrauma 28:1963-81. 
Andersson H, van den Berg A. 2003. Microfluidic devices for cellomics: a review. Sensors 
and Actuators B: Chemical 92:315-325. 
Araque A, Parpura V, Sanzgiri RP, Haydon PG. 1999. Tripartite synapses: glia, the 
unacknowledged partner. Trends Neurosci 22:208-15. 
Ashton RS, Conway A, Pangarkar C, Bergen J, Lim KI, Shah P, Bissell M, Schaffer DV. 
2012. Astrocytes regulate adult hippocampal neurogenesis through ephrin-B 
signaling. Nat Neurosci 15:1399-406. 
Ashwell KWS. 2009. Chapter 2 - Development of the Spinal Cord. In: Kayalioglu CWP, 
editor. The Spinal Cord. San Diego: Academic Press. p 8-16. 
Astashkina A, Mann B, Grainger DW. 2012. A critical evaluation of in vitro cell culture 
models for high-throughput drug screening and toxicity. Pharmacol Ther 134:82-
106. 
Bansal R, Kumar M, Murray K, Morrison RS, Pfeiffer SE. 1996. Regulation of FGF 
receptors in the oligodendrocyte lineage. Mol Cell Neurosci 7:263-75. 
Barnett SC, Hutchins AM, Noble M. 1993. Purification of olfactory nerve ensheathing 
cells from the olfactory bulb. Dev Biol 155:337-50. 
Barnett SC, Riddell JS. 2004. Olfactory ensheathing cells (OECs) and the treatment of 
CNS injury: advantages and possible caveats. Journal of Anatomy 204:57-67. 
Barrowcliffe TW. 2012. History of heparin. Handb Exp Pharmacol:3-22. 
Bartholdi D, Schwab ME. 1997. Expression of pro-inflammatory cytokine and chemokine 
mRNA upon experimental spinal cord injury in mouse: an in situ hybridization 
study. Eur J Neurosci 9:1422-38. 
 
 
182 
 
Bashaw GJ, Goodman CS. 1999. Chimeric Axon Guidance Receptors: The Cytoplasmic 
Domains of Slit and Netrin Receptors Specify Attraction versus Repulsion. Cell 
97:917-926. 
Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, Levison SW. 2002. The type 1 
interleukin-1 receptor is essential for the efficient activation of microglia and 
the induction of multiple proinflammatory mediators in response to brain injury. 
J Neurosci 22:6071-82. 
Beattie MS, Bresnahan JC, Komon J, Tovar CA, Van Meter M, Anderson DK, Faden AI, Hsu 
CY, Noble LJ, Salzman S and others. 1997. Endogenous repair after spinal cord 
contusion injuries in the rat. Exp Neurol 148:453-63. 
Beck KD, Nguyen HX, Galvan MD, Salazar DL, Woodruff TM, Anderson AJ. 2010. 
Quantitative analysis of cellular inflammation after traumatic spinal cord injury: 
evidence for a multiphasic inflammatory response in the acute to chronic 
environment. Brain 133:433-47. 
Becker-Catania SG, Nelson JK, Olivares S, Chen SJ, DeVries GH. 2011. Oligodendrocyte 
progenitor cells proliferate and survive in an immature state following treatment 
with an axolemma-enriched fraction. ASN Neuro 3:e00053. 
Beebe DJ, Mensing GA, Walker GM. 2002. Physics and applications of microfluidics in 
biology. Annu Rev Biomed Eng 4:261-86. 
Beller JA, Snow DM. 2014. Proteoglycans: road signs for neurite outgrowth. Neural 
Regen Res 9:343-55. 
Belmiro CL, Castelo-Branco MT, Melim LM, Schanaider A, Elia C, Madi K, Pavao MS, de 
Souza HS. 2009. Unfractionated heparin and new heparin analogues from 
ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem 284:11267-
78. 
Berlly M, Shem K. 2007. Respiratory Management During the First Five Days After Spinal 
Cord Injury. The Journal of Spinal Cord Medicine 30:309-318. 
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. 
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 
68:729-77. 
Bhatia SN, Ingber DE. 2014. Microfluidic organs-on-chips. Nat Biotech 32:760-772. 
Bhatt JM, Gordon PH. 2007. Current clinical trials in amyotrophic lateral sclerosis. 
Expert Opin Investig Drugs 16:1197-207. 
Bicker J, Alves G, Fortuna A, Falcão A. 2014. Blood–brain barrier models and their 
relevance for a successful development of CNS drug delivery systems: A review. 
European Journal of Pharmaceutics and Biopharmaceutics 87:409-432. 
Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans fine-tune 
mammalian physiology. Nature 446:1030-7. 
Blakemore WF. 1977. Remyelination of CNS axons by Schwann cells transplanted from 
the sciatic nerve. Nature 266:68-9. 
Bomze HM, Bulsara KR, Iskandar BJ, Caroni P, Skene JH. 2001. Spinal axon regeneration 
evoked by replacing two growth cone proteins in adult neurons. Nat Neurosci 
4:38-43. 
Bond LM, McKerracher L. 2014. Cervical spinal cord injury: tailoring clinical trial 
endpoints to reflect meaningful functional improvements. Neural Regeneration 
Research 9:1493-1497. 
Boomkamp SD, McGrath MA, Houslay MD, Barnett SC. 2014. Epac and the high affinity 
rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination 
using an in vitro spinal cord injury model. Br J Pharmacol 171:2385-98. 
Boomkamp SD, Riehle MO, Wood J, Olson MF, Barnett SC. 2012. The development of a 
rat in vitro model of spinal cord injury demonstrating the additive effects of Rho 
and ROCK inhibitors on neurite outgrowth and myelination. Glia 60:441-56. 
Booth R, Kim H. 2012. Characterization of a microfluidic in vitro model of the blood-
brain barrier (muBBB). Lab Chip 12:1784-92. 
Bowers SL, Banerjee I, Baudino TA. 2010. The extracellular matrix: at the center of it 
all. J Mol Cell Cardiol 48:474-82. 
 
 
183 
 
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, 
Flamm E, Leo-Summers L, Maroon J and others. 1990. A randomized, controlled 
trial of methylprednisolone or naloxone in the treatment of acute spinal-cord 
injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J 
Med 322:1405-11. 
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, 
Herr DL, Hitchon PW, Marshall LF and others. 1997. Administration of 
methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the 
treatment of acute spinal cord injury. Results of the Third National Acute Spinal 
Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury 
Study. Jama 277:1597-604. 
Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon 
SB. 2002. Chondroitinase ABC promotes functional recovery after spinal cord 
injury. Nature 416:636-640. 
Brambilla R, Bracchi-Ricard V, Hu W-H, Frydel B, Bramwell A, Karmally S, Green EJ, 
Bethea JR. 2005. Inhibition of astroglial nuclear factor κB reduces inflammation 
and improves functional recovery after spinal cord injury. The Journal of 
Experimental Medicine 202:145-156. 
Briona LK, Poulain FE, Mosimann C, Dorsky RI. 2015. Wnt/ss-catenin signaling is required 
for radial glial neurogenesis following spinal cord injury. Dev Biol 403:15-21. 
Brittis PA, Canning DR, Silver J. 1992. Chondroitin sulfate as a regulator of neuronal 
patterning in the retina. Science 255:733-6. 
Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, 
Johnson MH, Sofroniew MV. 1999. Leukocyte infiltration, neuronal degeneration, 
and neurite outgrowth after ablation of scar-forming, reactive astrocytes in 
adult transgenic mice. Neuron 23:297-308. 
Bushong EA, Martone ME, Jones YZ, Ellisman MH. 2002. Protoplasmic astrocytes in CA1 
stratum radiatum occupy separate anatomical domains. J Neurosci 22:183-92. 
Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, Brook GA. 2009. NG2 and 
phosphacan are present in the astroglial scar after human traumatic spinal cord 
injury. BMC Neurol 9:32. 
Cadwalader EL, Condic ML, Yost HJ. 2012. 2-O-sulfotransferase regulates Wnt signaling, 
cell adhesion and cell cycle during zebrafish epiboly. Development 139:1296-
305. 
Caja Ry. 1928. Degeneration and Regeneration of the Nervous System. 
Campenot RB. 1977. Local control of neurite development by nerve growth factor. Proc 
Natl Acad Sci U S A 74:4516-9. 
Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL. 1996. 
GGF/neuregulin is a neuronal signal that promotes the proliferation and survival 
and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17:229-
43. 
Capila I, Linhardt RJ. 2002. Heparin-protein interactions. Angew Chem Int Ed Engl 
41:391-412. 
Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. 1998. Acute inflammatory 
response in spinal cord following impact injury. Exp Neurol 151:77-88. 
Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, 
Snow AD. 1998. Sulfate content and specific glycosaminoglycan backbone of 
perlecan are critical for perlecan's enhancement of islet amyloid polypeptide 
(amylin) fibril formation. Diabetes 47:612-20. 
Casu B, Guerrini M, Torri G. 2004. Structural and conformational aspects of the 
anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr 
Pharm Des 10:939-49. 
Casu B, Naggi A, Torri G. 2010. Heparin-derived heparan sulfate mimics to modulate 
heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol 
29:442-52. 
Cepko CL, Austin CP, Yang X, Alexiades M, Ezzeddine D. 1996. Cell fate determination in 
the vertebrate retina. Proc Natl Acad Sci U S A 93:589-95. 
 
 
184 
 
Chan CC, Khodarahmi K, Liu J, Sutherland D, Oschipok LW, Steeves JD, Tetzlaff W. 
2005. Dose-dependent beneficial and detrimental effects of ROCK inhibitor 
Y27632 on axonal sprouting and functional recovery after rat spinal cord injury. 
Exp Neurol 196:352-64. 
Chang YH, Chiu YJ, Cheng HC, Liu FJ, Lai WW, Chang HJ, Liao PC. 2015. Down-
regulation of TIMP-1 inhibits cell migration, invasion, and metastatic 
colonization in lung adenocarcinoma. Tumour Biol 36:3957-67. 
Chapman E, Best MD, Hanson SR, Wong C-H. 2004. Sulfotransferases: Structure, 
Mechanism, Biological Activity, Inhibition, and Synthetic Utility. Angewandte 
Chemie International Edition 43:3526-3548. 
Chari DM, Zhao C, Kotter MR, Blakemore WF, Franklin RJ. 2006. Corticosteroids delay 
remyelination of experimental demyelination in the rodent central nervous 
system. J Neurosci Res 83:594-605. 
Chen G, Hu YR, Wan H, Xia L, Li JH, Yang F, Qu X, Wang SG, Wang ZC. 2010. Functional 
recovery following traumatic spinal cord injury mediated by a unique polymer 
scaffold seeded with neural stem cells and Schwann cells. Chin Med J (Engl) 
123:2424-31. 
Chen J, Leong SY, Schachner M. 2005. Differential expression of cell fate determinants 
in neurons and glial cells of adult mouse spinal cord after compression injury. 
Eur J Neurosci 22:1895-906. 
Chen ZJ, Ughrin Y, Levine JM. 2002. Inhibition of axon growth by oligodendrocyte 
precursor cells. Mol Cell Neurosci 20:125-39. 
Chi CW, Ahmed AR, Dereli-Korkut Z, Wang S. 2016. Microfluidic cell chips for high-
throughput drug screening. Bioanalysis 8:921-37. 
Cho H, Hashimoto T, Wong E, Hori Y, Wood LB, Zhao L, Haigis KM, Hyman BT, Irimia D. 
2013. Microfluidic chemotaxis platform for differentiating the roles of soluble 
and bound amyloid-beta on microglial accumulation. Sci Rep 3:1823. 
Chong SY, Rosenberg SS, Fancy SP, Zhao C, Shen YA, Hahn AT, McGee AW, Xu X, Zheng 
B, Zhang LI and others. 2012. Neurite outgrowth inhibitor Nogo-A establishes 
spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad 
Sci U S A 109:1299-304. 
Christie S, Thibault-Halman G, Casha S. 2011. Acute Pharmacological DVT Prophylaxis 
after Spinal Cord Injury. Journal of Neurotrauma 28:1509-1514. 
Chronis N. 2010. Worm chips: microtools for C. elegans biology. Lab Chip 10:432-7. 
Chung K, Rivet CA, Kemp ML, Lu H. 2011. Imaging single-cell signaling dynamics with a 
deterministic high-density single-cell trap array. Anal Chem 83:7044-52. 
Cole GJ, Loewy A, Glaser L. 1986. Neuronal cell-cell adhesion depends on interactions 
of N-CAM with heparin-like molecules. Nature 320:445-7. 
Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. 2001. Membrane blebbing 
during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell 
Biol 3:339-345. 
Collins MN, Birkinshaw C. 2013. Hyaluronic acid based scaffolds for tissue engineering--a 
review. Carbohydr Polym 92:1262-79. 
Coombe DR, Kett WC. 2005. Heparan sulfate-protein interactions: therapeutic potential 
through structure-function insights. Cell Mol Life Sci 62:410-24. 
Coombe DR, Kett WC. 2012. Heparin mimetics. Handb Exp Pharmacol:361-83. 
Cornelli U. 1996. Non-Anticoagulant Actions of Glycosaminoglycans (GAGs). In: 
Harenberg J, Casu B, editors. Nonanticoagulant Actions of Glycosaminoglycans. 
Boston, MA: Springer US. p 249-279. 
Court FA, Hendriks WT, MacGillavry HD, Alvarez J, van Minnen J. 2008. Schwann cell to 
axon transfer of ribosomes: toward a novel understanding of the role of glia in 
the nervous system. J Neurosci 28:11024-9. 
Crang AJ, Blakemore WF. 1991. Remyelination of demyelinated rat axons by 
transplanted mouse oligodendrocytes. Glia 4:305-13. 
Crossman AR, Neary D. 2010. Neuroanatomy: An Illustrated Colour Text. In: 4th, editor. 
Neuroanatomy: An Illustrated Colour Text 
Churchill Livingstone Elsevier. p 67-87. 
 
 
185 
 
Cui H, Freeman C, Jacobson GA, Small DH. 2013. Proteoglycans in the central nervous 
system: role in development, neural repair, and Alzheimer's disease. IUBMB Life 
65:108-20. 
Cullen DK, Wolf JA, Vernekar VN, Vukasinovic J, LaPlaca MC. 2011. Neural tissue 
engineering and biohybridized microsystems for neurobiological investigation in 
vitro (Part 1). Crit Rev Biomed Eng 39:201-40. 
Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Collin M, Esposito 
E, Bramanti P, Thiemermann C. 2006. Glycogen synthase kinase-3 beta inhibition 
reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp 
Ther 318:79-89. 
Dalton PD, Flynn L, Shoichet MS. 2002. Manufacture of poly(2-hydroxyethyl 
methacrylate-co-methyl methacrylate) hydrogel tubes for use as nerve guidance 
channels. Biomaterials 23:3843-51. 
Damus PS, Hicks M, Rosenberg RD. 1973. Anticoagulant action of heparin. Nature 
246:355-7. 
Dawson MR, Levine JM, Reynolds R. 2000. NG2-expressing cells in the central nervous 
system: are they oligodendroglial progenitors? J Neurosci Res 61:471-9. 
Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L. 2002. Rho 
signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-7. 
Dertinger SKW, Chiu DT, Jeon NL, Whitesides GM. 2001. Generation of Gradients Having 
Complex Shapes Using Microfluidic Networks. Analytical Chemistry 73:1240-1246. 
Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP. 2001. Regulation of 
Wnt Signaling and Embryo Patterning by an Extracellular Sulfatase. Science 
293:1663-1666. 
Dibaj P, Nadrigny F, Steffens H, Scheller A, Hirrlinger J, Schomburg ED, Neusch C, 
Kirchhoff F. 2010. NO mediates microglial response to acute spinal cord injury 
under ATP control in vivo. Glia 58:1133-44. 
Dickson BJ, Senti KA. 2002. Axon guidance: growth cones make an unexpected turn. 
Curr Biol 12:R218-20. 
Donnelly DJ, Popovich PG. 2008. Inflammation and its role in neuroprotection, axonal 
regeneration and functional recovery after spinal cord injury. Experimental 
Neurology 209:378-388. 
Dou CL, Levine JM. 1995. Differential effects of glycosaminoglycans on neurite growth 
on laminin and L1 substrates. J Neurosci 15:8053-66. 
Douglas MR, Morrison KC, Jacques SJ, Leadbeater WE, Gonzalez AM, Berry M, Logan A, 
Ahmed Z. 2009. Off-target effects of epidermal growth factor receptor 
antagonists mediate retinal ganglion cell disinhibited axon growth. Brain 
132:3102-21. 
Drake R, Vogl AW, Mitchell AWM. 2015. Gray's Anatomy, for Students 
The Anatomical Basis of Clinical Practice. Grays Anatomy: Elsevier. 
Dudas B, Semeniken K. 2012. Glycosaminoglycans and Neuroprotection. In: Lever R, 
Mulloy B, Page PC, editors. Heparin - A Century of Progress. Berlin, Heidelberg: 
Springer Berlin Heidelberg. p 325-343. 
Dumont RJ, Verma S, Okonkwo DO, Hurlbert RJ, Boulos PT, Ellegala DB, Dumont AS. 
2001. Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin 
Neuropharmacol 24:265-79. 
East E, de Oliveira DB, Golding JP, Phillips JB. 2010. Alignment of astrocytes increases 
neuronal growth in three-dimensional collagen gels and is maintained following 
plastic compression to form a spinal cord repair conduit. Tissue Eng Part A 
16:3173-84. 
Ekwall B. 1980. Screening of toxic compounds in tissue culture. Toxicology 17:127-42. 
Elkabes S, DiCicco-Bloom EM, Black IB. 1996. Brain microglia/macrophages express 
neurotrophins that selectively regulate microglial proliferation and function. J 
Neurosci 16:2508-21. 
Endo Y, Rubin JS. 2007. Wnt signaling and neurite outgrowth: insights and questions. 
Cancer Sci 98:1311-7. 
 
 
186 
 
Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, van 
Kuppevelt TH, Zcharia E, Vlodavsky I, Lindahl U and others. 2007. Transgenic or 
tumor-induced expression of heparanase upregulates sulfation of heparan 
sulfate. Nat Chem Biol 3:773-8. 
Etienne-Manneville S, Hall A. 2001. Integrin-mediated activation of Cdc42 controls cell 
polarity in migrating astrocytes through PKCzeta. Cell 106:489-98. 
Eyre JA. 2003. Development and plasticity of the corticospinal system in man. Neural 
Plast 10:93-106. 
Fairless R, Barnett SC. 2005. Olfactory ensheathing cells: their role in central nervous 
system repair. Int J Biochem Cell Biol 37:693-9. 
Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, Sanai N, Franklin RJ, Rowitch 
DH. 2009. Dysregulation of the Wnt pathway inhibits timely myelination and 
remyelination in the mammalian CNS. Genes Dev 23:1571-85. 
Fancy SP, Zhao C, Franklin RJ. 2004. Increased expression of Nkx2.2 and Olig2 identifies 
reactive oligodendrocyte progenitor cells responding to demyelination in the 
adult CNS. Mol Cell Neurosci 27:247-54. 
Farbman AI. 1990. Olfactory neurogenesis: genetic or environmental controls? Trends 
Neurosci 13:362-5. 
Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. 2004. Reactive 
astrocytes protect tissue and preserve function after spinal cord injury. J 
Neurosci 24:2143-55. 
Fawcett JW. 2006. Overcoming inhibition in the damaged spinal cord. J Neurotrauma 
23:371-83. 
Fawcett JW, Asher RA. 1999. The glial scar and central nervous system repair. Brain Res 
Bull 49:377-91. 
Fawcett JW, Housden E, Smith-Thomas L, Meyer RL. 1989. The growth of axons in three-
dimensional astrocyte cultures. Dev Biol 135:449-58. 
Fehlings MG. 2001. Summary statement: the use of methylprednisolone in acute spinal 
cord injury. Spine (Phila Pa 1976) 26:S55. 
Fehlings MG, Hawryluk GW. 2010. Scarring after spinal cord injury. J Neurosurg Spine 
13:165-7; discussion 167-8. 
Feldblum S, Arnaud S, Simon M, Rabin O, D'Arbigny P. 2000. Efficacy of a new 
neuroprotective agent, gacyclidine, in a model of rat spinal cord injury. J 
Neurotrauma 17:1079-93. 
Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, 
Lichtman JW, Sanes JR. 2000. Imaging neuronal subsets in transgenic mice 
expressing multiple spectral variants of GFP. Neuron 28:41-51. 
Ferreira Chacon JM, Mello de Andrea ML, Blanes L, Ferreira LM. 2010. Effects of topical 
application of 10,000 IU heparin on patients with perineal dermatitis and second-
degree burns treated in a public pediatric hospital. J Tissue Viability 19:150-8. 
Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. 2006. 
Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease 
expression early after spinal cord injury. J Neurochem 97:1314-26. 
Filbin MT. 2003. Myelin-associated inhibitors of axonal regeneration in the adult 
mammalian CNS. Nat Rev Neurosci 4:703-713. 
Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. 1999. Cellular and molecular 
mechanisms of glial scarring and progressive cavitation: in vivo and in vitro 
analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 
19:8182-98. 
Fitch MT, Silver J. 1997. Activated macrophages and the blood-brain barrier: 
inflammation after CNS injury leads to increases in putative inhibitory 
molecules. Exp Neurol 148:587-603. 
Fitch MT, Silver J. 2008. CNS Injury, Glial Scars, and Inflammation: Inhibitory 
extracellular matrices and regeneration failure. Experimental neurology 209:294-
301. 
 
 
187 
 
Ford-Perriss M, Turner K, Guimond S, Apedaile A, Haubeck HD, Turnbull J, Murphy M. 
2003. Localisation of specific heparan sulfate proteoglycans during the 
proliferative phase of brain development. Dev Dyn 227:170-84. 
Forsberg M, Holmborn K, Kundu S, Dagalv A, Kjellen L, Forsberg-Nilsson K. 2012. 
Undersulfation of heparan sulfate restricts differentiation potential of mouse 
embryonic stem cells. J Biol Chem 287:10853-62. 
Fournier AE, GrandPre T, Strittmatter SM. 2001. Identification of a receptor mediating 
Nogo-66 inhibition of axonal regeneration. Nature 409:341-6. 
Fournier AE, Takizawa BT, Strittmatter SM. 2003. Rho kinase inhibition enhances axonal 
regeneration in the injured CNS. J Neurosci 23:1416-23. 
Franklin RJ, Bayley SA, Blakemore WF. 1996. Transplanted CG4 cells (an 
oligodendrocyte progenitor cell line) survive, migrate, and contribute to repair 
of areas of demyelination in X-irradiated and damaged spinal cord but not in 
normal spinal cord. Exp Neurol 137:263-76. 
Franssen EH, de Bree FM, Verhaagen J. 2007. Olfactory ensheathing glia: their 
contribution to primary olfactory nervous system regeneration and their 
regenerative potential following transplantation into the injured spinal cord. 
Brain Res Rev 56:236-58. 
Freeman C, Liu L, Banwell MG, Brown KJ, Bezos A, Ferro V, Parish CR. 2005. Use of 
sulfated linked cyclitols as heparan sulfate mimetics to probe the 
heparin/heparan sulfate binding specificity of proteins. J Biol Chem 280:8842-9. 
Freier T, Montenegro R, Shan Koh H, Shoichet MS. 2005. Chitin-based tubes for tissue 
engineering in the nervous system. Biomaterials 26:4624-32. 
Freund P, Wannier T, Schmidlin E, Bloch J, Mir A, Schwab ME, Rouiller EM. 2007. Anti-
Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a 
unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 
502:644-59. 
Friese RS, Rehring TF, Wollmering M, Moore EE, Ketch LL, Banerjee A, Harken AH. 1994. 
Trauma primes cells. Shock 1:388-94. 
Fuerer C, Habib SJ, Nusse R. 2010. A study on the interactions between Heparan Sulfate 
Proteoglycans and Wnt proteins. Developmental dynamics : an official 
publication of the American Association of Anatomists 239:184-190. 
Fujita Y, Yamashita T. 2014. Axon growth inhibition by RhoA/ROCK in the central 
nervous system. Front Neurosci 8:338. 
Gao X, Wang Y, Chen J, Peng J. 2013. The role of peripheral nerve ECM components in 
the tissue engineering nerve construction. Rev Neurosci 24:443-53. 
Garg HG, Mrabat H, Yu L, Freeman C, Li B, Zhang F, Linhardt RJ, Hales CA. 2008. 
Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the 
growth inhibition of bovine pulmonary artery smooth muscle cells. Carbohydr Res 
343:2406-10. 
Geoffroy CG, Zheng B. 2014. Myelin-associated inhibitors in axonal growth after CNS 
injury. Curr Opin Neurobiol 27:31-8. 
Ghodbane M, Stucky EC, Maguire TJ, Schloss RS, Shreiber DI, Zahn JD, Yarmush ML. 
2015. Development and validation of a microfluidic immunoassay capable of 
multiplexing parallel samples in microliter volumes. Lab on a Chip 15:3211-3221. 
Goldberg LC, Barkoff JR. 1960. Treatment of dermatoses with intravenously given 
methylprednisolone sodium succinate. J Am Med Assoc 172:1514-7. 
Goldshmit Y, Frisca F, Pinto AR, Pebay A, Tang JK, Siegel AL, Kaslin J, Currie PD. 2014. 
Fgf2 improves functional recovery-decreasing gliosis and increasing radial glia 
and neural progenitor cells after spinal cord injury. Brain Behav 4:187-200. 
Gonzalez-Fernandez C, Fernandez-Martos CM, Shields SD, Arenas E, Javier Rodriguez F. 
2014. Wnts are expressed in the spinal cord of adult mice and are differentially 
induced after injury. J Neurotrauma 31:565-81. 
Gonzalez P, Fernandez-Martos CM, Gonzalez-Fernandez C, Arenas E, Rodriguez FJ. 2012. 
Spatio-temporal expression pattern of frizzled receptors after contusive spinal 
cord injury in adult rats. PLoS One 7:e50793. 
Graziadei PP. 1973. Cell dynamics in the olfactory mucosa. Tissue Cell 5:113-31. 
 
 
188 
 
Graziadei PP, Graziadei GA. 1979. Neurogenesis and neuron regeneration in the 
olfactory system of mammals. I. Morphological aspects of differentiation and 
structural organization of the olfactory sensory neurons. J Neurocytol 8:1-18. 
Greek R, Menache A. 2013. Systematic reviews of animal models: methodology versus 
epistemology. Int J Med Sci 10:206-21. 
Greene LA, Tischler AS. 1976. Establishment of a noradrenergic clonal line of rat 
adrenal pheochromocytoma cells which respond to nerve growth factor. 
Proceedings of the National Academy of Sciences 73:2424-2428. 
Grosberg A, Alford PW, McCain ML, Parker KK. 2011. Ensembles of engineered cardiac 
tissues for physiological and pharmacological study: heart on a chip. Lab Chip 
11:4165-73. 
Gross PG, Kartalov EP, Scherer A, Weiner LP. 2007. Applications of microfluidics for 
neuronal studies. J Neurol Sci 252:135-43. 
Gu L, Black B, Ordonez S, Mondal A, Jain A, Mohanty S. 2014. Microfluidic control of 
axonal guidance. Sci Rep 4:6457. 
Guan KL, Rao Y. 2003. Signalling mechanisms mediating neuronal responses to guidance 
cues. Nat Rev Neurosci 4:941-56. 
Gumbleton M, Audus KL. 2001. Progress and limitations in the use of in vitro cell 
cultures to serve as a permeability screen for the blood-brain barrier. J Pharm 
Sci 90:1681-98. 
Gumy LF, Tan CL, Fawcett JW. 2010. The role of local protein synthesis and degradation 
in axon regeneration. Experimental Neurology 223:28-37. 
Hall ED. 1992. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 
76:13-22. 
Hamilton NB, Attwell D. 2010. Do astrocytes really exocytose neurotransmitters? Nat 
Rev Neurosci 11:227-38. 
Hantaz-Ambroise D, Vigny M, Koenig J. 1987. Heparan sulfate proteoglycan and laminin 
mediate two different types of neurite outgrowth. J Neurosci 7:2293-304. 
Harel NY, Strittmatter SM. 2006. Can regenerating axons recapitulate developmental 
guidance during recovery from spinal cord injury? Nat Rev Neurosci 7:603-616. 
Hausmann ON. 2003. Post-traumatic inflammation following spinal cord injury. Spinal 
Cord 41:369-78. 
Hay JR, Johnson VE, Young AM, Smith DH, Stewart W. 2015. Blood-Brain Barrier 
Disruption Is an Early Event That May Persist for Many Years After Traumatic 
Brain Injury in Humans. J Neuropathol Exp Neurol 74:1147-57. 
Hayball PJ, Cosh DG, Ahern MJ, Schultz DW, Roberts-Thomson PJ. 1992. High dose oral 
methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and 
clinical response. Eur J Clin Pharmacol 42:85-8. 
Haydon PG, Carmignoto G. 2006. Astrocyte control of synaptic transmission and 
neurovascular coupling. Physiol Rev 86:1009-31. 
He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, 
Lugovskoy AA, Yoburn JC and others. 2005. Small-molecule inhibition of TNF-
alpha. Science 310:1022-5. 
Hering TM, Beller JA, Calulot CM, Centers A, Snow DM. 2015. Proteoglycans of reactive 
rat cortical astrocyte cultures: abundance of N-unsubstituted glucosamine-
enriched heparan sulfate. Matrix Biol 41:8-18. 
Hermann GE, Rogers RC, Bresnahan JC, Beattie MS. 2001. Tumor necrosis factor-alpha 
induces cFOS and strongly potentiates glutamate-mediated cell death in the rat 
spinal cord. Neurobiol Dis 8:590-9. 
Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D, 
3rd, Li X, Guthikonda M and others. 2011. The role of hypoxia-inducible factor-
1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier 
disruption and brain edema after traumatic brain injury. J Neurosurg 114:92-101. 
Higginson JR, Thompson SM, Santos-Silva A, Guimond SE, Turnbull JE, Barnett SC. 2012. 
Differential sulfation remodelling of heparan sulfate by extracellular 6-O-
sulfatases regulates fibroblast growth factor-induced boundary formation by glial 
cells: implications for glial cell transplantation. J Neurosci 32:15902-12. 
 
 
189 
 
Hirata K, Kawabuchi M. 2002. Myelin phagocytosis by macrophages and nonmacrophages 
during Wallerian degeneration. Microsc Res Tech 57:541-7. 
Hirsh J. 2001. New anticoagulants. Am Heart J 142:S3-8. 
Hosmane S, Fournier A, Wright R, Rajbhandari L, Siddique R, Yang IH, Ramesh KT, 
Venkatesan A, Thakor N. 2011. Valve-based microfluidic compression platform: 
single axon injury and regrowth. Lab Chip 11:3888-95. 
Hosmane S, Yang IH, Ruffin A, Thakor N, Venkatesan A. 2010. Circular 
compartmentalized microfluidic platform: Study of axon-glia interactions. Lab 
Chip 10:741-7. 
Huebner EA, Strittmatter SM. 2009. Axon Regeneration in the Peripheral and Central 
Nervous Systems. Results and problems in cell differentiation 48:339-351. 
Hurlbert RJ. 2000. Methylprednisolone for acute spinal cord injury: an inappropriate 
standard of care. J Neurosurg 93:1-7. 
Iacopetti P, Barsacchi G, Tirone F, Maffei L, Cremisi F. 1994. Developmental expression 
of PC3 gene is correlated with neuronal cell birthday. Mech Dev 47:127-37. 
Inman D, Guth L, Steward O. 2002. Genetic influences on secondary degeneration and 
wound healing following spinal cord injury in various strains of mice. J Comp 
Neurol 451:225-35. 
Jessen KR. 2004. Glial cells. The International Journal of Biochemistry & Cell Biology 
36:1861-1867. 
Joanne Wang C, Li X, Lin B, Shim S, Ming GL, Levchenko A. 2008. A microfluidics-based 
turning assay reveals complex growth cone responses to integrated gradients of 
substrate-bound ECM molecules and diffusible guidance cues. Lab Chip 8:227-37. 
Johns P. 2014. Clinical Neuroscience: An illustrated text. Elsevier Health Sciences. p 13. 
Johnson KG, Ghose A, Epstein E, Lincecum J, O'Connor MB, Van Vactor D. 2004. Axonal 
heparan sulfate proteoglycans regulate the distribution and efficiency of the 
repellent slit during midline axon guidance. Curr Biol 14:499-504. 
Jones LL, Margolis RU, Tuszynski MH. 2003. The chondroitin sulfate proteoglycans 
neurocan, brevican, phosphacan, and versican are differentially regulated 
following spinal cord injury. Exp Neurol 182:399-411. 
Jordan-Sciutto KL, Murray Fenner BA, Wiley CA, Achim CL. 2001. Response of cell cycle 
proteins to neurotrophic factor and chemokine stimulation in human neuroglia. 
Exp Neurol 167:205-14. 
Jullien J, Gurdon J. 2005. Morphogen gradient interpretation by a regulated trafficking 
step during ligand–receptor transduction. Genes & Development 19:2682-2694. 
Jung H, Yoon BC, Holt CE. 2012. Axonal mRNA localization and local protein synthesis in 
nervous system assembly, maintenance and repair. Nat Rev Neurosci 13:308-324. 
Kabu S, Gao Y, Kwon BK, Labhasetwar V. 2015. Drug delivery, cell-based therapies, and 
tissue engineering approaches for spinal cord injury. Journal of Controlled 
Release 219:141-154. 
Kacem K, Lacombe P, Seylaz J, Bonvento G. 1998. Structural organization of the 
perivascular astrocyte endfeet and their relationship with the endothelial 
glucose transporter: a confocal microscopy study. Glia 23:1-10. 
Kalinski AL, Sachdeva R, Gomes C, Lee SJ, Shah Z, Houle JD, Twiss JL. 2015. mRNAs and 
Protein Synthetic Machinery Localize into Regenerating Spinal Cord Axons When 
They Are Provided a Substrate That Supports Growth. J Neurosci 35:10357-70. 
Karumbaiah L, Anand S, Thazhath R, Zhong Y, McKeon RJ, Bellamkonda RV. 2011. 
Targeted downregulation of N-acetylgalactosamine 4-sulfate 6-O-
sulfotransferase significantly mitigates chondroitin sulfate proteoglycan-
mediated inhibition. Glia 59:981-96. 
Karus M, Samtleben S, Busse C, Tsai T, Dietzel ID, Faissner A, Wiese S. 2012. Normal 
sulfation levels regulate spinal cord neural precursor cell proliferation and 
differentiation. Neural Dev 7:20. 
Kayalioglu G. 2009. Chapter 3 - The Vertebral Column and Spinal Meninges. In: 
Kayalioglu CWP, editor. The Spinal Cord. San Diego: Academic Press. p 17-36. 
 
 
190 
 
Kennedy TE, Serafini T, de la Torre JR, Tessier-Lavigne M. 1994. Netrins are diffusible 
chemotropic factors for commissural axons in the embryonic spinal cord. Cell 
78:425-35. 
Kennedy TE, Wang H, Marshall W, Tessier-Lavigne M. 2006. Axon guidance by diffusible 
chemoattractants: a gradient of netrin protein in the developing spinal cord. J 
Neurosci 26:8866-74. 
Kettenmann H, Verkhratsky A. 2008. Neuroglia: the 150 years after. Trends Neurosci 
31:653-9. 
Khakh BS, Sofroniew MV. 2015. Diversity of astrocyte functions and phenotypes in neural 
circuits. Nat Neurosci 18:942-52. 
Kim YT, Karthikeyan K, Chirvi S, Dave DP. 2009. Neuro-optical microfluidic platform to 
study injury and regeneration of single axons. Lab Chip 9:2576-81. 
Kinnunen T, Townsend J, Turnbull J. 2004. Heparan sulfate is essential for neuron 
migration and axon outgrowth in Caenorhabditis elegans. International Journal of 
Experimental Pathology 85:A69-A70. 
Kippert A, Trajkovic K, Rajendran L, Ries J, Simons M. 2007. Rho regulates membrane 
transport in the endocytic pathway to control plasma membrane specialization in 
oligodendroglial cells. J Neurosci 27:3560-70. 
Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, 
Jones L, Krassioukov A, Mulcahey MJ and others. 2011. International standards 
for neurological classification of spinal cord injury (Revised 2011). The Journal of 
Spinal Cord Medicine 34:535-546. 
Klapka N, Hermanns S, Straten G, Masanneck C, Duis S, Hamers FP, Muller D, 
Zuschratter W, Muller HW. 2005. Suppression of fibrous scarring in spinal cord 
injury of rat promotes long-distance regeneration of corticospinal tract axons, 
rescue of primary motoneurons in somatosensory cortex and significant 
functional recovery. Eur J Neurosci 22:3047-58. 
Knoller N, Auerbach G, Fulga V, Zelig G, Attias J, Bakimer R, Marder JB, Yoles E, Belkin 
M, Schwartz M and others. 2005. Clinical experience using incubated autologous 
macrophages as a treatment for complete spinal cord injury: phase I study 
results. J Neurosurg Spine 3:173-81. 
Kocsis JD, Lankford KL, Sasaki M, Radtke C. 2009. Unique in vivo properties of olfactory 
ensheathing cells that may contribute to neural repair and protection following 
spinal cord injury. Neuroscience Letters 456:137-142. 
Komoly S, Hudson LD, Webster HD, Bondy CA. 1992. Insulin-like growth factor I gene 
expression is induced in astrocytes during experimental demyelination. Proc Natl 
Acad Sci U S A 89:1894-8. 
Koshinaga M, Sanon HR, Whittemore SR. 1993. Altered acidic and basic fibroblast growth 
factor expression following spinal cord injury. Exp Neurol 120:32-48. 
Kotter MR, Li WW, Zhao C, Franklin RJ. 2006. Myelin impairs CNS remyelination by 
inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 26:328-32. 
Koziara JM, Lockman PR, Allen DD, Mumper RJ. 2006. The blood-brain barrier and brain 
drug delivery. J Nanosci Nanotechnol 6:2712-35. 
Krishna G, Goel S, Krishna KA. 2014. Chapter 7 - Alternative animal toxicity testing and 
biomarkers A2 - Gupta, Ramesh C. Biomarkers in Toxicology. Boston: Academic 
Press. p 129-147. 
Krishna V, Andrews H, Jin X, Yu J, Varma A, Wen X, Kindy M. 2013. A contusion model of 
severe spinal cord injury in rats. J Vis Exp. 
Kubota Y, Morita T, Kusakabe M, Sakakura T, Ito K. 1999. Spatial and temporal changes 
in chondroitin sulfate distribution in the sclerotome play an essential role in the 
formation of migration patterns of mouse neural crest cells. Dev Dyn 214:55-65. 
Kuhlengel KR. 1988. Effect of implants prepared from tissue culture of dorsal root 
ganglion neurons and Schwann cells on growth of corticospinal fibers after spinal 
cord injury in neonatal rats. Prog Brain Res 78:199-204. 
Kuhlengel KR, Bunge MB, Bunge RP. 1990. Implantation of cultured sensory neurons and 
Schwann cells into lesioned neonatal rat spinal cord. I. Methods for preparing 
implants from dissociated cells. J Comp Neurol 293:63-73. 
 
 
191 
 
Kulkarni JR, Burt AA, Tromans AT, Constable PDL. 1992. Prophylactic low dose heparin 
anticoagulant therapy in patients with spinal cord injuries: a retrospective study. 
Paraplegia 30:169-172. 
Kumar S, Chakraborty S, Barbosa C, Brustovetsky T, Brustovetsky N, Obukhov AG. 2012. 
Mechanisms controlling neurite outgrowth in a pheochromocytoma cell line: The 
role of TRPC channels. Journal of cellular physiology 227:1408-1419. 
Kundi S, Bicknell R, Ahmed Z. 2013. SPINAL CORD INJURY: CURRENT MAMMALIAN 
MODELS. American Journal of Neuroscience 4:1-12. 
Laabs T, Carulli D, Geller HM, Fawcett JW. 2005. Chondroitin sulfate proteoglycans in 
neural development and regeneration. Current Opinion in Neurobiology 15:116-
120. 
Lakatos A, Barnett SC, Franklin RJ. 2003. Olfactory ensheathing cells induce less host 
astrocyte response and chondroitin sulphate proteoglycan expression than 
Schwann cells following transplantation into adult CNS white matter. Exp Neurol 
184:237-46. 
Lakatos A, Franklin RJM, Barnett SC. 2000. Olfactory ensheathing cells and Schwann 
cells differ in their in vitro interactions with astrocytes. Glia 32:214-225. 
Lamond R, Barnett SC. 2013. Schwann cells but not olfactory ensheathing cells inhibit 
CNS myelination via the secretion of connective tissue growth factor. J Neurosci 
33:18686-97. 
Lander AD, Fujii DK, Gospodarowicz D, Reichardt LF. 1982. Characterization of a factor 
that promotes neurite outgrowth: evidence linking activity to a heparan sulfate 
proteoglycan. J Cell Biol 94:574-85. 
Lanfer B, Hermann A, Kirsch M, Freudenberg U, Reuner U, Werner C, Storch A. 2010. 
Directed growth of adult human white matter stem cell-derived neurons on 
aligned fibrillar collagen. Tissue Eng Part A 16:1103-13. 
Lapierre F, Holme K, Lam L, Tressler RJ, Storm N, Wee J, Stack RJ, Castellot J, Tyrrell 
DJ. 1996. Chemical modifications of heparin that diminish its anticoagulant but 
preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic 
properties. Glycobiology 6:355-66. 
Larner AJ, Johnson AR, Keynes RJ. 1995. Regeneration in the vertebrate central nervous 
system: phylogeny, ontogeny, and mechanisms. Biol Rev Camb Philos Soc 70:597-
619. 
Leal-Filho MB. 2011. Spinal cord injury: From inflammation to glial scar. Surg Neurol Int 
2:112. 
Leavitt BR, Hernit-Grant CS, Macklis JD. 1999. Mature astrocytes transform into 
transitional radial glia within adult mouse neocortex that supports directed 
migration of transplanted immature neurons. Exp Neurol 157:43-57. 
Lee DH, Lee JK. 2013. Animal models of axon regeneration after spinal cord injury. 
Neurosci Bull 29:436-44. 
Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY, Xu J. 2008. Methylprednisolone protects 
oligodendrocytes but not neurons after spinal cord injury. J Neurosci 28:3141-9. 
Lee PJ, Hung PJ, Lee LP. 2007. An artificial liver sinusoid with a microfluidic 
endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng 
97:1340-6. 
Lee SI, Jeong SR, Kang YM, Han DH, Jin BK, Namgung U, Kim BG. 2010. Endogenous 
expression of interleukin-4 regulates macrophage activation and confines cavity 
formation after traumatic spinal cord injury. J Neurosci Res 88:2409-19. 
Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H. 1998. 
Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid 
precursor protein secretion and heparin binding to beta-amyloid peptide. J 
Neurochem 70:736-44. 
Levine JM, Reynolds R, Fawcett JW. 2001. The oligodendrocyte precursor cell in health 
and disease. Trends in Neurosciences 24:39-47. 
Li GL, Farooque M, Holtz A, Olsson Y. 1999. Apoptosis of oligodendrocytes occurs for 
long distances away from the primary injury after compression trauma to rat 
spinal cord. Acta Neuropathol 98:473-80. 
 
 
192 
 
Li J, Li JP, Zhang X, Lu Z, Yu SP, Wei L. 2012a. Expression of heparanase in vascular 
cells and astrocytes of the mouse brain after focal cerebral ischemia. Brain Res 
1433:137-44. 
Li J, Zhu L, Zhang M, Lin F. 2012b. Microfluidic device for studying cell migration in 
single or co-existing chemical gradients and electric fields. Biomicrofluidics 
6:24121-2412113. 
Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, 
Wolburg H, Fruttiger M and others. 2008. Wnt/beta-catenin signaling controls 
development of the blood-brain barrier. J Cell Biol 183:409-17. 
Ligon LA, Karki S, Tokito M, Holzbaur EL. 2001. Dynein binds to beta-catenin and may 
tether microtubules at adherens junctions. Nat Cell Biol 3:913-7. 
Lin RC, Matesic DF, Marvin M, McKay RD, Brustle O. 1995. Re-expression of the 
intermediate filament nestin in reactive astrocytes. Neurobiol Dis 2:79-85. 
Lindahl U. 2007. Heparan sulfate-protein interactions--a concept for drug design? 
Thromb Haemost 98:109-15. 
Lindahl U, Kusche-Gullberg M, Kjellen L. 1998. Regulated diversity of heparan sulfate. J 
Biol Chem 273:24979-82. 
Lindner M, Thummler K, Arthur A, Brunner S, Elliott C, McElroy D, Mohan H, Williams A, 
Edgar JM, Schuh C and others. 2015. Fibroblast growth factor signalling in 
multiple sclerosis: inhibition of myelination and induction of pro-inflammatory 
environment by FGF9. Brain 138:1875-93. 
Lingor P, Teusch N, Schwarz K, Mueller R, Mack H, Bahr M, Mueller BK. 2007. Inhibition 
of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate 
proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J 
Neurochem 103:181-9. 
Lipson AC, Widenfalk J, Lindqvist E, Ebendal T, Olson L. 2003. Neurotrophic properties 
of olfactory ensheathing glia. Exp Neurol 180:167-71. 
Logan A, Green J, Hunter A, Jackson R, Berry M. 1999. Inhibition of glial scarring in the 
injured rat brain by a recombinant human monoclonal antibody to transforming 
growth factor-beta2. Eur J Neurosci 11:2367-74. 
Lois C, Garcia-Verdugo JM, Alvarez-Buylla A. 1996. Chain migration of neuronal 
precursors. Science 271:978-81. 
Lord MS, Whitelock JM. 2014. Bioengineered heparin: is there a future for this form of 
the successful therapeutic? Bioengineered 5:222-6. 
Luo J, Shi R. 2004. Diffusive oxidative stress following acute spinal cord injury in guinea 
pigs and its inhibition by polyethylene glycol. Neurosci Lett 359:167-70. 
Lytle JM, Chittajallu R, Wrathall JR, Gallo V. 2009. NG2 cell response in the CNP-EGFP 
mouse after contusive spinal cord injury. Glia 57:270-85. 
Lyuksyutova AI, Lu CC, Milanesio N, King LA, Guo N, Wang Y, Nathans J, Tessier-Lavigne 
M, Zou Y. 2003. Anterior-posterior guidance of commissural axons by Wnt-
frizzled signaling. Science 302:1984-8. 
Ma Q, Cornelli U, Hanin I, Jeske WP, Linhardt RJ, Walenga JM, Fareed J, Lee JM. 2007. 
Heparin oligosaccharides as potential therapeutic agents in senile dementia. 
Curr Pharm Des 13:1607-16. 
Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J. 2002. 
The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. 
Thromb Res 105:447-53. 
MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias 
J, Minami T and others. 2006. Identifying off-target effects and hidden 
phenotypes of drugs in human cells. Nat Chem Biol 2:329-337. 
MacInnis BL, Campenot RB. 2002. Retrograde support of neuronal survival without 
retrograde transport of nerve growth factor. Science 295:1536-9. 
Maeki M, Yamaguchi H, Tokeshi M, Miyazaki M. 2016. Microfluidic Approaches for Protein 
Crystal Structure Analysis. Anal Sci 32:3-9. 
Marchand R, Woerly S, Bertrand L, Valdes N. 1993. Evaluation of two cross-linked 
collagen gels implanted in the transected spinal cord. Brain Res Bull 30:415-22. 
 
 
193 
 
Mark D, Haeberle S, Roth G, von Stetten F, Zengerle R. 2010. Microfluidic lab-on-a-chip 
platforms: requirements, characteristics and applications. Chemical Society 
Reviews 39:1153-1182. 
Masuda T, Fukamauchi F, Takeda Y, Fujisawa H, Watanabe K, Okado N, Shiga T. 2004. 
Developmental regulation of notochord-derived repulsion for dorsal root ganglion 
axons. Mol Cell Neurosci 25:217-27. 
Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. 2001. Early 
complications of high-dose methylprednisolone sodium succinate treatment in 
the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976) 26:426-
30. 
Mautes AE, Weinzierl MR, Donovan F, Noble LJ. 2000. Vascular events after spinal cord 
injury: contribution to secondary pathogenesis. Phys Ther 80:673-87. 
McAdoo DJ, Hughes MG, Nie L, Shah B, Clifton C, Fullwood S, Hulsebosch CE. 2005. The 
effect of glutamate receptor blockers on glutamate release following spinal cord 
injury. Lack of evidence for an ongoing feedback cascade of damage --> 
glutamate release --> damage --> glutamate release --> etc. Brain Res 1038:92-9. 
McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. 1977. Low-dose heparin as 
a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 2:800-1. 
McConnell SK. 1992. The control of neuronal identity in the developing cerebral cortex. 
Curr Opin Neurobiol 2:23-7. 
McDonald JC, Duffy DC, Anderson JR, Chiu DT, Wu H, Schueller OJ, Whitesides GM. 
2000. Fabrication of microfluidic systems in poly(dimethylsiloxane). 
Electrophoresis 21:27-40. 
McKeon RJ, Höke A, Silver J. 1995. Injury-Induced Proteoglycans Inhibit the Potential 
for Laminin-Mediated Axon Growth on Astrocytic Scars. Experimental Neurology 
136:32-43. 
McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. 1990. FGF modulates the PDGF-
driven pathway of oligodendrocyte development. Neuron 5:603-14. 
McTigue DM, Popovich PG, Morgan TE, Stokes BT. 2000. Localization of transforming 
growth factor-beta1 and receptor mRNA after experimental spinal cord injury. 
Exp Neurol 163:220-30. 
McTigue DM, Wei P, Stokes BT. 2001. Proliferation of NG2-positive cells and altered 
oligodendrocyte numbers in the contused rat spinal cord. J Neurosci 21:3392-
400. 
Mei F, Fancy SP, Shen YA, Niu J, Zhao C, Presley B, Miao E, Lee S, Mayoral SR, Redmond 
SA and others. 2014. Micropillar arrays as a high-throughput screening platform 
for therapeutics in multiple sclerosis. Nat Med 20:954-60. 
Meyza KZ, Blanchard DC, Pearson BL, Pobbe RL, Blanchard RJ. 2012. Fractone-
associated N-sulfated heparan sulfate shows reduced quantity in BTBR T+tf/J 
mice: a strong model of autism. Behav Brain Res 228:247-53. 
Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, Chang J, Thill G, Levesque 
M, Zhang M and others. 2005. LINGO-1 negatively regulates myelination by 
oligodendrocytes. Nat Neurosci 8:745-51. 
Miao QL, Ye Q, Zhang XH. 2014. Perineuronal net, CSPG receptor and their regulation of 
neural plasticity. Sheng Li Xue Bao 66:387-97. 
Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. 2009. Influence of nebulized 
unfractionated heparin and N-acetylcysteine in acute lung injury after smoke 
inhalation injury. J Burn Care Res 30:249-56. 
Mimura F, Yamagishi S, Arimura N, Fujitani M, Kubo T, Kaibuchi K, Yamashita T. 2006. 
Myelin-associated glycoprotein inhibits microtubule assembly by a Rho-kinase-
dependent mechanism. J Biol Chem 281:15970-9. 
Miron VE, Kuhlmann T, Antel JP. 2011. Cells of the oligodendroglial lineage, 
myelination, and remyelination. Biochim Biophys Acta 1812:184-93. 
Mocchetti I, Rabin SJ, Colangelo AM, Whittemore SR, Wrathall JR. 1996. Increased basic 
fibroblast growth factor expression following contusive spinal cord injury. Exp 
Neurol 141:154-64. 
 
 
194 
 
Mothe AJ, Tator CH. 2012. Advances in stem cell therapy for spinal cord injury. The 
Journal of Clinical Investigation 122:3824-3834. 
Nadanaka S, Clement A, Masayama K, Faissner A, Sugahara K. 1998. Characteristic 
hexasaccharide sequences in octasaccharides derived from shark cartilage 
chondroitin sulfate D with a neurite outgrowth promoting activity. J Biol Chem 
273:3296-307. 
Nadir Y, Brenner B. 2014. Heparanase multiple effects in cancer. Thromb Res 133 Suppl 
2:S90-4. 
Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-
Michaeli R, Vlodavsky I. 2005. Modulation of the heparanase-inhibiting activity of 
heparin through selective desulfation, graded N-acetylation, and glycol splitting. 
J Biol Chem 280:12103-13. 
Nagoshi N, Kaneko S, Fujiyoshi K, Takemitsu M, Yagi M, Iizuka S, Miyake A, Hasegawa A. 
2015. Characteristics of neuropathic pain and its relationship with quality of life 
in 72 patients with spinal cord injury. 
Nakajima K, Honda S, Tohyama Y, Imai Y, Kohsaka S, Kurihara T. 2001. Neurotrophin 
secretion from cultured microglia. J Neurosci Res 65:322-31. 
Nash B, Ioannidou K, Barnett SC. 2011a. Astrocyte phenotypes and their relationship to 
myelination. J Anat 219:44-52. 
Nash B, Thomson CE, Linington C, Arthur AT, McClure JD, McBride MW, Barnett SC. 
2011b. Functional duality of astrocytes in myelination. J Neurosci 31:13028-38. 
Nisbet DR, Crompton KE, Horne MK, Finkelstein DI, Forsythe JS. 2008. Neural tissue 
engineering of the CNS using hydrogels. Journal of Biomedical Materials Research 
Part B: Applied Biomaterials 87B:251-263. 
Nobes CD, Hall A. 1999. Rho GTPases control polarity, protrusion and adhesion during 
cell movement. J Cell Biol 144:1235-1244. 
Noble M. 2000. Precursor Cell Transitions in Oligodendrocyte Development. The Journal 
of Cell Biology 148:839-842. 
Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. 1988. Platelet-derived growth 
factor promotes division and motility and inhibits premature differentiation of 
the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 333:560-2. 
Nomura H, Tator CH, Shoichet MS. 2006. Bioengineered strategies for spinal cord repair. 
J Neurotrauma 23:496-507. 
Norenberg MD, Smith J, Marcillo A. 2004. The pathology of human spinal cord injury: 
defining the problems. J Neurotrauma 21:429-40. 
NSCISC. 2013. Spinal cord injury facts and figures at a glance. J Spinal Cord Med 36:170-
1. 
Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, 
Briet E. 1992. Low-molecular-weight heparin versus standard heparin in general 
and orthopaedic surgery: a meta-analysis. Lancet 340:152-6. 
Obermair FJ, Schroter A, Thallmair M. 2008. Endogenous neural progenitor cells as 
therapeutic target after spinal cord injury. Physiology (Bethesda) 23:296-304. 
Ogata K, Kosaka T. 2002. Structural and quantitative analysis of astrocytes in the mouse 
hippocampus. Neuroscience 113:221-33. 
Orange JS, May MJ. 2008. Cell penetrating peptide inhibitors of nuclear factor-kappa B. 
Cell Mol Life Sci 65:3564-91. 
Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB. 1999. Long-term effects of 
methylprednisolone following transection of adult rat spinal cord. European 
Journal of Neuroscience 11:2453-2464. 
Pannek J. 2011. Treatment of urinary tract infection in persons with spinal cord injury: 
guidelines, evidence, and clinical practice: A questionnaire-based survey and 
review of the literature. The Journal of Spinal Cord Medicine 34:11-15. 
Park E, Velumian AA, Fehlings MG. 2004. The role of excitotoxicity in secondary 
mechanisms of spinal cord injury: a review with an emphasis on the implications 
for white matter degeneration. J Neurotrauma 21:754-74. 
Park J, Koito H, Li J, Han A. 2009a. Microfluidic compartmentalized co-culture platform 
for CNS axon myelination research. Biomed Microdevices 11:1145-53. 
 
 
195 
 
Park J, Koito H, Li J, Han A. 2009b. A multi-compartment CNS neuron-glia Co-culture 
microfluidic platform. J Vis Exp. 
Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M and 
others. 2008. Promoting axon regeneration in the adult CNS by modulation of the 
PTEN/mTOR pathway. Science 322:963-6. 
Passeri M, Cucinotta D. 1989. Ateroid in the clinical treatment of multi-infarct 
dementia. Mod Probl Pharmacopsychiatry 23:85-94. 
Patey SJ, Edwards EA, Yates EA, Turnbull JE. 2006. Heparin Derivatives as Inhibitors of 
BACE-1, the Alzheimer's β-Secretase, with Reduced Activity against Factor Xa 
and Other Proteases. Journal of Medicinal Chemistry 49:6129-6132. 
Pedraza CE, Taylor C, Pereira A, Seng M, Tham CS, Izrael M, Webb M. 2014. Induction of 
oligodendrocyte differentiation and in vitro myelination by inhibition of rho-
associated kinase. ASN Neuro 6. 
Perry VH, Brown MC, Gordon S. 1987. The macrophage response to central and 
peripheral nerve injury. A possible role for macrophages in regeneration. J Exp 
Med 165:1218-23. 
Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim 
KS, Witte MH and others. 1999. Microglial and astrocyte chemokines regulate 
monocyte migration through the blood-brain barrier in human immunodeficiency 
virus-1 encephalitis. Am J Pathol 155:1599-611. 
Peterson SL, McDonald A, Gourley PL, Sasaki DY. 2005. Poly(dimethylsiloxane) thin films 
as biocompatible coatings for microfluidic devices: cell culture and flow studies 
with glial cells. J Biomed Mater Res A 72:10-8. 
Pfrieger FW, Barres BA. 1997. Synaptic Efficacy Enhanced by Glial Cells in Vitro. Science 
277:1684-1687. 
Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie RA. 
2006. Heparin-regulated release of growth factors in vitro and angiogenic 
response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. 
Biomaterials 27:5242-51. 
Pineau I, Lacroix S. 2007. Proinflammatory cytokine synthesis in the injured mouse 
spinal cord: multiphasic expression pattern and identification of the cell types 
involved. J Comp Neurol 500:267-85. 
Pitts LH, Ross A, Chase GA, Faden AI. 1995. Treatment with thyrotropin-releasing 
hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 
12:235-43. 
Popovich PG, Horner PJ, Mullin BB, Stokes BT. 1996. A quantitative spatial analysis of 
the blood-spinal cord barrier. I. Permeability changes after experimental spinal 
contusion injury. Exp Neurol 142:258-75. 
Powell AK, Yates EA, Fernig DG, Turnbull JE. 2004. Interactions of heparin/heparan 
sulfate with proteins: appraisal of structural factors and experimental 
approaches. Glycobiology 14:17r-30r. 
Prabhakarpandian B, Shen MC, Nichols JB, Mills IR, Sidoryk-Wegrzynowicz M, Aschner M, 
Pant K. 2013. SyM-BBB: a microfluidic Blood Brain Barrier model. Lab Chip 
13:1093-101. 
Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, Fontana A. 2000. 
TNFR1 signalling is critical for the development of demyelination and the 
limitation of T-cell responses during immune-mediated CNS disease. Brain 123 ( 
Pt 10):2005-19. 
Probst C, Grunberger A, Wiechert W, Kohlheyer D. 2013. Microfluidic growth chambers 
with optical tweezers for full spatial single-cell control and analysis of evolving 
microbes. J Microbiol Methods 95:470-6. 
Properzi F, Lin R, Kwok J, Naidu M, van Kuppevelt TH, Ten Dam GB, Camargo LM, Raha-
Chowdhury R, Furukawa Y, Mikami T and others. 2008. Heparan sulphate 
proteoglycans in glia and in the normal and injured CNS: expression of 
sulphotransferases and changes in sulphation. Eur J Neurosci 27:593-604. 
Purves D, Augustine GJ, D F. 2001. Neuroscience 2nd. 
 
 
196 
 
Raisman G. 2001. Olfactory ensheathing cells - another miracle cure for spinal cord 
injury? Nat Rev Neurosci 2:369-75. 
Ramon-Cueto A. 2000. Olfactory ensheathing glia transplantation into the injured spinal 
cord. Prog Brain Res 128:265-72. 
Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Soloman A, 
Gepstein R, Katz A, Belkin M and others. 1998a. Implantation of stimulated 
homologous macrophages results in partial recovery of paraplegic rats. Nat Med 
4:814-821. 
Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, 
Gepstein R, Katz A, Belkin M and others. 1998b. Implantation of stimulated 
homologous macrophages results in partial recovery of paraplegic rats. Nat Med 
4:814-21. 
Rauvala H, Peng HB. 1997. HB-GAM (heparin-binding growth-associated molecule) and 
heparin-type glycans in the development and plasticity of neuron-target 
contacts. Prog Neurobiol 52:127-44. 
Recknor JB, Recknor JC, Sakaguchi DS, Mallapragada SK. 2004. Oriented astroglial cell 
growth on micropatterned polystyrene substrates. Biomaterials 25:2753-67. 
Reichert F, Saada A, Rotshenker S. 1994. Peripheral nerve injury induces Schwann cells 
to express two macrophage phenotypes: phagocytosis and the galactose-specific 
lectin MAC-2. J Neurosci 14:3231-45. 
Reynolds BA, Weiss S. 1996. Clonal and population analyses demonstrate that an EGF-
responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 175:1-
13. 
Richardson PM, McGuinness UM, Aguayo AJ. 1980. Axons from CNS neurons regenerate 
into PNS grafts. Nature 284:264-5. 
Riento K, Ridley AJ. 2003. ROCKs: multifunctional kinases in cell behaviour. Nat Rev Mol 
Cell Biol 4:446-456. 
Robertson G, Bushell TJ, Zagnoni M. 2014. Chemically induced synaptic activity between 
mixed primary hippocampal co-cultures in a microfluidic system. Integr Biol 
(Camb) 6:636-44. 
Rochkind S, Shahar A, Amon M, Nevo Z. 2002. Transplantation of embryonal spinal cord 
nerve cells cultured on biodegradable microcarriers followed by low power laser 
irradiation for the treatment of traumatic paraplegia in rats. Neurol Res 24:355-
60. 
Rodgers JM, Robinson AP, Miller SD. 2013. Strategies for Protecting Oligodendrocytes 
and Enhancing Remyelination in Multiple Sclerosis. Discovery medicine 16:53-63. 
Rodriguez JP, Coulter M, Miotke J, Meyer RL, Takemaru K. 2014. Abrogation of beta-
catenin signaling in oligodendrocyte precursor cells reduces glial scarring and 
promotes axon regeneration after CNS injury.  34:10285-97. 
Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, Rechavi G, 
Schwartz M. 2008. Two faces of chondroitin sulfate proteoglycan in spinal cord 
repair: a role in microglia/macrophage activation. PLoS Med 5:e171. 
Rosen SD, Lemjabbar-Alaoui H. 2010. Sulf-2: an extracellular modulator of cell signaling 
and a cancer target candidate. Expert Opin Ther Targets 14:935-49. 
Rossi F, Perale G, Papa S, Forloni G, Veglianese P. 2013. Current options for drug 
delivery to the spinal cord. Expert Opin Drug Deliv 10:385-96. 
Rothman SM, Olney JW. 1986. Glutamate and the pathophysiology of hypoxic--ischemic 
brain damage. Ann Neurol 19:105-11. 
Saleh-Lakha S, Trevors JT. 2010. Perspective: microfluidic applications in microbiology. 
J Microbiol Methods 82:108-11. 
Salinas PC. 2012. Wnt signaling in the vertebrate central nervous system: from axon 
guidance to synaptic function. Cold Spring Harb Perspect Biol 4. 
Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan sulfate proteoglycans. Cold Spring 
Harb Perspect Biol 3. 
Sato GH, Yasumura Y. 1966. Retention of differentiated function in dispersed cell 
culture. Trans N Y Acad Sci 28:1063-79. 
 
 
197 
 
Saxena K, Schieborr U, Anderka O, Duchardt-Ferner E, Elshorst B, Gande SL, Janzon J, 
Kudlinzki D, Sreeramulu S, Dreyer MK and others. 2010. Influence of heparin 
mimetics on assembly of the FGF.FGFR4 signaling complex. J Biol Chem 
285:26628-40. 
Schmitt AB, Breuer S, Liman J, Buss A, Schlangen C, Pech K, Hol EM, Brook GA, Noth J, 
Schwaiger FW. 2003. Identification of regeneration-associated genes after 
central and peripheral nerve injury in the adult rat. BMC Neurosci 4:8. 
Schwab ME, Bartholdi D. 1996. Degeneration and regeneration of axons in the lesioned 
spinal cord. Physiol Rev 76:319-70. 
Schwartz G, Fehlings MG. 2001. Evaluation of the neuroprotective effects of sodium 
channel blockers after spinal cord injury: improved behavioral and 
neuroanatomical recovery with riluzole. J Neurosurg 94:245-56. 
Scremin OU. 2009. Chapter 5 - The Spinal Cord Blood Vessels. In: Kayalioglu CWP, 
editor. The Spinal Cord. San Diego: Academic Press. p 57-63. 
Seidi A, Kaji H, Annabi N, Ostrovidov S, Ramalingam M, Khademhosseini A. 2011. A 
microfluidic-based neurotoxin concentration gradient for the generation of an in 
vitro model of Parkinson's disease. Biomicrofluidics 5:22214. 
Sheng GJ, Oh YI, Chang SK, Hsieh-Wilson LC. 2013. Tunable heparan sulfate mimetics 
for modulating chemokine activity. J Am Chem Soc 135:10898-901. 
Shih YT, Wang MC, Peng HH, Chen TF, Chen L, Chang JY, Chiu JJ. 2012. Modulation of 
chemotactic and pro-inflammatory activities of endothelial progenitor cells by 
hepatocellular carcinoma. Cell Signal 24:779-93. 
Shoichet MS, Tate CC, Baumann MD, Reichert WM. 2008. Strategies for Regeneration and 
Repair in the Injured Central Nervous System. Indwelling Neural Implants: 
Strategies for Contending with the In Vivo Environment: Boca Raton (FL): CRC 
Press/Taylor & Francis. 
Siddique R, Thakor N. 2014. Investigation of nerve injury through microfluidic devices. 
Journal of the Royal Society Interface 11:20130676. 
Silbert JE, Sugumaran G. 2002. Biosynthesis of chondroitin/dermatan sulfate. IUBMB 
Life 54:177-86. 
Simard JM, Schreibman D, Aldrich EF, Stallmeyer B, Le B, James RF, Beaty N. 2010. 
Unfractionated heparin: multitargeted therapy for delayed neurological deficits 
induced by subarachnoid hemorrhage. Neurocrit Care 13:439-49. 
Simons M, Lyons DA. 2013. Axonal selection and myelin sheath generation in the central 
nervous system. Curr Opin Cell Biol 25:512-9. 
Simons M, Nave KA. 2015. Oligodendrocytes: Myelination and Axonal Support. Cold 
Spring Harb Perspect Biol. 
Small DH, Mok SS, Williamson TG, Nurcombe V. 1996. Role of Proteoglycans in Neural 
Development, Regeneration, and the Aging Brain. Journal of Neurochemistry 
67:889-899. 
Smith PD, Coulson-Thomas VJ, Foscarin S, Kwok JC, Fawcett JW. 2015. "GAG-ing with 
the neuron": The role of glycosaminoglycan patterning in the central nervous 
system. Exp Neurol. 
Snaidero N, Simons M. 2014. Myelination at a glance. Journal of Cell Science 127:2999-
3004. 
Snow AD, Kisilevsky R, Willmer J, Prusiner SB, DeArmond SJ. 1989. Sulfated 
glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol 
77:337-42. 
Snow AD, Willmer JP, Kisilevsky R. 1987. Sulfated glycosaminoglycans in Alzheimer's 
disease. Hum Pathol 18:506-10. 
Snyder EY, Teng YD. 2012. Stem cells and spinal cord repair. N Engl J Med 366:1940-2. 
Sofroniew MV. 2015. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 
16:249-63. 
Sofroniew MV, Vinters HV. 2010. Astrocytes: biology and pathology. Acta Neuropathol 
119:7-35. 
 
 
198 
 
Song HL, Shim S, Kim DH, Won SH, Joo S, Kim S, Jeon NL, Yoon SY. 2014. beta-Amyloid 
is transmitted via neuronal connections along axonal membranes. Ann Neurol 
75:88-97. 
Sorensen A, Moffat K, Thomson C, Barnett SC. 2008a. Astrocytes, but not olfactory 
ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. 
Glia 56:750-63. 
Sorensen A, Moffat K, Thomson C, Barnett SC. 2008b. Astrocytes, but not olfactory 
ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. 
Glia 56:750-763. 
Sotelo-Silveira JR, Calliari A, Kun A, Koenig E, Sotelo JR. 2006. RNA trafficking in axons. 
Traffic 7:508-15. 
Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, Ellaway PH, 
Fehlings MG, Guest JD, Kleitman N and others. 2007. Guidelines for the conduct 
of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: 
clinical trial outcome measures. Spinal Cord 45:206-21. 
Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP. 2008. 
Canonical Wnt signaling regulates organ-specific assembly and differentiation of 
CNS vasculature. Science 322:1247-50. 
Sterne GD, Brown RA, Green CJ, Terenghi G. 1997. Neurotrophin-3 delivered locally via 
fibronectin mats enhances peripheral nerve regeneration. Eur J Neurosci 9:1388-
96. 
Stevens B, Porta S, Haak LL, Gallo V, Fields RD. 2002. Adenosine: a neuron-glial 
transmitter promoting myelination in the CNS in response to action potentials. 
Neuron 36:855-68. 
Stieger B, Gao B. 2015. Drug transporters in the central nervous system. Clin 
Pharmacokinet 54:225-42. 
Straley K, Heilshorn SC. 2009. Designer protein-based scaffolds for neural tissue 
engineering. Conf Proc IEEE Eng Med Biol Soc 2009:2101-2. 
Straley KS, Foo CW, Heilshorn SC. 2010. Biomaterial design strategies for the treatment 
of spinal cord injuries. J Neurotrauma 27:1-19. 
Su Z, Yuan Y, Chen J, Cao L, Zhu Y, Gao L, Qiu Y, He C. 2009. Reactive Astrocytes in 
Glial Scar Attract Olfactory Ensheathing Cells Migration by Secreted TNF-α in 
Spinal Cord Lesion of Rat. PLoS ONE 4:e8141. 
Swarup VP, Mencio CP, Hlady V, Kuberan B. 2013. Sugar glues for broken neurons. 
Biomol Concepts 4:233-57. 
Tabakow P, Jarmundowicz W, Czapiga B, Fortuna W, Miedzybrodzki R, Czyz M, Huber J, 
Szarek D, Okurowski S, Szewczyk P and others. 2013. Transplantation of 
autologous olfactory ensheathing cells in complete human spinal cord injury. Cell 
Transplant 22:1591-612. 
Tamai I, Tsuji A. 1996. Drug delivery through the blood-brain barrier. Advanced Drug 
Delivery Reviews 19:401-424. 
Taoka Y, Okajima K. 2000. Role of leukocytes in spinal cord injury in rats. J 
Neurotrauma 17:219-29. 
Tator CH, Koyanagi I. 1997. Vascular mechanisms in the pathophysiology of human 
spinal cord injury. J Neurosurg 86:483-92. 
Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, Hawkins T, Li H, Ghandour S, 
Schumacher M, Massaad C. 2011. Wnt/beta-catenin signaling is an essential and 
direct driver of myelin gene expression and myelinogenesis. J Neurosci 31:3729-
42. 
Taylor AM, Blurton-Jones M, Rhee SW, Cribbs DH, Cotman CW, Jeon NL. 2005. A 
microfluidic culture platform for CNS axonal injury, regeneration and transport. 
Nature methods 2:599-605. 
Taylor AM, Jeon NL. 2010. Micro-scale and microfluidic devices for neurobiology. Curr 
Opin Neurobiol 20:640-7. 
Taylor AM, Jeon NL. 2011. Microfluidic and compartmentalized platforms for 
neurobiological research. Crit Rev Biomed Eng 39:185-200. 
 
 
199 
 
Tewarie RSN, Hurtado A, Bartels RH, Grotenhuis A, Oudega M. 2009. Stem Cell–Based 
Therapies for Spinal Cord Injury. The Journal of Spinal Cord Medicine 32:105-
114. 
Tharin S, Kothapalli CR, Ozdinler PH, Pasquina L, Chung S, Varner J, DeValence S, Kamm 
R, Macklis JD. 2012. A microfluidic device to investigate axon targeting by 
limited numbers of purified cortical projection neuron subtypes. Integr Biol 
(Camb) 4:1398-405. 
Thietje R, Pouw MH, Schulz AP, Kienast B, Hirschfeld S. 2011. Mortality in patients with 
traumatic spinal cord injury: descriptive analysis of 62 deceased subjects. J 
Spinal Cord Med 34:482-7. 
Thomson CE, McCulloch M, Sorenson A, Barnett SC, Seed BV, Griffiths IR, McLaughlin M. 
2008. Myelinated, synapsing cultures of murine spinal cord – validation as an in 
vitro model of the central nervous system. European Journal of Neuroscience 
28:1518-1535. 
Thuret S, Moon LDF, Gage FH. 2006. Therapeutic interventions after spinal cord injury. 
Nat Rev Neurosci 7:628-643. 
Tian B, Liu J, Dvir T, Jin L, Tsui JH, Qing Q, Suo Z, Langer R, Kohane DS, Lieber CM. 
2012. Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat 
Mater 11:986-94. 
Tkachenko E, Rhodes JM, Simons M. 2005. Syndecans: new kids on the signaling block. 
Circ Res 96:488-500. 
Toft A, Tome M, Lindsay SL, Barnett SC, Riddell JS. 2012. Transplant-mediated repair 
properties of rat olfactory mucosal OM-I and OM-II sphere-forming cells. J 
Neurosci Res 90:619-31. 
Tolg C, Telmer P, Turley E. 2014. Specific sizes of hyaluronan oligosaccharides stimulate 
fibroblast migration and excisional wound repair. PLoS One 9:e88479. 
Tripathi R, McTigue DM. 2007. Prominent oligodendrocyte genesis along the border of 
spinal contusion lesions. Glia 55:698-711. 
Tully SE, Mabon R, Gama CI, Tsai SM, Liu X, Hsieh-Wilson LC. 2004. A Chondroitin 
Sulfate Small Molecule that Stimulates Neuronal Growth. Journal of the 
American Chemical Society 126:7736-7737. 
Tumova S, Woods A, Couchman JR. 2000. Heparan sulfate proteoglycans on the cell 
surface: versatile coordinators of cellular functions. The International Journal of 
Biochemistry & Cell Biology 32:269-288. 
Turnbull J, Powell A, Guimond S. 2001. Heparan sulfate: decoding a dynamic 
multifunctional cell regulator. Trends in Cell Biology 11:75-82. 
Turner N, Grose R. 2010. Fibroblast growth factor signalling: from development to 
cancer. Nat Rev Cancer 10:116-129. 
Ughrin YM, Chen ZJ, Levine JM. 2003. Multiple regions of the NG2 proteoglycan inhibit 
neurite growth and induce growth cone collapse. J Neurosci 23:175-86. 
Vallstedt A, Klos JM, Ericson J. 2005. Multiple dorsoventral origins of oligodendrocyte 
generation in the spinal cord and hindbrain. Neuron 45:55-67. 
van Kesteren RE, Mason MRJ, MacGillavry HD, Smit AB, Verhaagen J. 2011. A Gene 
Network Perspective on Axonal Regeneration. Frontiers in Molecular 
Neuroscience 4:46. 
Verma P, Chierzi S, Codd AM, Campbell DS, Meyer RL, Holt CE, Fawcett JW. 2005. 
Axonal protein synthesis and degradation are necessary for efficient growth cone 
regeneration. J Neurosci 25:331-42. 
Villegas J. 1972. Axon-Schwann cell interaction in the squid nerve fibre. J Physiol 
225:275-96. 
Vlodavsky I, Ilan N, Naggi A, Casu B. 2007. Heparanase: structure, biological functions, 
and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 
13:2057-73. 
Wade A, McKinney A, Phillips JJ. 2014. Matrix regulators in neural stem cell functions. 
Biochimica et Biophysica Acta (BBA) - General Subjects 1840:2520-2525. 
 
 
200 
 
Wall D, Douglas S, Ferro V, Cowden W, Parish C. 2001. Characterisation of the 
anticoagulant properties of a range of structurally diverse sulfated 
oligosaccharides. Thromb Res 103:325-35. 
Wang H-Y, Lu C. 2008. Microfluidic electroporation for delivery of small molecules and 
genes into cells using a common DC power supply. Biotechnology and 
Bioengineering 100:579-586. 
Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z. 2002. 
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits 
neurite outgrowth. Nature 417:941-4. 
Wang L, Liang Z, Li G. 2011. Rab22 controls NGF signaling and neurite outgrowth in 
PC12 cells. Mol Biol Cell 22:3853-60. 
Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, Weinmaster G, Barres BA. 
1998. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 
21:63-75. 
Watson C, Kayalioglu G. 2009. Chapter 1 - The Organization of the Spinal Cord. In: 
Kayalioglu CWP, editor. The Spinal Cord. San Diego: Academic Press. p 1-7. 
Weitz JI. 1997. Low-molecular-weight heparins. N Engl J Med 337:688-98. 
Wells MR, Kraus K, Batter DK, Blunt DG, Weremowitz J, Lynch SE, Antoniades HN, 
Hansson HA. 1997. Gel matrix vehicles for growth factor application in nerve gap 
injuries repaired with tubes: a comparison of biomatrix, collagen, and 
methylcellulose. Exp Neurol 146:395-402. 
Wen Y, Yu S, Wu Y, Ju R, Wang H, Liu Y, Wang Y, Xu Q. 2015. Spinal cord injury repair 
by implantation of structured hyaluronic acid scaffold with PLGA microspheres in 
the rat. Cell Tissue Res. 
Wessel HP, Chucholowski A, Fingerle J, Iberg N, Märki HP, Müller R, Pech M, Pfister-
Downar M, Rouge M, Schmid G and others. 2005. From Glycosaminoglycans to 
Heparinoid Mimetics with Antiproliferative Activity. Carbohydrate Mimics: Wiley-
VCH Verlag GmbH & Co. KGaA. p 417-431. 
Whetstone WD, Hsu J-YC, Eisenberg M, Werb Z, Noble-Haeusslein LJ. 2003. Blood-Spinal 
Cord Barrier After Spinal Cord Injury: Relation to Revascularization and Wound 
Healing. Journal of neuroscience research 74:227-239. 
Whitesides GM. 2006. The origins and the future of microfluidics. Nature 442:368-73. 
Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE. 2001. Soft lithography in 
biology and biochemistry. Annu Rev Biomed Eng 3:335-73. 
Wilhelmsson U, Faiz M, de Pablo Y, Sjoqvist M, Andersson D, Widestrand A, Potokar M, 
Stenovec M, Smith PL, Shinjyo N and others. 2012. Astrocytes negatively regulate 
neurogenesis through the Jagged1-mediated Notch pathway. Stem Cells 30:2320-
9. 
Willis D, Li KW, Zheng JQ, Chang JH, Smit AB, Kelly T, Merianda TT, Sylvester J, van 
Minnen J, Twiss JL. 2005. Differential transport and local translation of 
cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J 
Neurosci 25:778-91. 
Wittig JH, Jr., Ryan AF, Asbeck PM. 2005. A reusable microfluidic plate with alternate-
choice architecture for assessing growth preference in tissue culture. J Neurosci 
Methods 144:79-89. 
Wolman L. 1965. The disturbance of circulation in traumatic paraplegia in acute and 
late stages: A pathological study. Paraplegia 2:213-26. 
Xu X, Dai Y. 2010. Heparin: an intervenor in cell communication. Journal of Cellular and 
Molecular Medicine 14:175-180. 
Yan D, Lin X. 2009. Shaping Morphogen Gradients by Proteoglycans. Cold Spring Harbor 
Perspectives in Biology 1:a002493. 
Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM. 2014. Microfluidic culture 
platform for studying neuronal response to mild to very mild axonal stretch 
injury. Biomicrofluidics 8:044110. 
Yates EA, Guimond SE, Turnbull JE. 2004. Highly diverse heparan sulfate analogue 
libraries: providing access to expanded areas of sequence space for bioactivity 
screening. J Med Chem 47:277-80. 
 
 
201 
 
Yin H, Marshall D. 2012. Microfluidics for single cell analysis. Curr Opin Biotechnol 
23:110-9. 
Yiu G, He Z. 2006. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617-27. 
Zhang LX, Yin YM, Zhang ZQ, Deng LX. 2015. Grafted bone marrow stromal cells: a 
contributor to glial repair after spinal cord injury. Neuroscientist 21:277-89. 
Zhang SC, Lundberg C, Lipsitz D, O'Connor LT, Duncan ID. 1998. Generation of 
oligodendroglial progenitors from neural stem cells. J Neurocytol 27:475-89. 
Zhang Y, Gazit Z, Pelled G, Gazit D, Vunjak-Novakovic G. 2011. Patterning osteogenesis 
by inducible gene expression in microfluidic culture systems. Integr Biol (Camb) 
3:39-47. 
Zhang Y, Yeung MN, Liu J, Chau CH, Chan YS, Shum DK. 2006. Mapping heparanase 
expression in the spinal cord of adult rats. J Comp Neurol 494:345-57. 
Zhong Y, Bellamkonda RV. 2008. Biomaterials for the central nervous system. J R Soc 
Interface 5:957-75. 
Zhou X, He X, Ren Y. 2014. Function of microglia and macrophages in secondary damage 
after spinal cord injury. Neural Regeneration Research 9:1787-1795. 
Zivraj KH, Tung YC, Piper M, Gumy L, Fawcett JW, Yeo GS, Holt CE. 2010. Subcellular 
profiling reveals distinct and developmentally regulated repertoire of growth 
cone mRNAs. J Neurosci 30:15464-78. 
Zorner B, Schwab ME. 2010. Anti-Nogo on the go: from animal models to a clinical trial. 
Ann N Y Acad Sci 1198 Suppl 1:E22-34. 
Zou Y. 2004. Wnt signaling in axon guidance. Trends Neurosci 27:528-32. 
 
